Acompanhe as atualizações!
Potential influence of COVID-19 and dexamethasone on the reproductive system: what we know and can expect
08 November de 2022 – Our review will help medical professionals in the prognosis and follow-up of patients treated with dexamethasone
Intensity of anticoagulant dosing in hospitalized patients with COVID-19: an observational, comparative effectiveness study
08 November de 2022 – Results of this real-world, comparative effectiveness study showed no differences in in-hospital death among newly admitted or deteriorating patients with COVID-19 who received intermediate-dose or full anticoagulation compared with standard prophylaxis
Antiviral effects of phytochemicals against severe acute respiratory syndrome coronavirus 2 and their mechanisms of action: A review
07 November de 2022 – Further experimental and preclinical investigations on the in vivo effects of phytochemicals have to be performed to provide sufficient efficacy and safety data before clinical studies can be performed to develop them into COVID-19 drugs. Phytochemicals are potential sources of new chemical leads for the development of safe and potent anti-SARS-CoV-2 agents
Analysis of the Prevalence of Binding and Neutralizing Antibodies against 39 Human Adenovirus Types in Student Cohorts Reveals Low-Prevalence Types and a Decline in Binding Antibody Levels during the SARS-CoV-2 Pandemic
07 November de 2022 – Our data indicate that mainly HAdV types of species A, B, and D show low seroprevalence with regard to both binding and neutralizing antibodies and may represent good candidates for further characterization and future development as novel vector systems
Protocol for characterizing the inhibition of SARS-CoV-2 infection by a protein of interest in cultured cells
05 November de 2022 – We describe the optimized procedure to analyze protein interference of viral attachment and entry into cells, and qRT-PCR-based quantification of viral infection. The protocol can be applied to characterize more antiviral candidates and clarify their functioning stage
Toxicity assessment of SARS-CoV-2-derived peptides in combination with a mix of pollutants on zebrafish adults: A perspective study of behavioral, biometric, mutagenic, and biochemical toxicity
04 November de 2022 – The principal component analysis (PCA) and hierarchical clustering analysis indicated a clear separation of the “Mix+PSPD” group from the others. Thus, we conclude that exposure to viral fragments, associated with the mix of pollutants, induced more significant toxicity in zebrafish adults than in others
Outlook of various diagnostics and nanodiagnostic techniques for COVID-19
03 November de 2022 – The advantages of nanodiagnostic devices over other techniques are discussed, along with their limitations. Additionally, the important implications of the utility of nanodiagnostic devices in COVID-19, their prospects for future development for use in clinical and POC settings, and personalized healthcare are also discussed
Advances And Challenges In Using Nirmatrelvir And Its Derivatives Against Sars-Cov-2 Infection
02 November de 2022 – We review the advances and challenges in using nirmatrelvir and its derivatives with the aim of providing knowledge to drug developers and physicians in the fight against COVID-19
Covid-19 Vaccine Protection among Children and Adolescents in Qatar
02 November de 2022 – Vaccination in children was associated with modest, rapidly waning protection against omicron infection. Vaccination in adolescents was associated with stronger, more durable protection, perhaps because of the larger antigen dose. (Funded by Weill Cornell Medicine–Qatar and others.)
Effect of Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Booster on Human Immunodeficiency Virus Reservoirs and Immune Markers
01 November de 2022 – In the present study, we set out to investigate the effects of the SARV-CoV-2 booster vaccine on HIV reservoir size, immune markers, and host immune responses to HIV and SARS-CoV-2 in a cohort of HIV-positive individuals receiving ART after the SARS-CoV-2 booster vaccination
Tempol inhibits SARS-CoV-2 replication and development of lung disease in the Syrian hamster model
21 October de 2022 – The inhibitory effect of TEMPOL on SARS-CoV-2 replication was observed in animals when the drug was administered 2 hours before infection in a high-risk exposure model. These data support the potential application of TEMPOL as a highly efficacious antiviral against SARS-CoV-2 infection in humans
Tixagevimab/cilgavimab for prevention and treatment of COVID-19: a review
11 October de 2022 – Importantly, despite the current effectiveness of tixagevimab/cilgavimab, we must recognize the possibility that resistant SARS-CoV-2 variants could emerge in the future
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
10 October de 2022 – In hamsters, COVID-HIGIV treatment reduced infection-associated lung pathology including lung inflammation, and pneumocyte hypertrophy in the lungs. These results support ongoing trials for outpatient treatment with COVID-HIGIV for safety and efficacy evaluation
Recent review of COVID-19 management: diagnosis, treatment and vaccination
10 October de 2022 – New developments like nanotechnology and AI can be beneficial in providing an efficient and reliable solution for the suppression of SARS-CoV-2. Public health concerns can be efficiently treated by a unified scientific approach, public engagement, and better diagnosis
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection
10 October de 2022 – In hamsters, COVID-HIGIV treatment reduced infection-associated lung pathology including lung inflammation, and pneumocyte hypertrophy in the lungs. These results support ongoing trials for outpatient treatment with COVID-HIGIV for safety and efficacy evaluation
Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
10 October de 2022 – This formulation of intranasal ChAdOx1 nCoV-19 showed an acceptable tolerability profile but induced neither a consistent mucosal antibody response nor a strong systemic response
Efficacy and safety of KL-A167 in previously treated recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm, phase 2 study
10 October de 2022 – In this study, KL-A167 showed promising efficacy and an acceptable safety profile in patients with previously treated R/M NPC. Baseline plasma EBV DNA copy number might be a potentially useful prognostic biomarker for KL-A167 treatment, and post-treatment EBV DNA decrease might be correlated with better response to KL-A167
A comprehensive SARS-CoV-2–human protein–protein interactome reveals COVID-19 pathobiology and potential host therapeutic targets
10 October de 2022 – Our study demonstrates the value of network systems biology to understand human–virus interactions and provides hits for further research on COVID-19 therapeutics
Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch
06 October de 2022 – This real-world analysis of a large cohort of high-risk patients demonstrates low rates of severe disease after treatment with sotrovimab during the era dominated by Omicron B.1.1.529 and after treatment with bebtelovimab during the era dominated by BA.2 and Omicron subvariants
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
06 October de 2022 – The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns
Effectiveness of an inactivated Covid-19 vaccine with homologous and heterologous boosters against Omicron in Brazil
06 October de 2022 – Waning against severe Covid-19 after 120 days was only observed after a homologous booster. Heterologous booster might be preferable to individuals with completed primary series inactivated vaccine
Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial
06 October de 2022 – These results indicate that bivalent booster vaccines can induce potent, durable and broad antibody responses against multiple variants, providing a new tool in response to emerging variants
Panax ginseng as a potential therapeutic for neurological disorders associated with COVID-19; Toward targeting inflammasome
04 October de 2022 – This review article discusses the current knowledge regarding the pathogenesis of neurological disorders related to COVID-19 and NLRP3 inflammasome activation and the possibility of using P. ginseng in a strategy targeting this pathway to treat neurological disorders
Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial
03 October de 2022 – The evidence on the benefit of high-dose dexamethasone is limited. The goal of this study was to assess the effects of 6 mg daily vs. 20 mg daily of dexamethasone in hospitalized patients with COVID-19 pneumonia
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
03 October de 2022 – The triple combination of camostat, brequinar, and molnupiravir further increased antiviral potency. These findings support the development of HTA+DAA combinations for pandemic response and preparedness
Live and let die: signaling AKTivation and UPRegulation dynamics in SARS-CoVs infection and cancer
03 October de 2022 -In particular, drug repositioning, the investigation of existing drugs for new therapeutic purposes, could significantly reduce time and costs compared to de novo drug Discovery
Spike-antibody responses to COVID-19 vaccination by demographic and clinical factors in a prospective community cohort study
02 October de 2022 – These findings suggest the need to continue prioritising vulnerable groups, who have been vaccinated earliest and have the most attenuated antibody responses, for future boosters
A Phylogenetic Perspective of Antiviral Species of the Genus Artemisia (Asteraceae-Anthemideae): A Proposal of Anti SARS-CoV-2 (COVID-19) Candidate Taxa
28 September de 2022 -Artemisia species from different subgenera with antiviral activity are prevalent in the genus, with most antiviral species belonging to the subgenus Artemisia. A detailed analysis of species from all subgenera, particularly the subgenus Artemisia, is therefore proposed in order to discover compounds with potential antiviral activities, including anti- SARS-CoV-2 activity
Robust therapeutic effects on COVID-19 of novel small molecules: Alleviation of SARS-CoV-2 S protein induction of ACE2/TMPRSS2, NOX2/ROS, and MCP-1
28 September de 2022 – Our findings for the first time demonstrate that these novel small molecules may be used as novel and robust therapeutic options for the treatment of patients with COVID-19, via effective attenuation of S protein induction of endothelial oxidative stress and inflammation
Thermal degradation of hazardous 3-layered COVID-19 face mask through pyrolysis: Kinetic, thermodynamic, prediction modelling using ANN and volatile product characterization
28 September de 2022 – The results demonstrated a strong correlation between real and anticipated values. The study proved the relevance of the ANN model and the applicability of pyrolysis for disposing of 3LFM while simultaneously producing energy products
Outcomes of Monoclonal Antibody Infusion Treatment During Delta (B.1.617.2) and Omicron (B.1.1.529) COVID 19 Variant Surges among Vaccinated and Unvaccinated Patients
27 September de 2022 -Monoclonal antibodies should be considered in both vaccinated and unvaccinated patients with COVID-19 infection if newer antiviral agents are contraindicated. Our study highlights the effectiveness of monoclonal antibody infusions when given early in the course of COVID-19 infection regardless of vaccination status
Coronavirus 2019 disease: Are corticosteroids the key treatment? A retrospective case-control study in Brazil
27 September de 2022 – In this study, the use of corticosteroids during the initial pulmonary phase of COVID-19 before desaturation, in addition to daily monitoring of patients, prevented disease progression, decreased the risk of complications and incidence of hospitalization and death
Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials
22 September 2022 – This meta-analysis of 21 RCTs in 390 459 participants showed no significant difference in efficacy between the FDA/EMA-approved and -unapproved vaccines for symptomatic or severe infection. Differences in study design, endpoint definitions, variants, and infection prevalence may have influenced results
Common human genetic variants of APOE impact murine COVID-19 mortality
21 September de 2022 – Our findings suggest APOE genotype to partially explain the heterogeneity of COVID-19 outcomes and warrant prospective studies to assess APOE genotyping as a means of identifying patients at high risk for adverse outcomes
Effect of intravenous almitrine on intubation or mortality in patients with COVID-19 acute hypoxemic respiratory failure: A multicentre, randomised, double-blind, placebo-controlled trial
21 September 2022 – In patients with COVID-19 acute hypoxemic respiratory failure, low-dose almitrine failed in reducing the need for MV or death at day 7
Casirivimab/imdevimab treatment for outpatient COVID-19 during a SARS-CoV-2 B1.617.2 (Delta) surge at a community hospital
20 September 2021 – Vaccination status has been shown to be linked to patient-centered outcomes in those with COVID-19. However, minimal data have explored the relationship between vaccination status and representation rates after receiving monoclonal antibodies (MABs) the Delta strain of severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) in a community setting
Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein
19 September 2022 – These results suggest that regions outside the HR2 helical region may offer new opportunities for potent peptide-derived therapeutics for SARS-CoV-2 and its variants, and even more distantly related viruses, and provide further support for the prehairpin intermediate of the S protein
Thiopurines inhibit coronavirus Spike protein processing and incorporation into progeny virions
19 September 2022 – The broad GTPase agonist ML099 countered the effects of 6-TG, suggesting that the antiviral activity of 6-TG requires the targeting of an unknown GTPase. Overall, these findings suggest that small GTPases are promising targets for host-targeted antivirals
Anti-SARS-CoV-2 Activity of Targeted Kinase Inhibitors: Repurposing Clinically Available Drugs for COVID-19 Therapy
18 September 2022 – This work supports further evaluation of AXL-targeting kinase inhibitors as potential antiviral agents and treatments for COVID-19. Additional mechanistic studies are needed to determine underlying differences in virus response
A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant
17 September 2022 – The results qualified RBD-HR/trimer vaccine as a promising next-generation vaccine candidate for prevention of SARS-CoV-2, which deserved further evaluation in clinical trials
Comparable Outcomes for Bebtelovimab and Ritonavir-Boosted Nirmatrelvir Treatment in High-Risk Patients With Coronavirus Disease-2019 During Severe Acute Respiratory Syndrome Coronavirus 2 BA.2 Omicron Epoch
17 September 2022 – Our findings support the emergency use authorization of bebtelovimab for treatment of COVID-19 during the Omicron epoch dominated by BA.2 and subvariants
A review post-vaccination SARS-CoV-2 serological test: Method and antibody titer response
17 September 2022 – This review can provide an understanding of the application of the body’s immune response to vaccines to get some new strategies for vacines
Use of low molecular weight heparin and hemoglobin fall in COVID-19 patients: A STROBE-compliant study
16 September 2022 – The results of multivariate regression analysis showed that after adjusting for confounding factors, LMWH use was not associated with a decrease in hemoglobin (P > .05). In nonsevere COVID-19 patients with pneumonia, the preventive use of LMWH did not lower hemoglobina
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
16 September 2022 – The bivalent omicron-containing vaccine mRNA-1273.214 elicited neutralizing antibody responses against omicron that were superior to those with mRNA-1273, without evident safety concerns
Spatial and temporal dynamics of SARS-CoV-2: modeling, analysis and simulation
14 September 2022 – Numerical simulations are performed to illustrate our theoretical results which reveal that diffusion, spatial heterogeneity and incidence types have evident impact on the SARS-CoV-2 infection process which should not be neglected for experiments and clinical treatments
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
14 September 2022 – Randomised participants who received at least one dose were included in the efficacy and safety analyses on a complete case basis (incomplete/missing data not imputed). Results up to 6 months after the second dose are reported
Consensus docking and MM-PBSA computations identify putative furin protease inhibitors for developing potential therapeutics against COVID-19
14 September 2022 – Propolis compounds have shown inhibitory effects against ACE2, TMPRSS2, and PAK1 signaling pathways of SARS-CoV-2 in previous studies. Likewise, quercitrin is structurally similar to isoquercetin, which is currently in clinical trials as possible medication for COVID-19
Research and development of Chinese anti-COVID-19 drugs
13 September 2022 – The promising anti-COVID-19 drugs originally developed and researched in China are summarized in this review, with the aim to contribute to the rational use and effective development of anti-COVID-19 drugs
Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial
13 September 2022 – BNT162b2 vaccination induced a robust immune response with acceptable tolerability in Han Chinese adults. However, follow-up duration was relatively short and COVID-19 rates were not assessed. Safety data collection is continuing until 12 months after the second dose
Zinc and COVID-19: Immunity, Susceptibility, Severity and Intervention
12 September 2022 – Zinc supplementation plays a potentially protective role in enhancing immunity, decreasing susceptibility, shortening illness duration, and reducing the severity of COVID-19. We recommend that zinc levels should be monitored, particularly in COVID-19 patients, and zinc as a preventive and adjunct therapy for COVID-19 should be considered for groups at risk of zinc deficiency to reduce susceptibility and disease severity
Molecular insights into the interaction of apo-lactoferrin with the receptor binding domain of the SARS-CoV-2 spike protein: a molecular dynamics simulation study
12 September 2022 – The simulations highlight that the C-lobe, followed by full-length apo-LF can form a multimeric complex with the RBD of SARS-CoV-2, indicating their potential use as novel therapeutics, particularly the cleaved C-lobe of apo-LF to disrupt the S proteins from binding to the host ACE-2 receptor
Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials
12 September 2022 – Withholding methotrexate after both ChAdOx1 nCov-19 vaccine doses and after only the second dose led to higher anti-RBD antibody titres compared with continuation of methotrexate. However, withholding methotrexate only after the second vaccine dose resulted in a similar humoral response to holding methotrexate after both vaccine doses, without an increased risk of arthritis flares
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies
12 September 2022 – In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains
An insight into the placental growth factor (PlGf)/angii axis in Covid-19: a detrimental intersection
12 September 2022 – Both AngII and PlGF are interacted and are involved in the progression of inflammatory disorders; therefore, we aimed in this review to highlight the potential role of the PlGF/AngII axis in Covid-19
Factors influencing neutralizing antibody titers elicited by coronavirus disease 2019 vaccines
09 September 2022 – Our study provided the international unit (IU) values of Neutralizing antibody Titers (NTs) in vaccinated individuals for the development of vaccines and implementation of non-inferiority trials. Correlation of the influencing factors with NTs can provide an indicator for selecting COVID-19 vaccines based on personal atributes
Methylprednisolone pulse therapy for critically ill patients with coronavirus disease 2019: A single-center retrospective observational study
06 September 2022 – Steroid pulse therapy might improve the 28-day and in-hospital mortality in critically ill patients with COVID-19 pneumonia
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial
05 September 2022 – VLA2001 has a favourable tolerability profile and met superiority criteria for neutralising antibodies and non-inferiority criterion for seroconversion rates compared with ChAdOx1-S
Dipeptidyl peptidase-1 inhibition in patients hospitalised with COVID-19: a multicentre, double-blind, randomised, parallel-group, placebo-controlled trial
05 September 2022 – Brensocatib treatment did not improve clinical status at day 29 in patients hospitalised with COVID-19
Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge
01 September 2022 – Among patients 65 years of age or older, the rates of hospitalization and death due to Covid-19 were significantly lower among those who received nirmatrelvir than among those who did not. No evidence of benefit was found in younger adults
Computational screening for investigating the synergistic regulatory potential of drugs and phytochemicals in combination with 2-deoxy-D-glucose against SARS-CoV-2
03 September 2022 -This study provides an insight into developing drug combinations utilizing integrated computational approaches to uncover their potential in synergistic drug therapy
Covid-19 Vaccines — Immunity, Variants, Boosters
31 August 2022 – For acute viral infections, including SARS-CoV-2, it is likely that neutralizing antibodies are critical for blocking acquisition of infection, whereas a combination of humoral and cellular immune responses most likely controls viral replication after infection and prevents progression to severe disease, hospitalization, and death
Major severe acute respiratory coronavirus-2 (SARS-CoV-2) vaccine-associated adverse effects; benefits outweigh the risks
24 August 2022 – Global vaccine development and vaccination of the population are the most promising cost-effective methods for overcoming the epidemic. However, following reports of post-vaccination thromboembolic adverse effects, there have been raising concerns about the safety profile of the COVID-19 vaccine
Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19
20 August 2022 – Treatment of coronavirus disease-2019 (Covid-19) with nirmatrelvir plus ritonavir (NMV-r) in high-risk non-hospitalized unvaccinated patients reduced the risk of progression to severe disease
Potential of FX06 to prevent disease progression in hospitalized non-intubated COVID-19 patients – the randomized, EU-wide, placebo-controlled, phase II study design of IXION
19 August 2022 – With IXION, the multidisciplinary consortium aims to deliver a new therapy in addition to standard care against SARS-CoV-2 for the clinical management of COVID-19 during mild and moderate stages
Remdesivir Administration in COVID-19 Patients With Renal Impairment: A Systematic Review
19 August 2022 – This systematic review aimed to collect data about the necessity and safety administration of RDV in the setting of renal impairment
Endoplasmic Reticulum Secretory pathway: Potential target against SARS-COV-2
18 August 2022 – Here we discuss the feasibility of off-patent, FDA-approved, pharmacological inhibitors of the ERS pathway to suppress the SARS-CoV-2 replication cycle, a promising approach that warrants investigation
Plant MicroRNA Potential in Targeting Sars-CoV-2 Genome Offering Efficient Antiviral MiRNA-Based Therapies
18 August 2022 – In our opinion, they are potent plant-derived miRNA candidates that have a great chance of targeting the Sars-CoV-2 genome in the 3’-UTR region in vitro. Therefore, we propose pvu-miR159a.2 for studying antiviral miRNA-based therapies without any essential side effects in vivo
In silico identification of novel SARS-CoV-2 main protease and non-structural protein 13 (nsp13) inhibitors through consensus docking and free binding energy calculations
18 August 2022 – A new strain of a novel disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been recently declared a pandemic by the World Health Organization (WHO)
Endoplasmic Reticulum Secretory pathway: Potential target against SARS-COV-2
18 August 2022 – Here we discuss the feasibility of off-patent, FDA-approved, pharmacological inhibitors of the ERS pathway to suppress the SARS-CoV-2 replication cycle, a promising approach that warrants investigation
Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19
18 August 2022 – None of the three medications that were evaluated prevented the occurrence of hypoxemia, an emergency department visit, hospitalization, or death associated with Covid-19
Monoclonal antibodies: a remedial approach to prevent SARS-CoV-2 infection
17 August 2022 – Here we present a summary of neutralizing mAbs isolated from COVID-19 infected patients which are anticipated to be a better therapeutic alternative against SARS-CoV-2. However, provided the vast escalation of the disease worldwide affecting people from all strata, affording expensive mAb therapy will not be feasible. Hence other strategies are also being employed to find suitable vaccine candidates and antivirals against SARS-CoV-2 that can be made easily available to the population
Pembrolizumab in combination with tocilizumab in high-risk hospitalized COVID-19 patients (COPERNICO): A randomized proof-of-concept phase II study
17 August 2022 – The addition of P and TCZ to SOC reduced the hospitalization period, with higher and faster discharges without sequelae than SOC alone
Punicalagin as an allosteric NSP13 helicase inhibitor potently suppresses SARS-CoV-2 replication in vitro
17 August 2022 – Our work demonstrates the potential application of PUG in the treatment of coronavirus disease 2019 (COVID-19) and identifies an allosteric inhibition mechanism for future drug design targeting the viral helicases
Clinical Practice Guidelines From the Association for the Advancement of Blood and Biotherapies (AABB): COVID-19 Convalescent Plasma
16 August 2022 – Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP
Interleukin-6 cytokine: An overview of the immune regulation, immune dysregulation, and therapeutic approach
12 August 2022 – Tocilizumab and Sarilumab are promising in COVID-19 cytokine storm management
Mesenchymal stem cells and their derived small extracellular vesicles for COVID-19 treatment
12 August 2022 – The preclinical studies and clinical trials using MSCs and small extracellular vesicles derived from MSCs (MSC-sEVs) in treating COVID-19 were summarized. Then, the molecular mechanism, feasibility, and safety of treating COVID-19 with MSCs and MSC-sEVs were also discussed
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19
12 August 2022 – Here we show that, while Apilimod and other PIKfyve inhibitors have potent antiviral activity in various cell lines against multiple human coronaviruses, these compounds worsen disease in a COVID-19 murine model when given prophylactically or therapeutically.
Structure-Based Identification of Naphthoquinones and Derivatives as Novel Inhibitors of Main Protease Mpro and Papain-like Protease PLpro of SARS-CoV-2
12 August 2022 – In summary, our structure-based computational and biochemical approach identified novel naphthoquinonal scaffolds that can be further explored as SARS-CoV-2 antivirals.
Evaluation of safety and immunogenicity of receptor-binding domain-based COVID-19 vaccine (Corbevax) to select the optimum formulation in open-label, multicentre, and randomised phase-1/2 and phase-2 clinical trials
12 August 2022 – We assessed the efficacy of a receptor-binding domain (RBD)-based protein subunit COVID-19 vaccine
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
11 August 2022 – During a period when the omicron variant was predominant, BNT162b2 vaccination reduced the risks of SARS-CoV-2 infection and Covid-19–related hospitalization among children 5 to 11 years of age
Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study
11 August 2022 – his study aimed to determine the frequency and nature of significant health events among pregnant females after COVID-19 vaccination, compared with unvaccinated pregnant controls and vaccinated non-pregnant individuals
Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study
10 August 2022 – We aimed to assess the immunogenicity of the ChAdOx1-nCoV-19 vaccine and the impact of different anticancer therapies for solid malignancies on immune response
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
10 August 2022 – Booster doses of SARS-CoV-2 vaccines might address these concerns by amplifying and broadening the immune responses seen with initial vaccination regimens. We aimed to assess the immunogenicity and safety of a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373)
Coronavirus disease 2019 convalescent plasma (CCP) has emerged as a potential treatment of COVID-19. However, meta-analysis data and recommendations are limited. The Association for the Advancement of Blood and Biotherapies (AABB) developed clinical practice guidelines for the appropriate use of CCP
09 August 2022 – The anti-inflammatory activities of schaftoside were confirmed on lipopolysaccharide-induced acute lung injury mice. Schaftoside showed good safety and pharmacokinetic property, and could be a promising drug candidate for the prevention and treatment of COVID-19
A Multiscale Model of COVID-19 Dynamics
09 August 2022 – Our work underlines the potential role that the environment can play in the transmission of COVID-19. Antiviral treatment of infected individuals can delay but cannot prevent the emergence of disease outbreaks
Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID-19 infection: prospects for use
09 August 2022 – If successful, these drugs can substantially reduce hospitalization and mortality rates, as well as allow for fully outpatient treatment for mild-to-moderate infections
Seasonal variation of the composition of essential oils from Piper cernuum Vell and Piper rivinoides Kunth, ADMET study, DFT calculations, molecular docking and dynamics studies of major components as potent inhibitors of the heterodimer methyltransferase complex NSP16-NSP10 SARS COV-2 protein
09 August 2022 – Molecular docking and molecular dynamics studies represent an initial step, being indicative for future in vitro studies of dihydroagarofuran and myristicin, as possible pharmacological tools for COVID-19
The mechanism of RNA capping by SARS-CoV-2
09 August 2022 – Collectively, our results reveal an unconventional mechanism by which SARS-CoV-2 caps its RNA genome, thus exposing a new target in the development of antivirals to treat COVID-19
Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study
08 August 2022 – We found waning vaccine protection of BNT162b2 against symptomatic COVID-19 infection among adolescents in Brazil and Scotland from 27 days after the second dose. However, protection against severe COVID-19 outcomes remained high at 98 days or more after the second dose in the omicron-dominant period. Booster doses for adolescents need to be considered
Direct capture of neutralized RBD enables rapid point-of-care assessment of SARS-CoV-2 neutralizing antibody titer
04 August 2022 – This methodology demonstrated superior performance in assessing NAb titer compared to either measurement of total anti-spike immunoglobulin G titer or quantification of the absolute reduction in binding between ACE2 and RBD
Multivalent ACE2 engineering-a promising pathway for advanced coronavirus nanomedicine development
04 August 2022 – Beyond coronaviruses, these approaches will serve as a paradigm to develop new and improved treatment technologies against pathogens that use ACE2 receptor for invasion
Scope of repurposed drugs against the potential targets of the latest variants of SARS-CoV-2
03 August 2022 – The interaction modelling of some important repurposed drugs has also been elucidated. Furthermore, the merits and demerits of drug repurposing are also discussed, with a focus on the scope and applications of the latest advancements in repurposing
Allosteric Binding Sites of the SARS-CoV-2 Main Protease: Potential Targets for Broad-Spectrum Anti-Coronavirus Agents
02 August 2022 – This review paper gives a detailed insight into the feasibility of developing new Mpro inhibitors to act as a potential treatment for the COVID-19 disease
Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron
29 July 2022 – These findings suggest an epitope-targeting strategy to identify potent and broadly neutralizing antibodies for design of pan-sarbecovirus vaccines and antibody therapeutics
Omicron SARS-CoV-2 epidemic in England during February 2022: A series of cross-sectional community surveys
28 July 2022 – The Omicron wave of COVID-19 in England peaked in January 2022 resulting from the rapid transmission of the Omicron BA.1 variant. We investigate the spread and dynamics of the SARS-CoV-2 epidemic in the population of England during February 2022, by region, age and main SARS-CoV-2 sub-lineage
A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
27 July 2022 – We report a live-attenuated SARS-CoV-2 vaccine candidate with (i) re-engineered viral transcription regulator sequences and (ii) deleted open-reading-frames (ORF) 3, 6, 7, and 8 (∆3678)
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines
27 July 2022 – Although the Omicron variant (BA.1, BA.1.1, and BA.2) shows the most escape from neutralization, sera collected after a third dose of vaccine (booster sera) retain moderate neutralizing activity against that variant. Therefore, vaccination remains an effective strategy during the COVID-19 pandemic
Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial
22 July 2022 – Vaccination has helped to mitigate the COVID-19 pandemic. Ten traditional and novel vaccines have been listed by the World Health Organization for emergency use. Additional alternative approaches may better address ongoing vaccination globally, where there remains an inequity in vaccine distribution
Neutralising antibody responses to SARS-CoV-2 omicron among elderly nursing home residents following a booster dose of BNT162b2 vaccine: A community-based, prospective, longitudinal cohort study
22 July 2022 – The protective immunity against omicron following a BNT162b2 Pfizer booster dose among elderly individuals (ie, those aged >65 years) is not well characterised
BNT162b2 Vaccine Effectiveness against Omicron in Children 5 to 11 Years of Age
21 July 2022 – The cumulative incidence of each outcome in the two study groups through January 7, 2022, was estimated with the use of the Kaplan–Meier estimator, and vaccine effectiveness was calculated as 1 minus the risk ratio. Vaccine effectiveness was also estimated in age subgroups
Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age
20 July 2022 – Since it was first identified in early November 2021, the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread quickly and replaced the B.1.617.2 (delta) variant as the dominant variant in many countries. Data on the real-world effectiveness of vaccines against the omicron variant in children are lacking
Effectiveness of BBIBP-CorV, BNT162b2 and mRNA-1273 vaccines against hospitalisations among children and adolescents during the Omicron outbreak in Argentina: A retrospective cohort study
16 July 2022 – Many countries started the vaccination rollout of children in 2021; still, information about effectiveness in the real-world setting is scarce. The aim of our study was to evaluate vaccine effectiveness (VE) against COVID-19-associated-hospitalisations in the 3–17-year population during the Omicron outbreak
Post-recovery COVID-19 and incident heart failure in the National COVID Cohort Collaborative (N3C) study
15 July 2022 -In conclusion, COVID-19 hospitalization is associated with increased risk of incident heart failure
SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial
12 July 2022 – Additional outpatient therapies which are readily accessible will be essential to reduce COVID-19 illness progression in high risk individuals. Especially as the virus continues to mutate with greater transmissibility despite increased global vaccination
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies
11 July 2022 – In recent months, Omicron variants of SARS-CoV-2 have become dominant in many regions of the world, and case numbers with Omicron subvariants BA.1 and BA.2 continue to increase. Due to numerous mutations in the spike protein, the efficacy of currently available vaccines, which are based on Wuhan-Hu 1 isolate of SARS-CoV-2, is reduced, leading to breakthrough infections. Efficacy of monoclonal antibody therapy is also likely impaired
Safety and efficacy of mesenchymal stem cells in severe/critical patients with COVID-19: A systematic review and meta-analysis
09 July 2022 – The present study aims to better understand the efficacy and safety of mesenchymal stromal cells (MSCs) in treating severe/critical patients with COVID-19
Robust long-term immunity to SARS-CoV-2 in patients recovered from severe COVID-19 after interleukin-6 blockade
08 July 2022 – Whether interleukin-6 (IL-6) blockade in patients with COVID-19 will affect the protective immunity against SARS-CoV-2 has become an important concern for anti-IL-6 therapy. We aimed to investigate the effects of IL-6 blockade on long-term immunity to SARS-CoV-2
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
07 July 2022 – Previous infection alone, BNT162b2 vaccination alone, and hybrid immunity all showed strong effectiveness (>70%) against severe, critical, or fatal Covid-19 due to BA.2 infection. Similar results were observed in analyses of effectiveness against BA.1 infection and of vaccination with mRNA-1273
Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine
04 July 2022 – In hamsters, two doses of the vaccine attenuated severe pneumonia and reduced inflammatory infiltrates after a challenge with live SARS-CoV-2. Inhalable and room-temperature-stable virus-like particles may become promising vaccine candidates
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection
29 June 2022 – Single-dose vaccination targeted to those previously infected may provide at least as good protection to two-dose vaccination among those without previous infection
Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance
16 June 2022 – Among the four sublineages of Omicron, the predicted VE varied between 11.9% and 33.3%, with the highest VE predicted against BA.1 and the lowest against BA.2, using the mRNA vaccine platform. The VE-GD framework enables predictions of vaccine protection in real time and offers a rapid evaluation method against novel variants that may inform vaccine deployment and public health responses
Expansion of cytotoxic tissue-resident CD8+ T cells and CCR6+CD161+ CD4+ T cells in the nasal mucosa following mRNA COVID-19 vaccination
10 June 2022 – Stimulation of nasal CD8+ T cells with SARS-CoV-2 spike peptides elevates expression of CD107a at 2- and 6-months (p = 0.0096) post second vaccine dose, with a subset of donors also expressing increased cytokines. These data suggest that nasal T cells may be induced and contribute to the protective immunity afforded by this vaccine
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
09 June 2022 – A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
09 June 2022 – Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provides natural immunity against reinfection. Recent studies have shown waning of the immunity provided by the BNT162b2 vaccine. The time course of natural and hybrid immunity is unknown
Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection
07 June 2022 – The SAM vaccine is currently being evaluated in clinical trials as both a homologous prime-boost regimen at low doses and as a boost following heterologous prime
Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine ZF2001 in Adults
02 June 2022 – In a large cohort of adults, the ZF2001 vaccine was shown to be safe and effective against symptomatic and severe-to-critical Covid-19 for at least 6 months after full vaccination
Alterations of blood monocyte subset distribution and surface phenotype are linked to infection severity in COVID-19 inpatients
02 May 2022 – These alterations of the myeloid leukocyte compartment during acute COVID-19 may be hallmarks of inefficient viral control and immune hyper-activation and may and help at risk prediction and treatment optimization
How effective is rescue therapeutic plasma exchange in treatment of SARS-Coronavirus-2?
01 May 2022 – SARS-CoV-2 patients who failed all other therapies had significant mortality with therapeutic plasma exchange; however, their survival was better than SARS-CoV-2 patients with stage 3 acute renal failure
Comprehensive Role of SARS-CoV-2 Spike Glycoprotein in Regulating Host Signaling Pathway
29 April 2022 – In this review, we summarize the molecular mechanisms of interaction between S protein and host factors, especially receptor-mediated viral modulation of host signaling pathways, and highlight the progression on potential therapeutic targets, prophylactic and therapeutic agents for prevention and treatment of SARS-CoV-2 infection
Phosphate-regulated expression of the SARS-CoV-2 receptor-binding domain in the diatom Phaeodactylum tricornutum for pandemic diagnostics
29 April 2022 – Our study shows that P. tricornutum is a scalable system with minimal biocontainment requirements for the inducible production of SARS-CoV-2 or other coronavirus antigens for pandemic diagnostics
Alterations in microbiota of patients with COVID-19: potential mechanisms and therapeutic interventions
29 April 2022 – This treatment strategy could modulate host microbiota and mitigate virus-induced inflammation
The Role of Autologous Micrografts Injection from The Scalp Tissue in The Treatment of Covid-19 Associated Telogen Effluvium: Clinical and Trichoscopic Evaluation
29 April 2022 – Autologous micrograft of the scalp showed marked improvement in the treatment of COVID 19 Telogen effluvium
A raising dawn of pentoxifylline in management of inflammatory disorders in Covid-19
29 April 2022 – Taken together, PTX seems to be an effective agent against Covid-19 severity
Breakthrough SARS-CoV-2 infections with the delta (B.1.617.2) variant in vaccinated patients with immune-mediated inflammatory diseases using immunosuppressants: a substudy of two prospective cohort studies
29 April 2022 – The incidence and severity of SARS-CoV-2 breakthrough infections in patients with immune-mediated inflammatory diseases on immunosuppressants was similar to that in controls. However, caution might still be warranted for those on anti-CD20 therapy and those with traditional risk factors
Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: A national post-authorization pharmacovigilance study
29 April 2022 – Very few cases of hyper-inflammatory syndrome with multi-organ involvement occurred following COVID-19 mRNA vaccine in 12–17-year-old children. The low reporting rate of this syndrome, compared to the rate of post-SARS-CoV-2 MIS-C in the same age-group, largely supports the vaccination in a context of an important circulation of SARS-CoV-2
Intramuscular AZD7442 (Tixagevimab–Cilgavimab) for Prevention of Covid-19
20 April 2022 – A single dose of AZD7442 had efficacy for the prevention of Covid-19, without evident safety concerns
Effect of BTN162b2 and Coronavac boosters on humoral and cellular immunity of individuals previously fully vaccinated with Coronavac against SARS-CoV-2: A longitudinal study
19 April 2022 – For this purpose, we aimed to determine the effects of BNT162b2 (BNT) and CoronaVac (CV) boosters on the humoral and cellular immunity of individuals who had two doses of CV vaccination
Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial
18 April 2022 – Previous exposure to SARS-CoV-2 decreased the risk and severity of subsequent COVID-19 infection, even against newly emerging variants. Protection is further enhanced by one or two doses of SCB-2019
An endogenously activated antiviral state restricts SARS-CoV-2 infection in differentiated primary airway epithelial cells
18 April 2022 – An endogenously activated IFNλ response, possibly due to genetic differences, may be one explanation for the differences in susceptibility to SARS-CoV-2 infection in humans. Importantly, our work supports the continued exploration of IFNλ as a potential pharmaceutical against SARS-CoV-2 infection
Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis
14 April 2022 – Two vaccine doses were found to be highly effective against both SARS-CoV-2 infection and severe COVID-19 outcomes in patients with rheumatoid arthritis, ankylosing spondylitis, psoriasis, and inflammatory bowel disease during the study period. Research is needed to determine the durability of effectiveness of three doses over time, particularly against emerging variants
PipeCoV shows better performance when compared to well-established SARS-CoV-2 pipelines, with a lower content of Ns and higher genome coverage when compared to the Wuhan reference. It also provides a variant report not offered by other tested pipelines
14 April 2022 – Here, we discussed about various therapeutic agents, their clinical trials, and limitations of trials for the management of COVID-19. Further, we have also spotlighted different vaccines in research in combating COVID-19
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
14 April 2022 – Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns
Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
13 April 2022 – A fourth dose of the BNT162b2 vaccine was effective in reducing the short-term risk of Covid-19–related outcomes among persons who had received a third dose at least 4 months earlier
PipeCoV: a pipeline for SARS-CoV-2 genome assembly, annotation and variant identification
13 April 2022 – PipeCoV shows better performance when compared to well-established SARS-CoV-2 pipelines, with a lower content of Ns and higher genome coverage when compared to the Wuhan reference. It also provides a variant report not offered by other tested pipelines
Dosing interval strategies for two-dose COVID-19 vaccination in 13 middle-income countries of Europe: Health impact modelling and benefit-risk analysis
11 April 2022 – We infer that longer dosing intervals of over six months could reduce COVID-19 mortality in MICs of Europe. Certain parameters, such as rapid waning of first-dose induced immunity and increased immune escape through the emergence of VOCs, could significantly shorten the optimal dosing intervals
Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)
09 April 2022 – The Abdala vaccine was safe, well tolerated, and induced humoral immune responses against SARS-CoV-2. These results, in the context of the emergency COVID-19 pandemic, support the 50 μg dose, applied in a 0-14-28 days schedule, for further clinical trials to confirm vaccine efficacy
Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern
08 April 2022 – This preliminary data shows that Omicron (R346K) variant infection can produce moderate to severe lung disease similar to that of the Delta variant and the neutralizing antibodies produced in response to Omicron (R346K) variant infection shows poor neutralizing ability against other co-circulating SARS-CoV-2 variants like Delta which necessitates caution as it may lead to increased cases of reinfection
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
08 April 2022 – After 5 months, vaccine effectiveness remained high among individuals younger than 55 years. Booster doses restore vaccine effectiveness. Adverse reactions after booster doses were similar to those after the second dose. Homologous booster schedules had fewer reported systemic side-effects than heterologous boosters
Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines
07 April 2022 – Among individuals with prior COVID-19, one dose of BNT162b2 or two doses of CoronaVac could induce detectable serum Omicron NAb. Our result would be particularly important for guiding vaccine policies in countries with COVID-19 vaccine shortage
FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation
06 April 2022 – These findings taken together suggest that antibody-mediated SARS-CoV-2 uptake by monocytes/macrophages triggers inflammatory cell death that aborts production of infectious virus but causes systemic inflammation that contributes to COVID-19 pathogenesis
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
05 April 2022 – Rates of confirmed SARS-CoV-2 infection and severe Covid-19 were lower after a fourth dose of BNT162b2 vaccine than after only three doses. Protection against confirmed infection appeared short-lived, whereas protection against severe illness did not wane during the study period
Characterisation and natural progression of SARS-CoV-2 infection in ferrets
05 April 2022 – Due to the absence of clinical signs after viral challenge, our ferret model is appropriate for studying asymptomatic SARS-CoV-2 infections and most suitable for use in vaccine efficacy studies
David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors
05 April 2022 – This review summarizes different evolution platforms that have been used to enhance ACE2-Fc (i.e., immunoadhesins) as potential therapeutics for the current pandemic or future outbreaks of SARS-associated betacoronaviruses
SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies
05 April 2022 – These findings underscore the potential benefit of mRNA vaccine boosters for protection against Omicron and the need for rapid development of antibody therapeutics that maintain potency against emerging variants
Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study
05 April 2022 – The multi-step virtual screening analyses suggested that compounds CASAntiV-865453-58-3, CASAntiV-865453-40-3, and CASAntiV-2043031-84-9 could be used as effective therapeutic agents for the treatment of SARS-CoV-2
Neutralizing activity of BBIBP-CorV vaccine-elicited sera against Beta, Delta and other SARS-CoV-2 variants of concern
04 April 2022 – Our work show diminished neutralization potency against multiple variants in vaccine-elicited sera, which indicates the potential need for additional boost vaccinations
Dichlorophenylpyridine-Based Molecules Inhibit Furin through an Induced-Fit Mechanism
04 April 2022 – He discovered furin conformation offers new opportunities for structure-based drug Discovery
Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2
02 April 2022 – This knowledge could further help understanding SARS-CoV2 infection and anti-viral mechanisms of plant-based therapeutics
Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): the interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India
02 April 2022 – In this interim analysis, ZyCoV-D vaccine was found to be efficacious, safe, and immunogenic in a phase 3 trial
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study
01 April 2022 – This could reflect appropriate clinical decision making, but the possibility of inequitable access to life-saving care should be considered
Induction of SARS-CoV-2 neutralizing antibodies by CoronaVac and BNT162b2 vaccines in naïve and previously infected individuals
01 April 2022 – The decay of nAbs titres in previously infected individuals over time indicates that vaccination is needed to boost humoral memory responses. Immunization of naïve individuals with two doses of CoronaVac induced nAbs titres that were significantly lower to that of convalescent patients, and similar to vaccination with one dose of BTN162b2
Telomere-length dependent T-cell clonal expansion: A model linking ageing to COVID-19 T-cell lymphopenia and mortality
31 March 2022 – Short HCTL might increase vulnerability of many older adults, and some younger individuals with inherently short HCTL, to COVID-19 T-cell lymphopenia and severe disease
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study
31 March 2022 – All four vaccines conferred additional protection against symptomatic infections and severe outcomes among individuals with previous SARS-CoV-2 infection. The provision of a full vaccine series to individuals after recovery from COVID-19 might reduce morbidity and mortality
BNT162b2 Protection against the Omicron Variant in Children and Adolescents
30 March 2022 – BNT162b2 vaccination reduced the risk of omicron-associated hospitalization by two thirds among children 5 to 11 years of age. Although two doses provided lower protection against omicron-associated hospitalization than against delta-associated hospitalization among adolescents 12 to 18 years of age, vaccination prevented critical illness caused by either variant
Early Outpatient Treatment for Covid-19 with Convalescent Plasma
30 March 2022 – In participants with Covid-19, most of whom were unvaccinated, the administration of convalescent plasma within 9 days after the onset of symptoms reduced the risk of disease progression leading to hospitalization
Effect of Early Treatment with Ivermectin among Patients with Covid-19
30 March 2022 – Treatment with ivermectin did not result in a lower incidence of medical admission to a hospital due to progression of Covid-19 or of prolonged emergency department observation among outpatients with an early diagnosis of Covid-19
Upstream cell culture process characterization and in-process control strategy development at pandemic speed
29 March 2022 – The strategies we present may be applied to accelerate late-stage process development for other biologics to reduce timelines
Human Galectin-9 Potently Enhances SARS-CoV-2 Replication and Inflammation in Airway Epithelial Cells
29 March 2022 – findings suggest that manipulation of Gal-9 should be explored as a therapeutic strategy for SARS-CoV-2 infection
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial
29 March 2022 – Ruxolitinib 5 mg twice per day showed no benefit in the overall study population. A larger sample is required to determine the clinical importance of trends for increased efficacy in patient subgroups
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic
28 March 2022 – This demonstrates that TTSP-mediated proteolytic maturation of spike is critical for SARS-CoV-2 infection in vivo and suggests that N-0385 provides a novel effective early treatment option against COVID-19 and emerging SARS-CoV-2 VOCs
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
23 March 2022 – A third dose of the BNT162b2 vaccine administered a median of 10.8 months after the second dose provided 95.3% efficacy against Covid-19 as compared with two doses of the BNT162b2 vaccine during a median follow-up of 2.5 months.
SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study
23 March 2022 – This study suggests that cross-reactive SARS-CoV-2-specific T-cell responses could be particularly important in the protection against severe disease caused by variants of concern whereas neutralising antibody responses seem to reduce over time.
Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19
21 March 2022 -Further, treatment with a PTGDR antagonist, asapiprant, protected aged mice from lethal infection. PTGDR antagonism is one of the first interventions in SARS-CoV-2-infected animals that specifically protects aged animals, suggesting that the PLA2G2D-PGD2/PTGDR pathway is a useful target for therapeutic interventions
Effectiveness of rAd26-rAd5, ChAdOx1 nCoV-19, and BBIBP-CorV vaccines for risk of infection with SARS-CoV-2 and death due to COVID-19 in people older than 60 years in Argentina: a test-negative, case-control, and retrospective longitudinal study
15 March 2022 – The vaccines used in Argentina showed effectiveness in reducing infection and death by SARS-CoV-2 and COVID-19
Effect of mRNA Vaccine Boosters against SARS-CoV-2 Omicron Infection in Qatar
09 March 2022 – The messenger RNA (mRNA) boosters were highly effective against symptomatic delta infection, but they were less effective against symptomatic omicron infection. However, with both variants, mRNA boosters led to strong protection against Covid-19–related hospitalization and death
Clinical frailty, and not features of acute infection, is associated with late mortality in COVID-19: a retrospective cohort study
07 March 2022 – In our cohort, late mortality in COVID-19 patients is more strongly associated with premorbid clinical frailty than with severity of the acute infection phase.
When RING Finger Family Proteins meet SARS-CoV-2
07 March 2022 – In this mini-review, we discuss the diverse antiviral mechanisms of RNF proteins and viral immune evasion in an RNF proteins-dependent manner. Understanding the crosstalk between RNF proteins and SARS-CoV-2 infection would help design potential novel targets for COVID-19 treatment.
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19
08 March 2022 – The pharmacological targets of these substances are described here for their possible synergism in counteracting SARS-CoV-2 replication and progression of the infection from the upper respiratory airways to the blood, avoiding vascular complications and cytokine and bradykinin storms
Monobodies with potent neutralizing activity against SARS-CoV-2 Delta and other variants of concern
7 March 2022 – The obtained monobodies would be useful as neutralizing proteins against current and potentially hazardous future SARS-CoV-2 variants
Infection control and the prevalence, management and outcomes of SARS-CoV-2 infections in mental health wards in London, UK: lessons learned from wave 1 to wave 2
08 March 2022 – Availability of infection control measures in line with a policy of parity of esteem between mental and physical health appears to have lowered within-hospital COVID-19 infections and deaths. Cautious management of vulnerable patient groups including mental health patients may reduce the future impact of COVID-19
Antimicrobial Peptides: A plausible approach for COVID-19 treatment
07 Mar 2022- Antiviral peptides are anticipated to be blockbuster drugs for the management of this serious infection because of their formulation and therapeutic advantages. Although they may act on different pathways, AVPs having a multi-targeted approach are considered to have the upper hand in the management of this infection
Effects and safety of COVID-19 vaccination on assisted reproductive technology and pregnancy: A comprehensive review and joint statements of the KSRM, the KSRI, and the KOSAR
February 22, 2022 – Accordingly, it is recommended that pregnant women receive COVID-19 vaccination. There is no rationale for adverse effects, or clinical cases of adverse reactions, in mothers or neonates after COVID-19 vaccination in lactating women. Instead, antibodies to SARS-CoV-2 can be delivered through breast milk. Therefore, breastfeeding mothers should consider vaccination. In summary, active administration of COVID-19 vaccines will help ensure the safe implementation of ART, pregnancy, and breastfeeding.
Inhibition of SARS-CoV-2 replication by zinc gluconate in combination with hinokitiol
1 March 2022 – Our studies provide the direct experimental evidence that elevated intracellular zinc concentration directly inhibits SARS-CoV-2 replication and suggest the potential benefits to use the zinc supplements for coronavirus disease 2019 (COVID-19) treatment.
The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges
1 March 2022 – The ACT trials will determine the efficacy of anti-inflammatory therapy with colchicine and antithrombotic therapy with aspirin given alone or in combination with rivaroxaban across the spectrum of mild, moderate, and severe COVID-19. Lessons learned from the conduct of these trials will inform planning of future trials
Optimizing peptide inhibitors of SARS-Cov-2 nsp10/nsp16 methyltransferase predicted through molecular simulation and machine learning
28 February 2022 – This results in the prediction that the H80R variant is a solid new candidate for potential new testing. We envision that this new lead is the beginning of a reputable foundation of a new computational method that combats coronaviruses and that is beneficial for new peptide drug development.
SARS-CoV-2 is associated with changes in brain structure in UK Biobank
07 March 2022 – These mainly limbic brain imaging results may be the in vivo hallmarks of a degenerative spread of the disease via olfactory pathways, of neuroinflammatory events, or of the loss of sensory input due to anosmia. Whether this deleterious impact can be partially reversed, or whether these effects will persist in the long term, remains to be investigated with additional follow up.
Whole genome sequencing reveals host factors underlying critical Covid-19
07 March 2022 – Our results are broadly consistent with a multi-component model of Covid-19 pathophysiology, in which at least two distinct mechanisms can predispose to life-threatening disease: failure to control viral replication, or an enhanced tendency towards pulmonary inflammation and intravascular coagulation. We show that comparison between critically-ill cases and population controls is highly efficient for detection of therapeutically-relevant mechanisms of disease
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
03 March 2022 – These findings indicate that these three sublineages of Omicron are antigenically equidistant from the wild-type SARS-CoV-2 and thus similarly threaten the efficacies of current vaccines. BA.2 also exhibited marked resistance to 17 of 19 neutralizing monoclonal antibodies tested, including S309 (sotrovimab)7, which had retained appreciable activity against BA.1 and BA.1+R346K2-4,6. This new finding shows that no authorized monoclonal antibody therapy could adequately cover all sublineages of the Omicron variant, except for the recently authorized LY-CoV1404 (bebtelovimab)
Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant
March 2, 2022Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
March 2, 2022 – Primary immunization with two doses of ChAdOx1 nCoV-19 or BNT162b2 vaccine provided limited protection against symptomatic disease caused by the omicron variant. A BNT162b2 or mRNA-1273 booster after either the ChAdOx1 nCoV-19 or BNT162b2 primary course substantially increased protection, but that protection waned over time.
Variation in the COVID-19 infection–fatality ratio by age, time, and geography during the pre-vaccine era: a systematic analysis
February 24, 2022 – During the pre-vaccine period, the estimated 33% decrease in median IFR over 8 months suggests that treatment for COVID-19 has improved over time. Estimating IFR for the pre-vaccine era provides an important baseline for describing the progression of COVID-19 mortality patterns.
Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination
21 February 2022 – This antiviral would be effective against current and future viral variants, since 3CL is not modified in them. The FDA approved this antiviral in November 2021 and EMA is in the final evaluation phase
Molnupiravir: First Approval
20 February 2022 – This article summarizes the milestones in the development of molnupiravir leading to this first approval for COVID-19
Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review
19 February 2022 – Future work basedon large-scale randomized, double-blind clinical trials to evaluate herbal medicines andtheir active ingredients in the treatment of new COVID-19 will be very meaningful
Evaluation of antibody response after two doses of the sinovac vaccine and the potential need for booster doses in cancer patients
18 February 2022 – As a result, the expected antibody response was not obtained with two doses of the Sinovac vaccine. Therefore, if the Sinovac vaccine is to be preferred for these patients, the appropriate booster time for the 3rd dose should be determined or other vaccines, such as mRNA vaccines, with reported higher antibody responses should be considered
A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
18 February 2022 – This review is principally focused on the mechanisms of NRTIs to introduce them as potential therapies for COVID-19. However, further in vitro and in vivo investigations will offer helpful information for the identification of drug candidates as a part of COVID-19 management
High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV
18 February 2022 – The high titer of IgGSP supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view
Immune transcriptome analysis of COVID-19 patients infected with SARS-CoV-2 variants carrying the E484K escape mutation identifies a distinct gene module
18 February 2022 – Our study offers insights into distinct molecular immune responses elicited by SARS-CoV-2 variants carrying the E484K escape mutation throughout the COVID-19 disease
Hypothesis: How far are we from predicting multi-drug interactions during treatment for COVID-19 infection?
18 February 2022 – Whether or not this approach can be extended to other diseases is uncertain. Still, we believe it represents a valuable pharmacological insight to help improve clinical outcomes for severely ill patients
Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19
16 February 2022 – Treatment of symptomatic Covid-19 with nirmatrelvir plus ritonavir resulted in a risk of progression to severe Covid-19 that was 89% lower than the risk with placebo, without evident safety concerns
Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19
16 February 2022 – Among patients who had recovered from Covid-19, the receipt of at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection
Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection
16 February 2022 – Two doses of BNT162b2 vaccine were associated with high short-term protection against SARS-CoV-2 infection; this protection waned considerably after 6 months. Infection-acquired immunity boosted with vaccination remained high more than 1 year after infection
Bat coronaviruses related to SARS-CoV-2 and infectious for human cells
16 February /2022 – Our findings therefore indicate that bat-borne SARS-CoV-2-like viruses potentially infectious for humans circulate in Rhinolophus spp. in the Indochinese peninsula
Molecular docking studies of phytochemicals from Terminalia chebula for identification of potential multi-target inhibitors of SARS-CoV-2 proteins
16 February 2022 – We believe that our study has the potential to help the scientific communities to develop the multi-target drug from T. chebula to combat against the deadly pathogen SARS-COV-2 in future with the support of extensive wet lab analysis
Human/SARS-CoV-2 Genome-Scale Metabolic Modeling to Discover Potential Antiviral Targets for COVID-19
15 February 2022 – Our predictions also indicate that CTP and UTP inhibition blocks viral RNA replication through a similar mechanism to that of molnupiravir
The Human Nose Organoid Respiratory Virus Model: an Ex Vivo Human Challenge Model To Study Respiratory Syncytial Virus (RSV) and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pathogenesis and Evaluate Therapeutics
15 February 2022 – Our study reports a breakthrough in both the development of a novel nose organoid model and in our understanding of the host cellular response to RSV and SARS-CoV-2 infection
Inhibition of Protein N-Glycosylation Blocks SARS-CoV-2 Infection
15 February 2022 – As new SARS-CoV-2 variants, with various degrees of resistance against current vaccines, are likely to continue appearing, halting virus glycosylation using repurposed human drugs could result in a complementary strategy to reducing the spread of COVID-19 worldwide
Genome-Wide Characterization of SARS-CoV-2 Cytopathogenic Proteins in the Search of Antiviral Targets
15 February 2022 – Since cellular oxidative stress and inflammation contribute to cell death and tissue damage linked to the severity of COVID-19, our findings suggest that ORF3a is a promising, novel therapeutic target against COVID-19
Monoclonal antibody therapies in the management of SARS-CoV-2 infection
14 February 2022 – This article highlights the accelerated regulatory processes established to facilitate the review and approval of potential therapies. An overview of treatment approaches for SARS-CoV-2 infection, with detailed examination of the preclinical and clinical evidence supporting the use of NAbs, is provided
Stapled peptides as potential inhibitors of SARS-CoV-2 binding to the hACE2 receptor
14 February 2022 – Several independent research initiatives have investigated the inhibitory effect of stapled peptides on binding of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19, to its receptor, angiotensin-converting-enzyme 2 (ACE2). These stapled peptides, which mimic Helix 1 of the human ACE2 receptor, have demonstrated mixed ability to prevent infection with SARS-CoV-2 in cell-based studies
Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis
14 February 2022 – The delta variant transmits more quickly in households than the alpha variant, which can be attributed to faster depletion of susceptible individuals in households and a possible decrease in the intrinsic generation time. Interventions such as contact tracing, testing, and isolation might be less effective if transmission of the virus occurs quickly
Identifying absorbable bioactive constituents of yupingfeng powder acting on COVID-19 through integration of UPLC-Q/TOF-MS and network pharmacology analysis
09 February 2022 – The approach of combining UPLC-Q/TOF-MS with network pharmacology is an effective tool to identify potentially bioactive constituents of YPF and its key targets on treatment of COVID-19
Severe COVID-19 during pregnancy treated with pulse corticosteroid therapy and mid-trimester termination: A case report
09 February 2022 – Due to the specific immune response, pregnant women with COVID-19 may differ from others in their clinical presentation, especially the probability of classic acute respiratory distress syndrome (ARDS). This report provides evidence related to the efficacy of pulse corticosteroids on this group and the influence of the mid-trimester termination on recovery
Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S
09 February 2022 – A single dose of Ad26.COV2.S provided 52.9% protection against moderate to severe–critical Covid-19. Protection varied according to variant; higher protection was observed against severe Covid-19, medical intervention, and death than against other end points and lasted for 6 months or longer
06 February 2022 – The findings of this study support the selection of effective CCP combined with use of A/UVA-PRT in the production of CCP for patients with COVID-19
04 February 2022 – We found progressively waning vaccine effectiveness against SARS-CoV-2 infection of any severity across all subgroups, but the rate of waning differed according to vaccine type. With respect to severe COVID-19, vaccine effectiveness seemed to be better maintained, although some waning became evident after 4 months
02 February 2022 – Because the androgen-responsive serine protease TMPRSS2 is involved in cleaving the SARS-CoV-2 spike protein allowing the virus to enter the cell, therefore, direct TMPRSS2 inhibition will inhibit virus activation and disease progression which make it an important target for drug discovery
01 February 2022 – In this article, we propose a mathematical model for examining the effects of antiviral treatment over viral mutation to control disease transmission. We have considered here three populations namely uninfected epithelial cells, infected epithelial cells, and SARS-CoV-2 virus
31 January 2022 – Therefore, it is highly acclaimed the requirements of the concerted efforts from multi-disciplinary basic studies and clinical trials, which improves the accurate treatment of COVID-19 and optimizes the contingency measures to emerging SARS-CoV-2 variants
The Effect of Phytocompounds of Medicinal Plants on Coronavirus (2019-NCOV) Infection
31 January 2022 – the bioactive compounds such as phenols, flavonoids, monoterpenes, and phenylpropanoids, derived from several herbs such as Eucalyptus globulus, Mentha spicata, Nigella sativa, Rosmarinus officinalis, Thymus capitatus and Zingiber officinale could be used to develop formal drugs against several diseases with no or minimal side effects
29 January 2022 – Moreover, viral RNA was abundant in the cerebrum of K18-hACE2 Tg mice, including the olfactory bulb. The K8-hACE2 Tg mouse, hACE2 Tg mouse, and hamster models could be used to investigate the pathology of SARS-CoV-2 infection in the upper respiratory tract and central nervous system. These models could help to provide a better understanding of the pathogenic process of this virus and to develop effective medications and prophylactic treatments
Human genetic and immunological determinants of critical COVID-19 pneumonia
28 January 2022 – The TLR3- and TLR7-dependent production of type I IFNs by respiratory epithelial cells and plasmacytoid dendritic cells, respectively, is essential for host defense against SARS-CoV-2. In ways that can depend on age and sex, insufficient type I IFN immunity in the respiratory tract during the first few days of infection may account for the spread of the virus, leading to pulmonary and systemic inflammation
Homologous and Heterologous Covid-19 Booster Vaccinations
26 January 2022 – Homologous and heterologous booster vaccines had an acceptable safety profile and were immunogenic in adults who had completed a primary Covid-19 vaccine regimen at least 12 weeks earlier
The Transmembrane Protease TMPRSS2 as a Therapeutic Target for COVID-19 Treatment
25 January 2022 – In this review, we provide an overview of the role of TMPRSS2 in the entry processes of different respiratory viruses. We then review the different classes of TMPRSS2 inhibitors and their clinical development, with a focus on COVID-19 treatment
Potential Genes Associated with COVID-19 and Comorbidity
24 January 2022 – The study provides a basis for further investigation of genes and pathways with predictive value for the risk of infection and prognosis and could help guide drug and vaccine development to improve treatment efficacy and the development of personalised treatments, especially for COVID-19 individuals with common comorbidities
21 January 2022 – Antibody concentrations were low at 6 months after previous immunisation with two doses of CoronaVac. However, all four vaccines administered as a third dose induced a significant increase in binding and neutralising antibodies, which could improve protection against infection. Heterologous boosting resulted in more robust immune responses than homologous boosting and might enhance protection
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
19 January 2022 – The Ad26.COV2.S and mRNA boosters had an acceptable safety profile and were immunogenic in health care workers who had received a priming
dose of Ad26.COV2.S vaccine. The strongest responses occurred after boosting with mRNA-based vaccines. Boosting with any available vaccine was better than not boosting
19 January 2022 – Following a sequential in-depth molecular docking and dynamics simulation, we report the compounds that exhibited promising efficacy against TMPRSS2. The molecular docking and MM/PBSA free energy calculation study indicates these compounds carry excellent binding affinity against TMPRSS2 and found them more effective than camostat
14 January 2022 – Our findings demonstrated an MD-associated mechanism underlying SARS-CoV-2-induced T lymphocytopenia and functional impairment during the acute phase of infection
14 January 2022 – Those cells also showed aberrant levels of mitochondrial superoxide and lipid peroxidation, both hallmarks of the oxidative stress response, which strongly correlated with caspase-1 activity. In addition, we found that NLRP3 inflammasome-derived IL-1β secretion by SARS-CoV-2-exposed monocytes in vitro was partially dependent on lipid peroxidation. Importantly, altered inflammasome and stress responses persisted after short-term patient recovery. Collectively, our findings suggest oxidative stress/NLRP3 signaling pathway as a potential target for host-directed therapy to mitigate early COVID-19 hyperinflammation and also its long-term outcomes
14 January 2022 – Surprisingly, despite severe lymphopenia the patient developed SARS-CoV-2-specific antibodies within 15 days, which was followed by clearance of SARS-CoV-2 and EBV with resolution of symptoms. Thereafter, parameters of immune dysregulation such as lymphopenia and B-cell dyshomeostasis, the latter characterised by elevated CD21low B cells and autoantibody expression, normalised. Moreover, we observed complete response of active chronic GvHD to treatment
ACE2 Shedding and the Role in COVID-19
14 January 2022 – Elevated concentrations of sACE2 are more related to disease. Recombinant human ACE2, an exogenous soluble ACE2, can be used to supplement endogenous ACE2. It may represent a potent COVID-19 treatment in the future. However, the specific administration concentration needs to be further investigated
14 January 2022 – Low-to-moderate dose short-term methylprednisolone can accelerate the chest CT imaging absorption of COVID-19 so as to improve symptoms and alleviate the condition in a short term, reduce the hospital stay, meanwhile avoid severe COVID-19 phases. The protocol has been proven to be effective and safe in clinical use
Angiotensin II Infusion in COVID-19: An International, Multicenter, Registry-based Study
14 January 2022 – Within the limitations of such a study design, our findings confirm previous observations of a potentially positive effect of ANGII on blood pressure and FiO2 but no effect on patient-centered outcomes
Multiple evanescent white dot syndrome following vaccination for COVID-19
14 January 2022 – Multiple evanescent white dot syndrome (MEWDS) is an acute, usually unilateral, retinal disorder of unknown etiology that predominantly occurs in healthy young women
13 January 2022 – Combinations of the inflammatory mediators IFN-β, PTX3, IFN-γ, IFN-λ2/3 and IL-6 associated with LC with 78.5–81.6% accuracy. This work defines immunological parameters associated with LC and suggests future opportunities for prevention and treatment
Potential therapeutic options for COVID-19: an update on current evidence
13 January 2022 – The present study summarized current evidence of these therapeutic approaches to assess their efficacy and safety for COVID-19 treatment
Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents
12 January 2022 – Among hospitalized adolescent patients, two doses of the BNT162b2 vaccine were highly effective against Covid-19–related hospitalization and ICU admission or the receipt of life support
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
12 January 2022 – We observed limited waning in vaccine effectiveness against Covid-19–related hospitalization and death at 20 weeks or more after vaccination with two doses of the ChAdOx1-S or BNT162b2 vaccine
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina
12 January /2022 – All three Covid-19 vaccines had durable effectiveness in reducing the risks of hospitalization and death. Waning protection against infection over time was due to both declining immunity and the emergence of the delta variant
07 January 2022 – Our study suggests that 5-ALA with SFC warrants accelerated clinical evaluation as an antiviral drug candidate for treating patients infected with SARS-CoV-2 variants
06 January 2022 – To evaluate the efficacy of 10 mg oral montelukast every 24 h versus placebo in improving quality of life associated with mild to moderate respiratory symptoms in patients with long COVID as measured with the COPD Assessment Test (CAT) questionnaire
06 January 2022 – Our data suggested that obatoclax should be further explored as clinical drug for the treatment of COVID-19
The societal economic value of COVID-19 vaccines in the United States
06 January 2022 – The magnitude of economic benefit from vaccination highlights the need for coordinated policy decisions to support continued widespread vaccine uptake in the US
Neutralizing antibody: a savior in the Covid-19 disease
06 January 2022 – In this review, we have discussed details about neutralizing antibodies and their role in combating Covid-19 disease
Effect of Covid-19 Vaccination on Transmission of Alpha and Delta Variants
05 January 2022 – Vaccination was associated with a smaller reduction in transmission of the delta variant than of the alpha variant, and the effects of vaccination decreased over time. PCR Ct values at diagnosis of the index patient only partially explained decreased transmission
01 January 2022 – Treatment with intravenous immunoglobulins, however, could mask the ability of anti-PF4-heparin antibodies to bind and activate platelets in the presence of heparin, leading to false negative results at the immunoassay functional test. Therefore, if VITT is suspected, blood samples for diagnostic confirmation should be collected prior to any treatment to improve diagnostic performance
Evolution of enhanced innate immune evasion by SARS-CoV-2
23 December 2021 – The importance of mutations outside Spike in adaptation of SARS-CoV-2 to humans is underscored by the observation that similar mutations exist in the Delta and Omicron N/Orf9b regulatory regions
Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
22 December 2021 – Among nonhospitalized patients who were at high risk for Covid-19 progression, a 3-day course of remdesivir had an acceptable safety profile and resulted in an 87% lower risk of hospitalization or death than placebo
14 December 2021 – Collectively, our data suggests that due to continuous variation in the spike glycoprotein structures, the use of coronavirus specific attachment inhibitors may not be the current choice of therapy for emerging SARS-CoV-2 VOCs. Hence, we need to proceed with a sense of urgency in this matter
High-Throughput Activity Assay for Screening Inhibitors of the SARS-CoV-2 Mac1 Macrodomain
14 December 2021 – Our study demonstrates the feasibility of identifying selective inhibitors based on ADP-ribosylhydrolase activity, paving the way for the screening of large compound libraries to identify improved macrodomain inhibitors and to explore their potential as antiviral therapies for SARS-CoV-2 and future viral threats
Controlling the Burden of COVID-19 by Manipulating Host Metabolism
13 December 2021 – Manipulating metabolic activities to control the outcome of COVID-19 has to date received minimal attention. Manipulating host metabolism will never replace vaccines to control COVID-19 but could be used as an adjunct therapy to the extent of ongoing infection
13 December 2021 – Baricitinib plus the standard of care treatment might be a potential strategy in hospitalized patients with severe COVID-19
10 December 2021 – OM-85 inhibits SARS-CoV-2 epithelial cell infection in vitro by downregulating SARS-CoV-2 receptor expression. Further studies are warranted to assess whether OM-85 may prevent and/or reduce the severity of COVID-19
09 December 2021 – These results may therefore shed more light on the relationship between PD as well as T2DM and the SARS-CoV-2 disease and their molecular underpinnings. Since dysregulation of G4Q formation by rationally designed targeting compounds affects the control of cellular processes, this study should contribute to the development of specific ligands for intervention
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
08 December 2021 – Participants who received a booster at least 5 months after a second dose of BNT162b2 had 90% lower mortality due to Covid-19 than participants who did not receive a booster
Protection against Covid-19 by BNT162b2 Booster across Age Groups
08 December 2021 – Across the age groups studied, rates of confirmed Covid-19 and severe illness were substantially lower among participants who received a booster dose of the BNT162b2 vaccine than among those who did not
Effect of Crizanlizumab, a P-Selectin Inhibitor, in COVID-19: A Placebo-Controlled, Randomized Trial
08 December 2021 – There were no significant differences between crizanlizumab and placebo for clinical endpoints. Crizanlizumab was well tolerated. Crizanlizumab may induce thrombolysis in the setting of COVID-19
The emergence, genomic diversity and global spread of SARS-CoV-2
08 December 2021 – More broadly, we highlight our currently limited understanding of coronavirus diversity in nature, the rapid spread of the virus and its variants in such an increasingly connected world, the reduced protection of vaccines, and the urgent need for coordinated global surveillance using genomic techniques
07 December 2021- Integrating unbalanced bi-random walks, Laplacian regularized least squares, molecular docking, and molecular dynamics simulation, this work initially screened a few anti-SARS-CoV-2 drugs and may contribute to preventing COVID-19 transmission
Signature of long-lived memory CD8+ T cells in acute SARS-CoV-2 infection
7 December 2021 – Tracking individual clones of SARS-CoV-2-specific CD8+ T cells, we reveal that an interferon signature marks clones giving rise to long-lived cells, whereas prolonged proliferation and mammalian target of rapamycin (mTOR) signaling are associated with clonal disappearance from the blood. Collectively, we describe a transcriptional signature that marks long-lived, circulating human memory CD8+ T cells following an acute virus infection
07 December 2021 – CoronaVac vaccine was associated with low reactogenicity, low immunogenicity but reduced incidence of COVID-19 among kidney transplant recipients. The lack of reduction in lethality rates is perhaps associated with the low percentage of patients developing humoral response after the second dose
06 December 2021 – Heterologous second dosing with m1273, but not NVX, increased transient systemic reactogenicity compared with homologous schedules. Multiple vaccines are appropriate to complete primary immunisation following priming with BNT or ChAd, facilitating rapid vaccine deployment globally and supporting recognition of such schedules for vaccine certification
5 December 2021 – Pharmacophore model analysis further revealed that the aromatic ring, hydrogen bond donor, and hydrophobic group are the essential infrastructure of Mpro inhibitors. Overall, this study applied computational simulation methods to study the interaction mechanism of HIV-1 protease inhibitors with SARS-CoV-2 Mpro, and the findings provide useful insights for the development of novel anti-SARS-CoV-2 agents for the treatment of COVID-19
Understanding the clinical utility of favipiravir (T-705) in coronavirus disease of 2019: a review
04 December 2021 – This review provides evidence-based insights and throws light on the current clinical trials examining the efficacy of favipiravir in tackling COVID-19, including its mechanism, pharmacodynamics, and pharmacokinetics
02 December 2021 – This is the first trial testing a cognitive behavioural intervention targeting severe fatigue after COVID-19. If Fit after COVID is effective in reducing fatigue severity following COVID-19, this intervention could contribute to alleviating the long-term health consequences of COVID-19 by relieving one of its most prevalent and distressing long-term symptoms
Spherical Neutralizing Aptamer Inhibits SARS-CoV-2 Infection and Suppresses Mutational Escape
02 December 2021 – Overall, the SNAP strategy provides a new direction for the development of antivirus agents against SARS-CoV-2 and other emerging coronaviruses
In-silico screening of naturally derived phytochemicals against SARS-CoV Main protease
02 December 2021 – This study paves the way towards discovering a lead used in the treatment of COVID-19 from natural sources and introduces phytomedicines with dual therapeutic effects against COVID-19 besides their original pharmacological effects
02 December 2021 – The proof of a role of these immunological phenomena on the development of COVID-19 are bases for implementation of therapeutic immunomodulatory treatments
Drug Repurposing strategies and key challenges for Covid-19 management
02 December 2021 – The key benefit of drug repurposing is drug is the wealth of information related to its safety, and easy accessibility. Altogether allows for quick access to regulatory approval as well as sophisticated clinical studies
01 December 2021 – Molecular docking simulations reveal the binding modes of C1 in the dimer interface and substrate-binding pocket of the target. In addition, C1 shows outstanding metabolic stability in the gastrointestinal tract, human plasma, and human liver microsome, suggesting that this agent has the potential to be developed as an orally administrated SARS-CoV-2 3CLpro inhibitor
01 December 2021 – Autoimmune encephalitis can occur via three possible proposed pathophysiological mechanism and can manifest during or after the acute infection period. It is more common in adult but can also occur in the paediatric patients. There were various spectra of autoantibody panels reported including antineuronal antibody, anti-gangliosides antibody and onconeural antibody. Majority of the patients responded well to the immunomodulating therapy and achieved good recovery
01 December 2021 – A screen of known viroporin inhibitors on Protein E, ORF7b, ORF10 and Protein 3a from SARS-CoV-2 revealed inhibition of Protein E and ORF7b by emodin and xanthene, the latter also blocking Protein 3a. This illustrates a general potential of well-known ion channel blockers against SARS-CoV-2 and specifically a dual molecular basis for the promising effects of amantadine in COVID-19 treatment
Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
01 December 2021 – The 24-week risk of Covid-19 outcomes was low after vaccination with mRNA-1273 or BNT162b2, although risks were lower with mRNA-1273 than with BNT162b2. This pattern was consistent across periods marked by alpha- and delta-variant predominance
Covid-19 Vaccine Effectiveness in New York State
01 December 2021 – The effectiveness of the three vaccines against Covid-19 declined after the delta variant became predominant. The effectiveness against hospitalization remained high, with modest declines limited to BNT162b2 and mRNA-1273 recipients 65 years of age or older
30 November 2021 – Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia
Involvement of the ACE2/Ang-(1–7)/MasR Axis in Pulmonary Fibrosis: Implications for COVID-19
30 November 2021 – This review aimed to characterize the ACE2-Ang-(1–7)-MasR Axis in the context of pulmonary fibrosis with an emphasis on risk factors, including the SARS-CoV-2 virus and exposure to environmental toxicants. In the context of the pandemic, there is a dire need for an understanding of pulmonary fibrotic events. More research is needed to understand the interplay between ACE2, pulmonary fibrosis, and susceptibility to coronavirus infection
28 November 2021 – The therapeutic potential of cannabinoids as anti-inflammatory compounds is hypothesized for the treatment of COVID-19. However, more systemic investigations are warranted to establish the best efficacy and their toxic effects, followed by preclinical trials on a large number of participants
Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation
25 November 2021 – Our data suggest that the P681R mutation is a hallmark of the virological phenotype of the B.1.617.2/Delta variant and is associated with enhanced pathogenicity
The N501Y spike substitution enhances SARS-CoV-2 infection and transmission
24 November 2021 – The N501Y substitution recapitulated the phenotype of enhanced viral transmission seen with the combined 8 Alpha spike mutations, suggesting it is a major determinant of increased transmission of this variant. Mechanistically, the N501Y substitution improved the affinity of the viral spike protein for cellular receptors. As suggested by its convergent evolution in Brazil, South Africa, and elsewhere2,3, our results indicate that N501Y substitution is a major adaptive spike mutation of major concern
Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients
17 November 2021 – Our experience suggests that MAB treatment, with respect to the available MAB formulations and circulating viral variants present during our study period, may provide favorable outcomes for mild to moderate COVID-19 in SOT recipients.
17 November 2021 – When Tocilizumab and Remdisivir were administered together, 44.0% of patients survived while 56% expired. 79.7% of patients survived while 20.3% expired when neither Tocilizumab nor Remdesivir was administered.
Organ-specific genome diversity of replication-competent SARS-CoV-2
17 November 2021 – Our results provide insights about the pathogenesis and intra-host evolution of SARS-CoV-2 and show that COVID-19 treatment and hygiene measures need to be tailored to specific needs of immunocompromised patients, even when respiratory symptoms cease
SARS-CoV-2 Variants and Their Relevant Mutational Profiles: Update Summer 2021
17 November 2021 – Overall, this review sheds light and assists in defining the genetic signatures characterizing the currently circulating variants and their clinical relevance.
Optimization of Non-Coding Regions for a Non-Modified mRNA COVID-19 Vaccine
17 November 2021 – These data demonstrate that optimization of non-coding regions can greatly improve the immunogenicity and protective efficacy of a non-modified mRNA SARS-CoV-2 vaccine in nonhuman primates.
November 17, 2021 – In patients hospitalised with COVID-19, aspirin was not associated with reductions in 28 day mortality or in the risk of progressing to invasive mechanical ventilation or death, but was associated with a small increase in the rate of being discharged alive within 28 days.
November 17, 2021 – To our knowledge, this substudy is the first to show the safety, immunogenicity, and efficacy profile of a COVID-19 vaccine when co-administered with seasonal influenza vaccines. Our results suggest concomitant vaccination might be a viable immunisation strategy.
Two years into COVID-19 – Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters
16 November 2021- Here, I highlight the recent COVID-19 papers which have been published and collected in a Virtual Issue in FEBS Letters, and discuss their implications towards understanding the molecular, biochemical and cellular mechanisms of SARS-CoV-2 infections, vaccine development and antiviral discovery strategies
16 Nov 2021 – Such evidence, along with the significant and varied physical interactions of these drugs with the key viral enzyme outlined in this investigation, indicates that they might have a prospective therapeutic potential in the treatment of COVID-19 as monotherapy or combination therapy with Remdesivir
November 15, 2021 – The goal of this work is to summarize the information available on two antimetabolites – remdesivir and favipiravir – and to compare clinical experience obtained so far with these two agents in COVID-19 patients.
The role of microRNAs in solving COVID-19 puzzle from infection to therapeutics: A mini-review
14 November 2021 – Accordingly, miRNAs represent potential biomarkers and therapeutic targets for this devastating viral disease. Therefore, in this current review, we present the recent discoveries regarding the clinical relevance and biological roles of miRNAs in COVID-19
November 11, 2021 – Concomitant vaccination with ChAdOx1 or BNT162b2 plus an age-appropriate influenza vaccine raises no safety concerns and preserves antibody responses to both vaccines. Concomitant vaccination with both COVID-19 and influenza vaccines over the next immunisation season should reduce the burden on health-care services for vaccine delivery, allowing for timely vaccine administration and protection from COVID-19 and influenza for those in need.
November 11, 2021 – BBV152 was highly efficacious against laboratory-confirmed symptomatic COVID-19 disease in adults. Vaccination was well tolerated with no safety concerns raised in this interim analysis.
Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age
November 9, 2021 – A Covid-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age.
03 November 2021 – The initial roll-out of the US COVID-19 vaccination programme was associated with reductions in COVID-19 cases, emergency department visits, and hospital admissions among older adults
Phenylethanoid glycosides as a possible COVID-19 protease inhibitor: a virtual screening approach
03 November 2021 – This kinase inhibitory activity is very beneficial in fighting viruses inside the body as kinases are required for viral entry, metabolism, and/or reproduction. The dual activity (kinase/protease) of phenylethanoid glycosides makes them very promising anit-COVID-19 agents
Dasabuvir Inhibits Human Norovirus Infection in Human Intestinal Enteroids
03 November 2021 – Dasabuvir’s inhibitory effect was also demonstrated in the cases of SARS-CoV-2 and RVA infection, highlighting the usefulness of the HIE platform for screening antiviral agents against various viruses that target the intestines
03 November 2021 – Overall, these data suggest that inflammation and cell death are key drivers of severe COVID-19 pathogenesis in the absence of corticosteroid therapy
03 November 2021 – The acceptable safety and immunogenicity data from this phase 1b trial of ChAdOx1 MERS vaccine candidate in Healthy Middle Eastern adults, combined with previous safety and immunogenicity data from a trial in the UK, support selecting the ChAdOx1 MERS vaccine for advancement into phase 2 clinical evaluation
Hemin as a novel candidate for treating COVID-19 via heme oxygenase-1 induction
02 November 2021 – Overall, the findings suggested that HO-1, induced by hemin, effectively suppressed SARS-CoV-2 in vitro. Therefore, HO-1 could be potential therapeutic candidate for COVID-19
1 November 2021 – Thus, it is important to inform immunosuppressed patients about the risk of vaccine non-responsiveness and the necessity to maintain non-pharmaceutical protection measures. In these risk patients antibody testing and cellular analysis are helpful to estimate the benefit/responsiveness to further booster vaccinations
October 29, 2021 – Our findings suggest that a third dose of the BNT162b2 mRNA vaccine is effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least 5 months ago.
Immunology and controlling of coronaviruses; the current enemy for humanity: A review
31 October 2021 – The potential of antibodies, natural metabolites, and current suggest vaccines were applied to the face of this new threat
29 October 2021 – Our findings suggest that a third dose of the BNT162b2 mRNA vaccine is effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least 5 months ago
29 October 2021 – Primary outcomes for the viral load kinetics analysis were to detect differences in the peak viral load, viral growth rate, and viral decline rate between participants according to SARS-CoV-2 variant and vaccination status
Antimicrobial prescription in severe COVID-19 and CAP: a matched case-control study
28 October 2021 – In severe coronavirus diseases 2019 (COVID-19), a high and potentially excessive use of antimicrobials for suspected bacterial co-infection and intensive care unit (ICU)-acquired infections has been repeatedly reported
Waning Immunity after the BNT162b2 Vaccine in Israel
27 October 2021 – These findings indicate that immunity against the delta variant of SARS-CoV-2 waned in all age groups a few months after receipt of the second dose of vaccine
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
27 October 2021 – Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified
27 October 2021 – Our findings show that the risk of a large wave of COVID-19 hospital admissions resulting from lifting NPIs can be substantially mitigated if the timing of NPI relaxation is carefully balanced against vaccination coverage
27 October 2021 – This study demonstrates distinct roles and potency of type I and type III interferons and their therapeutic potential during coronavirus lung infection
Successful treatment of severe COVID-19 pneumonia with tocilizumab: A series of three cases
27 October 2021 – In this research letter, 3 consecutive patients are presented with severe COVID-19 pneumonia who between January and March 2021 were successfully treated with tocilizumab (a humanized antibody to the soluble interleukin-6 receptor) added to the standard therapy
27 October 2021 – Our findings show that the risk of a large wave of COVID-19 hospital admissions resulting from lifting NPIs can be substantially mitigated if the timing of NPI relaxation is carefully balanced against vaccination coverage
Cerebral venous sinus thrombosis after ChAdOx1 vaccination: the first case of definite thrombosis with thrombocytopenia syndrome from India
27 October 2021 – Early recognition of adenoviral vector vaccine-related TTS, which resembles heparin-induced thrombocytopenia syndrome, is important as heparin and heparin analogues are best avoided in the treatment
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab
27 October 2021 – Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified
COVID-19 mRNA Vaccine-induced Pneumonitis: A Case Report
26 October 2021 – The timing of the onset of pneumonitis after vaccination and the results of intradermal testing suggest that Type IV hypersensitivity against COVID-19 vaccine may have been responsible for this clinical condition
Nanoparticle approaches against SARS-CoV-2 infection
25 October 2021 – Overall, nanoparticles bring numerous new opportunities to improve our response to the current COVID-19 pandemic and enhance our preparedness for future viral outbreaks
Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave
25 October 2021 – Our approach complements phylogenetic analyses and other surveillance approaches and provides insights that can be used to design innovative, model-driven surveillance systems that guide enhanced testing and response strategies
Untimely TGFβ responses in COVID-19 limit antiviral functions of NK cells
25 October 2021 – Our data reveal that untimely production of TGFβ is a hallmark of severe COVID-19 and may inhibit NK cell function and early virus control
Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination
21 October 2021 – The ChAdOx1-S-nCoV-19 vaccine induced a weaker IgG response but a stronger T cell response than the BNT162b2 vaccine after the priming dose, which could explain the complementarity of both vaccines when used in combination. The heterologous vaccination regimen could therefore be particularly suitable for immune compromised individuals
Immunogenicity and efficacy of heterologous ChadOx1/BNT162b2 vaccination
21 October 2021 – The heterologous vaccination regimen could therefore be particularly suitable for immune compromised individuals
21 October 2021 – A delayed therapeutic plasma exchange (TPE) was pursued on day 32 of admission as salvage therapy, with a sustained improvement in his platelet count. Our case serves as proof-of-concept of the efficacy of TPE in VITT
20 October 2021 – Overall, these results highlight the potential of single B cell screening for the rapid and reliable identification of high-affinity, potent neutralizing antibodies for infectious disease applications
COVA1-18 neutralizing antibody protects against SARS-CoV-2 in three preclinical models
20 October 2021 – Our findings demonstrate that COVA1-18 has a strong antiviral activity in three preclinical models and could be a valuable candidate for further clinical evaluation
Hybrid immunity improves B cells and antibodies against SARS-CoV-2 variants
20 October 2021 – Our data suggest that people that are seropositive following infection or primary vaccination will produce antibodies with increased potency and breadth and will be able to better control SARS-CoV-2 emerging variants
18 October 2021 – Our data show that neutralizing mAbs administered preventatively to high-risk populations may mitigate the adverse inflammatory consequences of SARS-CoV-2 exposure
14 October 2021 – Together, a high content screen coupled with transcriptome and metabolic profiling reveals a key role of the HIF1α-glycolysis axis in mediating SARS-CoV-2 infection of human airway epithelium
A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
14 October 2021 – Its epitope defines a promising target for the development of a pan-sarbecovirus vaccine
13 October 2021 – Monoclonal antibody 5B8, targeting the cryptic inflammatory fibrin epitope, inhibited thromboinflammation. Our results reveal a procoagulant role for the SARS-CoV-2 Spike and propose fibrin-targeting interventions as a treatment for thromboinflammation in COVID-19
13 October 2021 – These results provide a new human-sourced neutralizing antibody against the S-RBD and assist vaccine development
13 October 2021 – Selective targeting of SARS-CoV-2 spike S1-to-ACE2 interaction by wtSPIDAR may be beneficial for coronavirus disease 2019
Molecular Insights of SARS-CoV-2 Infection and Molecular Treatments
13 October 2021 – Despite the limited availability of literatures, our attempt in this work to provide a relatively comprehensive overview of current SARS-CoV-2 studies can be helpful for quickly acquiring the key information of COVID-19 and further promoting this important research to control and diminish the pandemic
Dexamethasone for treating SARS-CoV-2 infection: a systematic review and meta-analysis
11 October 2021 – This study suggests that dexamethasone may significantly improve the outcome among hospitalized patients with SARS-CoV-2 infection and associated severe respiratory complications. Further studies need to consider both dose-dependent administration and outcomes in early and later stages of the disease
Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity
11 October 2021 – While both groups retained neutralization capacity against all variants, plasma from previously infected vaccinated individuals displayed overall better neutralization capacity when compared to plasma from uninfected individuals that also received two vaccine doses, pointing to vaccine boosters as a relevant future strategy to alleviate the impact of emerging variants on antibody neutralizing activity
Vitamin D supplementation to treat SARS-CoV-2 positive patients. Evidence from meta-analysis
08 October 2021 – Vitamin D supplementation in SARS-CoV-2 positive patients has the potential to positively impact patients with both mild and severe symptoms
Potent and Selective Covalent Inhibitors of the Papain-like Protease from SARS-CoV-2
08 October 2021 – These findings present an opportunity for further development of potent and selective covalent PLpro inhibitors
Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination
07 October 2021 – These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with equivalent breadth to those obtained by vaccinating convalescent individuals
Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective
07 October 2021 – This experimental paradigm is essential to the discovery and development of therapeutics targeting viral polymerases
Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination
07 October 2021 – These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with equivalent breadth to those obtained by vaccinating convalescent individuals
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
06 October 2021 – Six months after receipt of the second dose of the BNT162b2 vaccine, humoral response was substantially decreased, especially among men, among persons 65 years of age or older, and among persons with immunosuppression
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
06 October 2021 – BNT162b2-induced protection against SARS-COV-2 infection appeared to wane rapidly following its peak after the second dose, but protection against hospitalization and death persisted at a robust level for 6 months after the second dose
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
06 October 2021 – The incidence of myocarditis, although low, increased after the receipt of the BNT162b2 vaccine, particularly after the second dose among young male recipients. The clinical presentation of myocarditis after vaccination was usually mild
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization
06 October 2021 – Among patients in a large Israeli health care system who had received at least one dose of the BNT162b2 mRNA vaccine, the estimated incidence of myocarditis was 2.13 cases per 100,000 persons; the highest incidence was among male patients between the ages of 16 and 29 years. Most cases of myocarditis were mild or moderate in severity
05 October 2021 – Nb15-NbH-Nb15, a trimer constituted of three Nbs, is constructed to be bispecific for human serum albumin (HSA) and RBD of SARS-CoV-2. Nb15-NbH-Nb15 exhibits single-digit ng/ml neutralization potency against the wild-type and Delta variants of SARS-CoV-2 with a long half-life in vivo. In addition, we show that intranasal administration of Nb15-NbH-Nb15 provides effective protection for both prophylactic and therapeutic purposes against SARS-CoV-2 infection in transgenic hACE2 mice. Nb15-NbH-Nb15 is a potential candidate for both the prevention and treatment of SARS-CoV-2 through respiratory administration
Defining the Innate Immune Responses for SARS-CoV-2-Human Macrophage Interactions
04 October 2021 – We conclude that the SARS-CoV-2-infected host mounts a robust innate immune response characterized by a pro-inflammatory storm heralding end-organ tissue damage
03 October 2021 – These findings were robust to sensitivity analysis and to conservative assumptions limiting the clinical benefits of baricitinib to the statistically significant reduction in mortality demonstrated in the COV-BARRIER trial
02 October 2021 -The combination of molnupiravir with the protease inhibitor GC376 resulted in enhanced antiviral activity
29 September 2021 – They inhibited SARS-CoV-2 Mpro (by 6.6–100.0% at 50 μM) and bound directly to the Mpro protein (with dissociation constants from 1.1 × 10–6 to 5.3 × 10–5 M). This study sheds light on the inhibitory effects of tannins and their metabolites on SARS-CoV-2 Mpro
29 September 2021 – The article would certainly provide a lead to the scientific community for the effective therapeutic antiviral use of flavonoids using potential cost-effective tools for improvement of the pharmacokinetics, bioavailability and bio-distribution of such compounds for the concrete action along with the promotion of human health
29 September 2021 – COVID-19 hospitalisations and deaths were uncommon 14 days or more after the first vaccine dose in this national analysis in the context of a high background incidence of SARS-CoV-2 infection and with extensive social distancing measures in place
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
29 September 2021 – AZD1222 was safe and efficacious in preventing symptomatic and severe Covid-19 across diverse populations that included older adults
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
29 September 2021 – REGEN-COV reduced the risk of Covid-19–related hospitalization or death from any cause, and it resolved symptoms and reduced the SARS-CoV-2 viral load more rapidly than placebo
27 September 2021 – Our results could be promising for more advanced preclinical and clinical studies especially on rutin 2 either alone or in combination with other isolates for COVID-19 management
25 September 2021 – Neonates born to mothers vaccinated during pregnancy have higher antibody titers and may therefore have more prolonged protection than those born to women infected during pregnancy
23 September 2021 – Although serological studies have shown that antibodies against SARS-CoV-2 play an important role in protection against (re)infection, the dynamics of mucosal antibodies during primary infection and their potential impact on viral load and the resolution of disease symptoms remain unclear
No significant benefit of moderate-dose vitamin C on severe COVID-19 cases
22 September 2021 – Our findings revealed that in patients with severe COVID-19, treatment with moderate dose of intravenous vitamin C had no significant benefit on reducing the risk of death and obtaining clinical improvement
Remdesivir use and outcomes during the FDA COVID-19 emergency use authorization period
22 September 2021 – Time to RDV initiation appeared to affect recovery and 28-day mortality, a finding that should be explored further. Mortality rate decreased over the analysis period, which could be related to dexamethasone use and improved management of COVID-19
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
22 September 2021 – The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427
22 September 2021 – Without the national vaccination campaign, Israel probably would have had triple the number of hospitalisations and deaths compared with what actually occurred during its largest wave of the pandemic to date, and the health-care system might have become overwhelmed. Indirect effects and long-term benefits of the programme, which could be substantial, were not included in these estimates and warrant future research
21 September 2021 – The results clearly indicate the effectiveness of fatty acylation to improve the half-life of RDV
New Insights Into Drug Repurposing for COVID-19 Using Deep Learning
21 September 2021 – Its ability can also be extended to repurpose drugs for other complex diseases, develop appropriate treatment strategies for new diseases, and provide precision medical treatment to patients, thus paving the way to discover new drugs that can potentially be effective for treating COVID-19
COVID-19 and the Cardiovascular System: Insights into Effects and Treatments
21 September 2021 – The development of new guidelines for effective treatment strategies requires concerted efforts to refine our understanding of the mechanisms underlying cardiovascular disease and large-scale clinical trials to reduce the burden of COVID-19 hospitalization and mortality.
Low-dose radiation therapy for COVID-19 pneumonia: a pilot study
21 September 2021 – The results of our pilot study suggest that LDRT is feasible in COVID-19 patients having moderate to severe disease. Its clinical efficacy may be tested by conducting randomized controlled trials.
The critical role of mesenchymal stromal/stem cell therapy in COVID-19 patients: An updated review
20 September 2021 – Accordingly, in this paper, we will focus on the therapeutic impacts of MSCs and their critical role in cytokine storm of COVID-19 patients
Multi-level inhibition of coronavirus replication by chemical ER stress
20 September 2021 – To investigate how CoVs modulate ER stress components at the mRNA compared to the protein level, we determined the expression levels of 166 components of the ER stress pathway KEGG hsa04141 “protein processing in ER” in human HuH7 liver cells, a commonly used cellular model for CoV replication, in response to infections with HCoV-229E and MERS-CoV, respectively
16 September 2021 – These observations support the absence of antibody-dependent enhancement of infection (ADE) by IgG and IgA isotypes found in CCP
Immune and cellular damage biomarkers to predict COVID-19 mortality in hospitalized patients
16 September 2021 – The features that had the greatest impact on this model’s prediction were age, LDH, platelets, and %lymphocytes, more than comorbidities or inflammation markers, and these findings were highly consistent in both datasets, likely reflecting the virus effect at the very beginning of the disease
Assessment of the binding interactions of SARS-CoV-2 spike glycoprotein variants
16 September 2021 – To understand the impact of spike protein mutations on the binding interactions required for virus infection and the effectiveness of neutralizing monoclonal antibody (mAb) therapies, the binding activities of the original spike protein receptor binding domain (RBD) sequence and the reported spike protein variants were investigated using surface plasmon resonance (SPR)
Novel ACE2 protein interactions relevant to COVID-19 predicted by evolutionary rate correlations
15 September 2021 – We propose that ACE2 has novel protein interactions that are disrupted during SARS-CoV-2 infection, contributing to the spectrum of COVID-19 pathologies
15 September 2021 – The inactivated COVID-19 vaccine BBIBP-CorV is safe and well tolerated at all tested dose levels in participants aged 3–17 years
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
15 September 2021 – Through 6 months of follow-up and despite a gradual decline in vaccine efficacy, BNT162b2 had a favorable safety profile and was highly efficacious in preventing Covid-19
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
15 September 2021 – In this study involving participants who were 60 years of age or older and had received two doses of the BNT162b2 vaccine at least 5 months earlier, we found that the rates of confirmed Covid-19 and severe illness were substantially lower among those who received a booster (third) dose of the BNT162b2 vaccine
15 September 2021 – The Fcγbp-mediated mechanism can be a key factor in explaining why SARS-CoV-2 is less infective/lethal in children, and may also be involved in the unique Ab response, recurrent infection, and effects of serum therapy and vaccination
New-onset IgG autoantibodies in hospitalized patients with COVID-19
14 September 2021 – We conclude that SARS-CoV-2 causes development of new-onset IgG autoantibodies in a significant proportion of hospitalized COVID-19 patients and are positively correlated with immune responses to SARS-CoV-2 proteins
14 September 2021 – Early, pneumonia targeted LPV/r-based antiviral therapy resulted in a significantly higher probability of negative conversion of PCR within 28 days compared to symptomatic treatment
14 September 2021 – Our findings provide comprehensive and high-quality evidence for the use of standard-dose prophylactic anticoagulation over an escalated-dose regimen as routine standard of care for hospitalized patients with COVID-19 who do not have an indication for therapeutic anticoagulation, irrespective of disease severity
14 September 2021 – These data define the nature of the SARS-CoV-2 vaccine-induced immune landscape in aCD20-treated patients and provide insights into coordinated mRNA vaccine-induced immune responses in humans
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
14 September 2021 – The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic
ASGARD: A Single-cell Guided pipeline to Aid Repurposing of Drugs
14 September 2021 – The top-ranked drugs, such as fulvestrant and neratinib for breast cancer, tretinoin and vorinostat for leukemia, and chloroquine and enalapril for severe COVID19, are either approved by FDA or in clinical trials treating corresponding diseases. In conclusion, ASGARD is a promising pipeline guided by single-cell RNA-seq data, for repurposing personalized drugs and drug combinations
13 September 2021 – This underpowered study was limited by small sample size and low incidence of primary adverse events. A larger trial could determine efficacy
11 September 2021 – MAT reduced both hospitalization and mortality in this predominantly Hispanic patient population with mild to moderate COVID-19 with high risk factors for disease progression
COVID-19 and low-dose radiation therapy
10 September 2021 – This review aims to summarize the potential rationales and mechanisms of LDR therapy for COVID-19 patients, and its current clinical status and potential use
9 September 2021 – Accounting for the SARS-CoV-2 vaccination population groups in Michigan, the ED encounters/hospitalizations rate relevant to COVID-19 was 96% lower in FV versus UV (multiplicative effect:0.04, 95% CI 0.03 to 0.06, p < 0.001) in negative binomial regression
9 September 2021 – In this interim analysis, adding oral L-arginine to standard therapy in patients with severe COVID-19 significantly decreases the length of hospitalization and reduces the respiratory support at 10 but not at 20 days after starting the treatment
09 September 2021 – This review aims to: (1) present an overview on the infection, the developed thrombo-inflammatory responses and mechanisms of induced thrombosis of COVID-19 compared to other similar pathogenesis; (2) underline the role of natural compounds such as anticoagulant, antiplatelet and thrombolytic agents; (3) investigate the management of coagulopathy related to COVID-19 and provide insight on therapeutic such as venom compounds
09 September 2021 – In an attempt to accelerate drug repurposing, we tested a panel of L-type calcium channel blocker (CCB) drugs currently developed for other conditions to determine whether they would inhibit SARS-CoV-2 infection in cell culture. All the CCBs tested showed varying degrees of inhibition, with felodipine and nifedipine strongly limiting SARS-CoV-2 entry and infection in epithelial lung cells at concentrations where cell toxicity was minimal
09 September 2021 – IgG seropositivity was lower after CoronaVac than after BNT162b2 and declined over time since vaccination for CoronaVac recipients but not BNT162b2 recipients. Prolonged IgG monitoring will allow further evaluation of seropositivity overtime, providing data, in conjunction with effectiveness studies, for possible future re-assessment of vaccination strategies
09 September 2021 – An open-label, randomized controlled trial of convalescent plasma for adults with COVID-19 receiving oxygen within 12 d of respiratory symptom onset (NCT04348656)
The next phase of SARS-CoV-2 surveillance: real-time molecular epidemiology
09 September 2021 – To prepare for the next phase of the pandemic, a systematic approach is needed to link global genomic surveillance and timely assessment of the phenotypic characteristics of novel variants, which will support the development and updating of diagnostics, vaccines, therapeutics and nonpharmaceutical interventions
09 September 2021 – Subsequently, these studies outcome were supported through simulation trajectories that further proved anthraquinolone and quinolizine derivatives as potential small molecules to be tested experimentally in treating COVID-19 patients
Immunogenic amino acid motifs and linear epitopes of COVID-19 mRNA vaccines
09 September 2021 – Dominant linear epitopes were identified in the C-terminal domains of the S1 and S2 subunits (aa 558–569, 627–638, and 1148–1159) which have been previously associated with SARS-CoV-2 neutralization in vitro and demonstrate identity to bat coronavirus and SARS-CoV, but limited homology to non-pathogenic human coronavirus. The identified COVID-19 mRNA vaccine epitopes should be considered in the context of variants, immune escape and vaccine and therapy design moving forward
09 September 2021 – This analysis demonstrated the survival benefit associated with anti-inflammatory therapy of GC, with or without tocilizumab, with the combination providing the most benefit. More studies are needed to assess the optimal timing of anti-inflammatory therapy initiation
08 September 2021 – In our study, tocilizumab was not associated with decreased hospital mortality among patients with severe COVID-19
Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings
08 September 2021 – Covid-19 vaccines in the United States were highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an emergency department or urgent care clinic visit. This vaccine effectiveness extended to populations that are disproportionately affected by SARS-CoV-2 infection
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
08 September 2021 – Calculated proportions of adverse pregnancy and neonatal outcomes in persons vaccinated against Covid-19 who had a completed pregnancy were similar to incidences reported in studies involving pregnant women that were conducted before the Covid-19 pandemic
Discovery of novel inhibitors of SARS-CoV-2 main protease
02 September 2021 – Corona Virus Disease 2019 (COVID-19), referred to as ‘New Coronary Pneumonia’, is a type of acute infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection
01 September 2021 – We further analyzed the blocking effect of the active compounds on the interactions of mutated S-RBD and ACE2 by computational studies. Moreover, antiinflammatory activities were evaluated using qRT-PCR, enzyme-linked immune sorbent assay, and Western blot analysis
In-silico strategies to combat COVID-19: A comprehensive review
01 September 2021 – We have focused on designing a comprehensive review on in-silico approaches concerning COVID-19 to discuss the relevant bioinformatics and computational resources, tools, patterns of research, outcomes generated so far and their future implications to efficiently model data based on epidemiology; identify drug targets to design new drugs; predict epitopes for vaccine design and conceptualize diagnostic models
Are laboratory-made, COVID-19-specific monoclonal antibodies an effective treatment for COVID-19?
September 2021 – BackgroundMonoclonal antibodies (mAbs) are laboratory-produced molecules derived from the B cells of an infected host. They are being investigatedas a potential therapy for coronavirus disease 2019 (COVID-19)
Development of Effective Therapeutic Molecule from Natural Sources against Coronavirus Protease
30 August 2021 – Through in silico approach, selected flavonoids were docked into the active site of Mpro. The free energies of the ligands complexed with Mpro were computationally estimated using the molecular mechanics-generalized Born surface area (MM/GBSA) method. In addition, the inhibition process of SARS-CoV-2 Mpro with these ligands was simulated at 100 ns in order to uncover the dynamic behavior and complex stability
Metoprolol in Critically Ill Patients With COVID-19
30 August 2021 – Severe coronavirus disease-2019 (COVID-19) can progress to an acute respiratory distress syndrome (ARDS)
GalNAc-siRNA conjugates: Prospective tools on the frontier of anti-viral therapeutics
30 August 2021 – The growing use of short-interfering RNA (siRNA)-based therapeutics for viral diseases reflects the most recent innovations in anti-viral vaccines and drugs
30 August 2021 – Judicious use of COVID-19 biomarkers could help in disease prognostication and thereby provide guidance to devise appropriate management strategies
28 August 2021 – These findings indicate that RBD protein could be used for the prevention and treatment of SARS-CoV-2 infection
The rapid adaptation of SARS-CoV-2–rise of the variants: transmission and resistance
27 August 2021 – The causative factor of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuously mutating
27 August 2021 – SARS-COV-2 infection has affected millions of individuals with a wide range of clinical manifestations, including central and peripheral nervous systems through several mechanisms
Use of Thiols in the Treatment of COVID-19: Current Evidence
27 August 2021 – There is a possible role for oxidative stress, a state characterized by an altered balance between the production of free radicals or reactive oxygen species (ROS) and antioxidant defences, in coronavirus disease 2019 (COVID-19), the genesis of which is quite complex
MD simulation and MM/PBSA identifies phytochemicals as bifunctional inhibitors of SARS-CoV-2
27 August 2021 – The global spread of SARS-CoV-2 has resulted in millions of fatalities worldwide, making it crucial to identify potent antiviral therapeutics to combat this vírus
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
26 August 2021 – Thrombosis and inflammation may contribute to the risk of death and complications among patients with coronavirus disease 2019 (Covid-19)
Safety of the BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting
25 August 2021 – Preapproval trials showed that messenger RNA (mRNA)–based vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had a good safety profile, yet these trials were subject to size and patient-mix limitations
24 August 2021 – Our study elucidated in detail the binding mechanism of the potent PF-07321332 to 3CLpro along with the low potency of lopinavir and ritonavir due to weak binding affinity demonstrated by the binding energy data. This study will be helpful for the development and optimization of more specific compounds to combat coronavirus disease
24 August 2021 – To determine the molecular mechanism of multiple organ dysfunction, a bioinformatics analysis method based on a time-order gene co-expression network (TO-GCN) was performed
Tocilizumab: A retrospective multi-center cohort study of critically ill patients with COVID-19
August 2021 – Coronavirus disease 19 (COVID-19) can have a severe presentation characterized by a dysregulated immune response requiring admission to the intensive care unit (ICU)
10 August 2021 – A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown
Bioactive recombinant human oncostatin M for NMR-based screening in drug discovery
10 August 2021 – To pursue a high-throughput screening and structure-based drug discovery strategy to design a small molecule inhibitor of OSM, milligram quantities of highly pure, bioactive OSM are required
Immunophenotyping assessment in a COVID-19 cohort (IMPACC): A prospective longitudinal study
10 August 2021 – In this report we summarize the IMPACC study design and protocols including clinical criteria and recruitment, multi-site standardized sample collection and processing, virologic and immunologic assays, harmonization of assay protocols, high-level analyses and the data sharing plans
Remdesivir in the COVID-19 Pandemic: An Analysis of Spontaneous Reports in VigiBase During 2020
10 August 2021 – This study aimed to provide a descriptive analysis of COVID-19 ICSR data focusing on remdesivir, including a disproportionality analysis (DA) of ADRs
10 August 2021 – In this study, it is aimed to develop a biocompatible and biodegradable polymeric drug delivery system that is targeted to the relevant receptor binding site and provides controlled drug release
10 August 2021 – This study aimed to characterize the classes and subclasses of antibody responses to a recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients and investigated the reactivity of these antibodies in patients with other tropical infections and healthy individuals in Thailand
10 August 2021 – While vaccines remain the primary option for COVID-19 prevention, neutralizing monoclonal antibodies (mAbs), such as bamlanivimab and etesevimab, have been shown to benefit certain subpopulations after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2
10 August 2021 – A previous efficacy trial found benefit from inhaled budesonide for COVID-19 in patients not admitted to hospital, but effectiveness in high-risk individuals is unknown
9 August 2021 – We identify two potent antibodies, nCoVmab1 and nCoVmab2, targeting the SARS-CoV-2 spike protein receptor-binding domain (RBD) with high affinities from a naïve human phage-displayed Fab library. nCoVmab1 and nCoVmab2 neutralize authentic SARS-CoV-2 with picomolar and nanomolar IC50 values, respectively
8 August 2021 – The SARS-CoV-2 receptor angiotensin converting enzyme 2 (ACE2) was previously engineered into a high affinity tetravalent format (ACE2-Fc-TD) that is a potential decoy protein in SARS-CoV-2 infection.We report that this protein shows greatly enhanced binding to SARS-CoV-2 spike proteins of the SARS-CoV-2 variants of concern B.1.1.7
8 August 2021 – The virus spike protein (S protein) can recognize the angiotensin-converting enzyme 2 (ACE2) receptor on the host cell membrane and undergo a series of conformational changes, protease cleavage and membrane fusion to complete the virus entry, so S protein is an important target for vaccine and drug development
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
04 August 2021 – Subcutaneous REGEN-COV prevented symptomatic Covid-19 and asymptomatic SARS-CoV-2 infection in previously uninfected household contacts of infected persons. Among the participants who became infected, REGEN-COV reduced the duration of symptomatic disease and the duration of a high viral load
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19
04 August 2021 – In noncritically ill patients with Covid-19, an initial strategy of therapeutic-dose anticoagulation with heparin increased the probability of survival to hospital discharge with reduced use of cardiovascular or respiratory organ support as compared with usual-care thromboprophylaxis
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19
04 August 2021 – We hypothesized that therapeutic-dose anticoagulation would improve outcomes in critically ill patients with Covid-19
3 August 2021 – Developing strategies to block this interaction has therefore been identified as a way to treat this infection
The TMPRSS2 Inhibitor Nafamostat Reduces SARS-CoV-2 Pulmonary Infection in Mouse Models of COVID-19
03 August 2021 – In mice sensitized to SARS-CoV-2 infection by transduction with human ACE2, intranasal nafamostat treatment prior to or shortly after SARS-CoV-2 infection significantly reduced weight loss and lung tissue titers
02 August 2021 – Favipiravir and warfarin might have previously unidentified drug interactions that elevated the INR. Therefore, INR must be closely monitored when they are concomitantly administered in COVID-19 patients
S100A8 may govern hyper-inflammation in severe COVID-19
02 August 2021 – The underlying evidence includes accumulating clinical information that S100A8 is upregulated in severe forms of COVID-19, pathological similarities of the affected lungs between COVID-19 and S100A8-induced acute respiratory distress syndrome (ARDS) model
SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies
02 August 2021 – The objectives of this study are to investigate the distinctive structural features of SARS-CoV-2 S protein, its essential role in pathogenesis, and its use in the development of potential therapies and vaccines
NSAIDs and COVID-19: A Systematic Review and Meta-analysis
02 August 2021 – Nonsteroidal anti-inflammatory drugs (NSAIDs) have been discouraged for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, fearing that they could increase the risk of infection or the severity of SARS-CoV-2
31 July 2021 – The purpose of the article is to review available preclinical, clinical, and post-marketing data to assess the safety and efficacy of remdesivir in the treatment of COVID-19 patients
Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2
30 July 2021 – In the battle against COVID-19, drugs discovered in repurposing screens are of particular interest because these could be rapidly implemented as treatments
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
29 July 2021 – Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo
29 July 2021 – Inhibitors of 3CLpro activity are screened in enzyme assays before further development of the most promising leads
A Novel Therapeutic Peptide Blocks SARS-CoV-2 Spike Protein Binding with Host Cell ACE2 Receptor
29 July 2021 – A critical step in the crosstalk between the virus and the host cell is the binding of the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein to the peptidase domain of the angiotensin-converting enzyme 2 (ACE2) receptor present on the surface of host cells
29 July 2021 – The present study aims at predicting the antiviral activity of two novel compounds using in silico approaches that might become potential leads against SARS-CoV-2.
Topological network based drug repurposing for coronavirus 2019
29 July 2021 – The global effort started to identify the best drug compounds to treat COVID-19, but going through a series of clinical trials and our lack of information about the details of the virus’s performance has slowed down the time to reach this goal
29 July 2021 – To better inform clinical practice, we summarized the findings from randomized controlled trials (RCTs) of antivirals for COVID-19
Rapid and stable mobilization of CD8+ T cells by SARS-CoV-2 mRNA vaccine
28 July 2021 – We show on a single epitope level that a stable and fully functional CD8+ T cell response is vigorously mobilized one week after bnt162b2 prime vaccination when circulating CD4+ T cells and neutralizing antibodies are still weakly detectable
Potential protective role of the anti-PD-1 blockade against SARS-CoV-2 infection
28 July 2021 – The findings may demonstrate the hypothesis that a winning strategy to combat SARS-CoV-2 infection could be the restoration of exhausted T-cells
28 July 2021 – The method was extensively tested for various unbiased datasets based on different criteria such as drugs recalled worldwide for failing to meet safety standards, organ-specific toxicities, cytochrome P450 inhibitors, and Food and Drug Administration (FDA) approved drugs with remarkable successes
27 July 2021 – This study is an attempt to find a suitable therapy using antimicrobial peptides (AMPs) by identifying peptide-protein interaction of AMPs and nucleocapsid protein of SARS and SARS-CoV- 2
27 July 2021 – Inactivated SARS-CoV-2 vaccine does not influence the profile of antiphospholipid antibody and anti-PF4-heparin antibody nor increase the risk of thrombosis
The virological impacts of SARS-CoV-2 D614G mutation
21 July 2021 – The current prevalent D614G variant, with glycine substituted for aspartic acid at position 614 in the spike glycoprotein (S protein), is one of such variants that became the main circulating strain worldwide in a short period of time
Structural insights into the distinctive RNA recognition and therapeutic potentials of RIG-I-like receptors
21 July 2021 – RNA viruses, including the coronavirus, develop a unique strategy to evade the host immune response by interrupting the normal function of cytosolic retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs)
Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
21 July 2021 – The B.1.617.2 (delta) variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has contributed to a surge in cases in India and has now been detected across the globe, including a notable increase in cases in the United Kingdom. The effectiveness of the BNT162b2 and ChAdOx1 nCoV-19 vaccines against this variant has been unclear
Antiviral Effect of Budesonide against SARS-CoV-2
20 July 2021 – Our results are encouraging as they could indicate a multimodal mode of action of budesonide against SARS-CoV-2 and COVID-19, which could contribute to an improved clinical performance
15 July 2021 – These data suggest that hiPSC-derived AT2 and club cells provide a useful in vitro model for drug development
Glycan Nanostructures of Human Coronaviruses
15 July 2021 – Glycans are one of the main structural components of all microbes and organismic structures, including viruses—playing multiple essential roles in virus infection and immunity
15 July 2021 – Emerging experimental reports have highlighted the beneficial effects of mesenchymal stem cell (MSC) administration against COVID-19.
15 July 2021 – In this study, the inhibitory potential of more than 50 antiviraldrugs on three important proteins of SARS-CoV-2, was investigated using the molecular docking method.
Intranasal gene therapy to prevent infection by SARS-CoV-2 variants
15 July 2021 – Here we present an approach for preventing clinical sequelae and the spread of SARS-CoV-2 variants.
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
14 July 2021 – Here, we comprehensively characterize escape, breadth, and potency across a panel of SARS-CoV-2 antibodies targeting the receptor-binding domain (RBD).
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19
14 July 2021 – Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over time, neutralizing monoclonal-antibody treatment provides immediate, passive immunity and may limit disease progression and complications.
Systems vaccinology of the BNT162b2 mRNA vaccine in humans
12 July 2021 – Here we used a systems vaccinology approach to comprehensively profile the innate and adaptive immune responses of 56 healthy volunteers vaccinated with the Pfizer-BioNTech mRNA vaccine.
Prevention and therapy of SARS-CoV-2 and the B.1.351 variant in mice
10 July 2021 – Small-molecule antivirals like remdesivir (RDV) and biologics such as human monoclonal antibodies (mAbs) have demonstrated therapeutic efficacy against SARS-CoV-2, the causative agent of coronavirus disease 2019 (COVID-19)
Mapping the human genetic architecture of COVID-19
08 July 2021 – Identifying host-specific genetic factors may reveal biological mechanisms of therapeutic relevance and clarify causal relationships of modifiable environmental risk factors for SARS-CoV-2 infection and outcomes.
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
08 July 2021 – Here, we isolated an infectious Delta strain from a traveller returning from India. We examined its sensitivity to monoclonal antibodies (mAbs) and to antibodies present in sera from COVID-19 convalescent individuals or vaccine recipients, in comparison to other viral strains.
Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia
07 July 2021 – The objective of this study was to determine the binding site on PF4 of antibodies from patients with VITT.
Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile
07 July 2021 – A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021.
July 6, 2021 – To investigate the duration of humoral immune response in convalescent coronavirus disease 2019 (COVID-19) patients, we conduct a 12-month longitudinal study through collecting a total of 1,782 plasma samples from 869 convalescent plasma donors in Wuhan, China and test specific antibody responses
The molecular dynamics of possible inhibitors for SARS-CoV-2
July 6, 2021 – The novel coronavirus SARS-CoV-2, responsible for the present COVID-19 global pandemic, is known to bind to the angiotensin converting enzyme-2 (ACE2) receptor in human cells
July 6, 2021 – Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority
05 July 2021 – Two proteins namely S-ACE2 and Mpro have been taken for the present study based on the higher resolution. SARS-CoV-2 contains a spike (S) protein that helps viral entry into the host cell and releases virus particles by attaching to a cell surface receptor called human angiotensin-converting enzyme 2 (ACE2) which facilitates viral transcription and replication
Post-anticoagulant D-dimer is a highly prognostic biomarker of COVID-19 mortality
July 5, 2021 – Clinical biomarkers that accurately predict mortality are needed for the effective management of patients with severe coronavirus disease 2019 (COVID-19) illness
July 1, 2021 – The porcine epidemic diarrhea virus (PEDV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are two highly pathogenic viruses causing tremendous damages to the swine and human populations, respectively
July 1, 2021 – The COVID-19 pandemic has clearly brought the healthcare systems worldwide to a breaking point, along with devastating socioeconomic consequences
CRISPR-Cas System: The Powerful Modulator of Accessory Genomes in Prokaryotes
June 30, 2021 – Being frequently exposed to foreign nucleic acids, bacteria and archaea have developed an ingenious adaptive defense system, called CRISPR-Cas
Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2
June 30, 2021 – Although two-dose mRNA vaccination provides excellent protection against SARS-CoV-2, data are scarce on vaccine efficacy against variants of concern (VOC) in individuals above 80 years of age
Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
June 30, 2021 – Information is limited regarding the effectiveness of the two-dose messenger RNA (mRNA) vaccines BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) in preventing infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and in attenuating coronavirus disease 2019 (Covid-19) when administered in real-world conditions
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
June 30, 2021 – Early clinical data from studies of the NVX-CoV2373 vaccine (Novavax), a recombinant nanoparticle vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that contains the full-length spike glycoprotein of the prototype strain plus Matrix-M adjuvante
June 28, 2021 – Recent outbreak of 2019 novel Corona virus poses serious challenge for the global health system. In lieu of paucity of experimental data, tools and the very basic understanding of host immune responses against SARS-CoV-2, well thought effective measures are needed to control COVID-19 pandemic
SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses
June 28, 2021 – Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) messenger RNA (mRNA)-based vaccines are ~95% effective in preventing coronavirus disease 2019
June 28, 2021 – A vaccine against SARS-CoV-2 for children and adolescents will play an important role in curbing the COVID-19 pandemic
June 26, 2021 – The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect
June 26, 2021 – Tenofovir and emtricitabine interfere with the SARS CoV-2 ribonucleic acid (RNA)-dependent RNA polymerase (RdRp)
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
June 23, 2021 – The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines
Protective efficacy of Ad26.COV2.S against SARS-CoV-2 B.1.351 in macaques
June 23, 2021 – The emergence of SARS-CoV-2 variants that partially evade neutralizing antibodies poses a threat to the efficacy of current COVID-19 vaccines1,2
TRP channels in COVID-19 disease: Potential targets for prevention and treatment
June 22, 2021 – Coronavirus disease 2019 [COVID-19] is a global health threat caused by severe acute respiratory syndrome coronavirus 2 [SARS-CoV2] that requires two proteins for entry: angiotensin-converting enzyme 2 [ACE2] and trans-membrane protease serine 2 [TMPRSS2]
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains
June 21, 2021 – Rapidly-emerging variants jeopardize antibody-based countermeasures against SARS-CoV-2
Molecular insight into the genomic variation of SARS-CoV-2 strains from current outbreak
June 18 , 2021 – Coronavirus disease 2019 (COVID-19) is the newly emerging viral disease, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia
June 16, 2021 – The efficacy and safety of tofacitinib, a Janus kinase inhibitor, in patients who are hospitalized with coronavirus disease 2019 (Covid-19) pneumonia are unclear
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
June 14, 2021 – Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains difficult to control despite the availability of several excellent vaccines
Multiplexed and High-Throughput Label-Free Detection of RNA/Spike Protein/IgG/IgM Biomarkers of SARS-CoV-2 Infection Utilizing Nanoplasmonic Biosensors
June 14, 2021 – To tackle the COVID-19 outbreak, which is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), there is an unmet need for highly accurate diagnostic tests at all stages of infection with rapid results and high specificity
Molecular biology of the SARs-CoV-2 spike protein: A review of current knowledge
June 14, 2021 – The global coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to an unprecedented worldwide public health emergency
Understanding individual SARS-CoV-2 proteins for targeted drug development against COVID-19
June 14, 2021 – SARS-CoV-2 causes the COVID-19 pandemic responsible for millions of deaths globally
Dynamic Profiling of β-Coronavirus 3CL Mpro Protease Ligand-Binding Sites
June 14, 2021 – β-coronavirus (CoVs) alone has been responsible for three major global outbreaks in the 21st century
A long-term perspective on immunity to COVID
June 14, 2021 – Determining the duration of protective immunity to infection by SARS-CoV-2 is crucial for understanding and predicting the course of the COVID-19 pandemic. Clinical studies now indicate that immunity will be long-lasting
Interferon therapy in patients with SARS, MERS, and COVID-19: A systematic review and meta-analysis of clinical studies
June 12, 2021 – Concern regarding coronavirus (CoV) outbreaks has stayed relevant to global health in the last decades
Renin–Angiotensin–Aldosterone System Inhibitors and SARS-CoV-2 Infection: An Analysis from the Veteran’s Affairs Healthcare System: Sandhu. ACEI, ARB, and Association with COVID
June 12, 2021 – Angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are known to impact the functional receptor for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
June 10, 2021 – The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2
June 08, 2021 – In this study we profiled vaccine-induced polyclonal antibodies as well as plasmablast-derived mAbs from individuals who received SARS-CoV-2 spike mRNA vaccine
Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species
June 08, 2021 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants continue to emerge during the global pandemic and may facilitate escape from current antibody therapies and vaccine protection
Inhibitory Potential of Phytochemicals on Interleukin-6-Mediated T-Cell Reduction in COVID-19 Patients: A Computational Approach
June 08, 2021 – A recent COVID-19 pandemic has resulted in a large death toll rate globally and even no cure or vaccine has been successfully employed to combat this disease
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence
June 07, 2021 – Convalescent plasma has been used worldwide to treat patients hospitalized with coronavirus disease 2019 (COVID-19) and prevent disease progression
Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants
June 07, 2021 – Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths worldwide
Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants
June 03, 2021 – Resistance represents a major challenge for antibody-based therapy for coronavirus disease 2019 (COVID-19)1–4
Therapeutic use of specific tumour necrosis factor inhibitors in inflammatory diseases including COVID-19
May 28, 2021- Coronavirus disease 2019 (COVID-19) has caused significant devastation globally
Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis
May 27, 2021- Favipiravir possesses high utility for treating patients with COVID-19. However, research examining the efficacy and safety of favipiravir for patients with COVID-19 is limited
Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents
May 27, 2021- Until very recently, vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) had not been authorized for emergency use in persons younger than 16 years of age
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
May 27, 2021 – BNT162b2, a lipid nanoparticle (LNP) formulated nucleoside-modified messenger RNA (mRNA) that encodes the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) stabilized in the prefusion conformation, has demonstrated 95% efficacy in preventing coronavirus disease-19 (COVID-19)
Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection
May 27, 2021 – In a randomized clinical trial of 86 hospitalized COVID-19 patients comparing standard care to treatment with 300mL convalescent plasma containing high titers of neutralizing SARS-CoV-2 antibodies, no overall clinical benefit was observed
The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials
May 26, 2021 – The novel coronavirus outbreak began in late December 2019 and rapidly spread worldwide, critically impacting public health systems
Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2
May 26, 2021 – Among the therapies against the pandemic SARS-CoV-2 virus, monoclonal Antibodies (mAbs) targeting the Spike glycoprotein represent good candidates to interfere in the Spike/ACE2 interaction, preventing virus cell entry
Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp
May 26, 2021 – Coronavirus disease 2019 (COVID-19) is a fatal respiratory illness caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Reckoning γ-Glutamyl-S-allylcysteine as a potential Main protease (Mpro) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation
May 26, 2021 – Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2 or COVID-19), outbreak was first reported in December 2019 in the Wuhan, China
Association of Intravenous Bamlanivimab Use with Reduced Hospitalization, Intensive Care Unit Admission, and Mortality in Patients with Mild to Moderate COVID-19
May 25, 2021- Clinical data to support the use of bamlanivimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed
Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial
May 25, 2021 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 pandemic
Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case–control study
May 25, 2021 – Although more than a year past since COVID-19 was defined, there is no specific treatment yet.
Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19
May 24, 2021 – Severe coronavirus disease 2019 (COVID-19) is characterized by interstitial pneumonia/acute respiratory distress syndrome and hyperinflammation, with elevated levels of proinflammatory cytokines, such as interleukin-6 (IL-6), associated with mortality and patients requiring ventilator suppor
Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication
May 24, 2021 – Treatment options for COVID-19 remain limited, especially during the early or asymptomatic phase. Here, we report a novel SARS-CoV-2 viral replication mechanism mediated by interactions between ACE2 and the epigenetic eraser enzyme LSD1, and its interplay with the nuclear shuttling importin pathway
Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants
23/mai – Monoclonal antibodies targeting the receptor binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 spike protein are important outpatient treatment options in coronavirus disease 2019 to mitigate progression of disease and prevent hospitalization
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
May 22, 2021 – Encouraging results have been observed from initial studies evaluating vaccines targeting the novel beta coronavirus which causes severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Existing Drugs Considered as Promising in COVID-19 Therapy
May 21, 2021- COVID-19 is a respiratory disease caused by newly discovered severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease at first was identified in the city of Wuhan, China in December 2019
Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling and drug screening
May 19, 2021 – Although the main cellular target of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is thought to be alveolar cells, the absence of their tractable culture system precludes the development of a clinically relevant SARS-CoV-2 infection model
Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate
May 19, 2021- In late December 2019, a novel coronavirus, namely severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), escaped the animal–human interface and emerged as an ongoing global pandemic with severe flu-like illness, commonly known as coronavirus disease 2019 (COVID-19)
Aptamer BC 007’s Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies
May 18, 2021- COVID-19 is a pandemic respiratory disease that is caused by the highly infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Anti-SARS-CoV-2 antibodies are essential weapons that a patient with COVID-19 has to combat the disease
Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection
May 14, 2021- Since its emergence in December 2019 in Wuhan, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) created a worldwide pandemic of coronavirus disease (COVID-19) with nearly 136 million cases and approximately 3 million deaths
Interferon‐α‐2b Aerosol Inhalation is Associated with Improved Clinical Outcomes in Patients with Coronavirus Disease‐2019
May 13, 2021 – Type 1 interferon (IFN) is used to treat patients with coronavirus disease‐2019 (COVID‐19) but robust supporting evidence is lacking
Problems associated with antiviral drugs and vaccines development for COVID-19: approach to intervention using expression vectors via GPI anchor
May 13, 2021 – The outbreak of a novel coronavirus responsible for the severe acquired respiratory syndrome: SARS-CoV-2, also known as coronavirus disease 2019: COVID-19, represents a pandemic threat that has been declared a public health emergency of international concern
Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro
May 13, 2021 – Remdesivir is one of the first drugs approved for the treatment of coronavirus disease 2019. Currently, it is administered via an injection into the bloodstream
A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID‐19
May 13, 2021 – Camostat mesylate, an oral serine protease inhibitor, is used to treat chronic pancreatitis and reflux esophagitis
Antibody responses to single‐dose SARS‐CoV‐2 vaccination in patients receiving immunomodulators for immune‐mediated inflammatory disease
May 12, 2021 – There are few data on whether immunomodulator therapy attenuates humoral response to vaccines for severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)
The interferon-stimulated exosomal hACE2 potently inhibits SARS-CoV-2 replication through competitively blocking the virus entry
May 12, 2021 – Since the outbreak of coronavirus disease 2019 (COVID-19), it has become a global pandemic
SARS-CoV-2 uses a multipronged strategy to impede host protein synthesis
May 12, 2021 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing coronavirus disease 19 pandemic
Candesartan as a tentative treatment for COVID-19: a prospective non-randomized open-label study
May 11, 2021 – Candesartan as a tentative treatment for COVID-19: a prospective non-randomized open-label study
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses
May 10, 2021 – Betacoronaviruses (betaCoVs) caused the severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) outbreaks, and the SARS-CoV-2 pandemic
Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study
May 10, 2021 – Coronavirus disease 2019 (COVID-19) outbreaks are frequent occurrences in nursing homes and long-term care facilities (LTCFs), resulting in subsequent hospitalization and death
siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses
May 04, 2021 – The ongoing pandemic of global concern has killed about three million humans and affected around 151 million people worldwide, as of April 30, 2021
Determinants of IgG antibodies kinetics after severe and critical COVID‐19
May 04, 2021 – The kinetics of IgG antibodies after COVID‐19 remain poorly understood. We investigated factors influencing severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) IgG antibody levels and time to seronegativation during the follow‐up of severe and critically ill patients.
Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial
May 04, 2021 – Convalescent plasma has been used for numerous viral diseases including influenza, severe acute respiratory syndrome, Middle East respiratory syndrome and Ebola virus; however, evidence to support its use is weak.
How COVID-19 has fundamentally changed clinical research in global health
May 01, 2021 – COVID-19 has had negative repercussions on the entire global population
Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2
April 30, 2021 – Repurposing clinically available drugs to treat the new coronavirus disease 2019 (COVID-19) is an urgent need in the course of the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) pandemic, as very few treatment options are available.
Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice—A Refined Approach in the COVID-19 Era
April 29, 2021 – The diagnostic and therapeutic management of the Coronavirus Disease 2019 (COVID-19) pandemic in the HIV population brought some known criticalities (and opportunities) to the forefront, for both those who are facing their first therapeutic line today, and for those already well viro-suppressed.
Type I Interferon-Mediated Regulation of Antiviral Capabilities of Neutrophils
April 29, 2021 – Interferons (IFNs) are induced by viruses and are the main regulators of the host antiviral response.
Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus
April 29, 2021 – There is an urgent need for specific antiviral treatments directed against SARS-CoV-2 to prevent the most severe forms of COVID-19. By drug repurposing, affordable therapeutics could be supplied worldwide in the present pandemic context.
Genome-Wide B Cell, CD4+, and CD8+ T Cell Epitopes That Are Highly Conserved between Human and Animal Coronaviruses, Identified from SARS-CoV-2 as Targets for Preemptive Pan-Coronavirus Vaccines
April 28, 2021 – Over the last two decades, there have been three deadly human outbreaks of coronaviruses (CoVs) caused by SARS-CoV, MERS-CoV, and SARS-CoV-2, which has caused the current COVID-19 global pandemic
Inhibitors of coronavirus 3CL proteases protect cells from protease-mediated cytotoxicity
April 28, 2021 – We describe a mammalian cell-based assay to identify coronavirus 3CL protease (3CLpro) inhibitors
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)
April 28, 2021 – A dysregulated immune response characterized by the hyperproduction of several pro-inflammatory cytokines (a.k.a. ‘cytokine storm’) plays a central role in the pathophysiology of severe coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials
April 27, 2021 – The year 2020 witnessed a heavy death toll due to COVID-19, calling for a global emergency
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy
April 27, 2021 – Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been documented, raising public health concerns
Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study
April 27, 2021 – The Pfizer-BioNTech (BNT162b2) and the Oxford-AstraZeneca (ChAdOx1 nCoV-19) COVID-19 vaccines have shown excellent safety and efficacy in phase 3 trials
Drug-utilisation profiles and COVID-19
April 26, 2021 – Coronavirus disease 2019 (COVID-19) has substantially challenged healthcare systems worldwide
Analysis of IgM, IgA, and IgG isotype antibodies Directed against SARS-CoV-2 spike glycoprotein and ORF8 in the course of COVID-19
April 26, 2021 – Immunoassays are a standard diagnostic tool that assesses immunity in severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) infection
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
April 24, 2021 – The global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires an urgent need to find effective therapeutics for the treatment of coronavirus disease 2019 (COVID-19)
Biomolecular interactions with nanoparticles: Applications for COVID-19
April 23, 2021 – Nanoparticles are small particles sized 1 to 100 nm, which have a large surface to volume ratio, allowing efficient adsorption of drugs, proteins and other chemical compounds
COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study
April 23, 2021 – BNT162b2 mRNA and ChAdOx1 nCOV-19 adenoviral vector vaccines have been rapidly rolled out in the UK from December, 2020
Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus
April 22, 2021 – The expansion of the novel coronavirus known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), COVID-19 (coronavirus disease 2019), or 2019-nCoV (2019 novel coronavirus) is a global concern over its pandemic potential
Eicosanoid signaling as a therapeutic target in middle-aged mice with severe COVID-19
April 21, 2021 – Coronavirus disease 2019 (COVID-19) is especially severe in aged populations1
Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons
April 21, 2021 – Many pregnant persons in the United States are receiving messenger RNA (mRNA) coronavirus disease 2019 (Covid-19) vaccines, but data are limited on their safety in pregnancy
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
April 21, 2021 – Emerging variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are of clinical concern
Roles of Type I and III Interferons in COVID-19
April 20, 2021 – Coronavirus disease 2019 (COVID-19) is an ongoing global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19
April 19, 2021 – Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in humans
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
April 19, 2021 – The development of a portfolio of COVID-19 vaccines to vaccinate the global population remains an urgent public health imperative1
High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors
April 17, 2021 – A new coronavirus (SARS-CoV-2) has been identified as the etiologic agent for the COVID-19 outbreak
A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum
April 17, 2021 – As global confirmed cases and deaths from coronavirus disease 2019 (COVID-19) surpass 100 and 2.2 million, respectively, quantifying the effects of the widespread treatment of remdesivir (GS-5734, Veklury) and the steroid dexamethasone is becoming increasingly important
Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19
April 16, 2021 – In 2020, a new coronavirus, SARS-CoV-2, quickly spread worldwide within a few months. Although coronaviruses typically infect the upper or lower respiratory tract, the virus RNA can be detected in plasma
Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination
April 16, 2021 – The mainstay of control of the coronavirus disease 2019 (Covid-19) pandemic is vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Multi-platform omics analysis reveals molecular signature for COVID-19 pathogenesis, prognosis and drug target discovery
April 15, 2021 – Disease progression prediction and therapeutic drug target discovery for Coronavirus disease 2019 (COVID-19) are particularly important, as there is still no effective strategy for severe COVID-19 patient treatment
Current update on SARS-CoV-2 vaccine development with a special emphasis on gene therapy viral vector design and construction for vaccination
April 15, 2021 – Severe acute respiratory syndrome (SARS) is a newly emerging infectious disease (COVID-19) caused by the novel coronavirus SARS-CoV-2
Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report
April 15, 2021 – To describe a potential drug interaction between warfarin and the combination of remdesivir with dexamethasone
Identifying clinical and biochemical phenotypes in acute respiratory distress syndrome secondary to coronavirus disease-2019
April 15, 2021 – Acute respiratory distress syndrome (ARDS) secondary to coronavirus disease-2019 (COVID-19) is characterized by substantial heterogeneity in clinical, biochemical, and physiological characteristics
Novel 1,2,3-Triazole Derivatives as Potential Inhibitors against Covid-19 Main Protease: Synthesis, Characterization, Molecular Docking and DFT Studies
April 14, 2021 -The highly contagious nature of Covid-19 attracted us to this challenging area of research, mainly because the disease is spreading very fast and until now, no effective method of a safe treatment or a vaccine is developed
Initiation of psychotropic medication in hospitalized patients with COVID‐19: Association with clinical and biological characteristics
April 14, 2021 – Inpatients with coronavirus disease 2019 (COVID‐19) show a high rate of neuropsychiatric manifestations, possibly related to a higher risk of serious illness or death
COVID-19 pathophysiology and pharmacology: What do we know and how did Canadians respond? A review of Health Canada authorized clinical vaccine and drug trials
April 14, 2021 – Coronavirus disease 2019 (COVID-19) has resulted in the death of over 18000 Canadians and has impacted the lives of all Canadians
Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
April 14, 2021 – A novel coronavirus, designated SARS-CoV-2, caused an international outbreak of a respiratory illness, termed COVID-19 in December 2019
PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses
April 14, 2021 – The rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on a global scale urges prompt and effective countermeasures
The role of CD4+FoxP3+ regulatory T cells in the immunopathogenesis of COVID-19: implications for treatment
April 10, 2021 – The severe cases of Coronavirus Disease 2019 (COVID-19) frequently exhibit excessive inflammatory responses, acute respiratory distress syndrome (ARDS), coagulopathy, and organ damage
Development and application of therapeutic antibodies against COVID-19
April 10, 2021 – The pandemic of Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome 2 coronavirus (SARS-CoV-2) continues to be a global health crisis
Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
April 9, 2021 – Several cases of unusual thrombotic events and thrombocytopenia have developed after vaccination with the recombinant adenoviral vector encoding the spike protein antigen of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (ChAdOx1 nCov-19, AstraZeneca)
How Are Emerging Data Translated Into Clinical Practice? A Mixed Methods Investigation of Coronavirus Disease 2019 Institutional Treatment Protocols
April 07, 2021 – Early in the coronavirus disease 2019 (COVID-19) pandemic, there was minimal data to guide treatment, and we lacked understanding of how clinicians translated this limited evidence base for potential therapeutics to bedside care
Cytotoxic T-lymphocyte elicited vaccine against SARS-CoV-2 employing immunoinformatics framework
April 07, 2021 – Development of effective counteragents against the novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strains, requires clear insights and information for understanding the immune responses associated with it
SARS-CoV-2 drives JAK1/2-dependent local complement hyperactivation
April 07, 2021 – Patients with coronavirus disease 2019 (COVID-19) present a wide range of acute clinical manifestations affecting the lungs, liver, kidneys and gut
Drugs that inhibit TMEM16 proteins block SARS-CoV-2 Spike-induced syncytia
April 07, 2021 – COVID-19 is a disease with unique characteristics including lung thrombosis1, frequent diarrhoea2, abnormal activation of the inflammatory response3 and rapid deterioration of lung function consistent with alveolar oedema4
Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis
April 07, 2021 – The COVID-19 pandemic, caused by a novel coronavirus termed SARS-CoV-2, has spread quickly worldwide
Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS‐CoV‐2 infection in vitro
April 06, 2021 – The SARS‐COV‐2 pandemic and the global spread of coronavirus disease 2019 (COVID‐19) urgently call for efficient and safe antiviral treatment strategies
A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19
April 06, 2021 – Coronavirus disease 19 (COVID-19) is spreading globally and treatment options remain limited
Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells
April 05, 2021 – COVID-19, caused by the novel coronavirus SARS-CoV-2, is a global health issue with more than 2 million fatalities to date. Viral replication is shaped by the cellular microenvironment, and one important factor to consider is oxygen tension, in which hypoxia inducible factor (HIF) regulates transcriptional responses to hypoxia
COVID-19 and Pembrolizumab-Induced Secondary Hemophagocytic Lymphohistiocytosis: a Case Report
April 02, 2021 – Our case highlights SARS-CoV-2 and pembrolizumab as trigger of secondary hemophagocytic lymphohistiocytosis
Design and Identification of Novel Annomontine Analogues Against SARS-CoV-2: An In-Silico Approach
April 02, 2021 – COVID-19 has currently emerged as the major global pandemic affecting the lives of people across the globe
Renin-Angiotensin-Aldosterone System Inhibitors in COVID-19: A Review
March 30, 2021 – Among the multiple uncertainties surrounding the novel coronavirus disease (COVID-19) pandemic, a research letter published in The Lancet implicated drugs that antagonize the renin-angiotensin-aldosterone system (RAAS) in an unfavorable prognosis of COVID-19
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
March 30, 2021 – A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020
A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples
March 30, 2021 – COVID -19 is an acute infectious disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor
March 30, 2021 – Remdesivir (RDV, Veklury®) is a once-daily, nucleoside ribonucleic acid polymerase inhibitor of severe acute respiratory syndrome coronavirus 2 replication
Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
March 30, 2021 – Type III interferons have been touted as promising therapeutics in outpatients with coronavirus disease 2019 (COVID-19)
SARS-CoV-2 in severe COVID-19 induces a TGF-β-dominated chronic immune response that does not target itself
March 30, 2021 – The pathogenesis of severe COVID-19 reflects an inefficient immune reaction to SARS-CoV-2
Precision therapeutic targets for COVID-19
March 29, 2021 – Beginning in late 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged as a novel pathogen that causes coronavirus disease 2019 (COVID-19)
The potential of miRNA-based therapeutics in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a review
March 24, 2021 – Since the World Health Organization (WHO) declared COVID-19, the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), as a pandemic in March 2020, and more than 117 million people worldwide have been confirmed to have been infected
Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications
March 22, 2021 – The coronavirus disease-2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has infected more than 116 million individuals globally and resulted in over 2.5 million deaths since the first report in December 2019
Comparison of clinical manifestations, pre-existing comorbidities, complications and treatment modalities in severe and non-severe COVID-19 patients: A systemic review and meta-analysis
March 22, 2021 – The global pandemic of novel coronavirus disease 2019 (COVID-19) has become an emergency of major international concern
A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2
March 22, 2021 – The scientific community is focused on developing antiviral therapies to mitigate the impacts of the ongoing novel coronavirus disease 2019 (COVID-19) outbreak
Computational Mutagenesis at the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Binding Interface: Comparison with Experimental Evidence
March 18, 2021 – The coronavirus disease-2019 (COVID-19) pandemic, caused by the pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), started in China during late 2019 and swiftly spread worldwide
COVID-19: pathogenesis, advances in treatment and vaccine development and environmental impact—an updated review
March 18, 2021 – Diseases negatively impact the environment, causing many health risks and the spread of pollution and hazards
Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication
March 17, 2021 – The current pandemic is caused by a newly discovered coronavirus, severe-acute-respiratory-syndrome-related coronavirus 2 (SARS-CoV-2)
Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial
March 17, 2021 – In patients with COVID-19, granulocyte-macrophage colony stimulating factor (GM-CSF) might be a mediator of the hyperactive inflammatory response associated with respiratory failure and death
Antiviral Efficacy of Pralatrexate against SARS-CoV-2
March 17, 2021 – Novel coronavirus (SARS-CoV-2) has caused more than 100 million confirmed cases of human infectious disease (COVID-19) since December 2019 to paralyze our global community
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
March 16, 2021 – Assessment of the safety and efficacy of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in different populations is essential, as is investigation of the efficacy of the vaccines against emerging SARS-CoV-2 variants of concern, including the B.1.351 (501Y.V2) variant first identified in South Africa
Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients
March 15, 2021 – Intensive care unit (ICU) admissions and mortality in severe COVID-19 patients are driven by “cytokine storms” and acute respiratory distress syndrome (ARDS)
Integrated cytokine and metabolite analysis reveals immunometabolic reprogramming in COVID-19 patients with therapeutic implications
March 12, 2021 – Cytokine release syndrome (CRS) is a major cause of the multi-organ injury and fatal outcome induced by SARS-CoV-2 infection in severe COVID-19 patients
Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 – Spike protein interaction in vitro
March 11, 2021 – Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has resulted in an ongoing pandemic
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
March 11, 2021 – SARS-CoV-2 transmission is uncontrolled in many parts of the world, compounded in some areas by higher transmission potential of the B1.1.7 variant1 now reported in 94 countries
Structure, Dynamics, Receptor Binding, and Antibody Binding of the Fully Glycosylated Full-Length SARS-CoV-2 Spike Protein in a Viral Membrane
March 10, 2021 – The spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mediates host cell entry by binding to angiotensin-converting enzyme 2 (ACE2) and is considered the major target for drug and vaccine development
A Dual Target-Directed Single Domain-Based Fusion Protein Against Interleukin-6 Receptor Decelerate Experimental Arthritis Progression Via Modulating JNK Expression
March 10, 2021 – The currently used anti-cytokine therapeutic antibodies cannot selectively neutralize pathogenic cytokine signalling that cause collateral damage to protective signalling cascades
Overexpression of angiotensin-converting enzyme 2 by renin-angiotensin system inhibitors. Truth or myth? A systematic review of animal studies
March 10, 2021 – Angiotensin-converting enzyme 2 (ACE2) protects against organ damage in hypertension and cardiovascular diseases by counter regulating the renin-angiotensin system (RAS)
Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2
March 9, 2021 – Up to date, effective antivirals have not been widely available for treating COVID-19
Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial
March 9, 2021 – Early inhibition of entry and replication of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a very promising therapeutic approach
Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks
March 9, 2021 – While the COVID-19 pandemic caused by SARS-CoV-2 is continuing, it may become worse in the coming winter months with a high potential for the emergence and spread of escape variants of SARS-CoV-2
Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 In Vitro
March 9, 2021 – Ribavirin is a guanosine analog and has a broad-spectrum antiviral activity against RNA viroses
Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection
March 08, 2021 – Synthetic ssDNA aptamers containing a conserved sequence motif that specifically targets the receptor-binding domain (RBD) of the SARS-CoV-2 spike have the capacity to neutralize the virus and prevent host cell infection in vitro, suggesting a new therapeutic approach to treat COVID-19
Temporal dynamics of the host molecular responses underlying severe COVID-19 progression and disease resolution
March 07, 2021 – The coronavirus disease-19 (COVID-19) pandemic has cost lives and economic hardships globally
Contribution of STAT3 to the pathogenesis of COVID-19
March 7, 2021 – Hyper-inflammatory responses, lymphopenia, unbalanced immune responses, cytokine storm, large viral replication and massive cell death play fundamental roles in the pathogenesis of COVID-19
Interferon antagonism by SARS-CoV-2: a functional study using reverse genetics
March 4, 2021 – The COVID-19 agent, SARS-CoV-2, is conspecific with SARS-CoV, the causal agent of the severe acute respiratory syndrome epidemic in 2002–03
Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial
March 4, 2021 – Global randomised controlled trials of the anti-IL-6 receptor antibody tocilizumab in patients admitted to hospital with COVID-19 have shown conflicting results but potential decreases in time to discharge and burden on intensive care
Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial
March 4, 2021 – Elevated proinflammatory cytokines are associated with greater COVID-19 severity
Clinical evidence of an interferon–glucocorticoid therapeutic synergy in COVID-19
March 3, 2021 – Synthetic glucocorticoid dexamethasone is the first trial-proven drug that reduces COVID-19 mortality by suppressing immune system
Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro
March 2, 2021 – COVID-19 cases showed a significant decrease in the number of peripheral CD4+ and CD8+ T cells accompanied by overactivation of cells
Design, Synthesis and Biological Evaluation of 2-Aminoquinazolin-4(3H)-one Derivatives as Potential SARS-CoV-2 and MERS-CoV Treatments
March 2, 2021 – Despite the rising threat of fatal coronaviruses, there are no general proven effective antivirals to treat them
S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates
March 1, 2021 – SARS-CoV-2 is the underlying cause for the COVID-19 pandemic. Like most enveloped RNA viruses, SARS-CoV-2 uses a homotrimeric surface antigen to gain entry into host cells
Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection
February 25, 2021 – Hyperinflammatory response caused by infections such as Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) increases organ failure, intensive care unit admission, and mortality
BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
February 24, 2021 – As mass vaccination campaigns against coronavirus disease 2019 (Covid-19) commence worldwide, vaccine effectiveness needs to be assessed for a range of outcomes across diverse populations in a noncontrolled setting
Akt‐independent effects of triciribine on ACE2 expression in human lung epithelial cells: Potential benefits in restricting SARS‐CoV2 infection
February 24, 2021 – The severe acute respiratory syndrome coronavirus 2 that causes coronavirus disease 2019 (COVID‐19) binds to the angiotensin‐converting enzyme 2 (ACE2) to gain cellular entry
Insights into SARS-CoV-2 evolution, potential antivirals, and vaccines
February 22 , 2021 – SARS-CoV-2 is a novel coronavirus, spread among humans, and to date, more than 100 million of laboratory-confirmed cases have been reported worldwide
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
February 19, 2021 – The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4–12 weeks
Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2
February 19, 2021 – In 2020 SARS-CoV-2 reached pandemic status, reaching Brazil in mid-February. As of now, no specific drugs for treating the disease are available
Efficacy and harms of convalescent plasma for treatment of hospitalized COVID-19 patients: a systematic review and meta-analysis
18 February 2021 – In comparison to SOC or placebo + SOC, CP did not reduce all-cause mortality in RCTs of hospitalized COVID-19 patients
Maintaining Safety with SARS-CoV-2 Vaccines
February 18, 2021 – To date, the development of mRNA vaccines for the prevention of infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been a success story, with no serious concerns identified in the ongoing phase 3 clinical trials
The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2
February 18, 2021 – Convalescent plasma therapy has been used successfully in the past to treat respiratory infections
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
February 18, 2021 – Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia
February 18, 2021 – Convalescent plasma is frequently administered to patients with Covid-19 and has been reported, largely on the basis of observational data, to improve clinical outcomes
Carvacrol, a Plant Metabolite Targeting Viral Protease (M pro) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19
February 16, 2021 – The recent outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) started in December 2019, resulting in the coronavirus disease-19 (COVID-19) pandemic
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection
February 12, 2021 – SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of action in vivo is incompletely understood
Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment
February 12, 2021 – The COVID-19 pandemic is unlikely to end until there is global roll-out of vaccines that protect against severe disease and preferably drive herd immunity
Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study
February 11, 2021 – Our aim was to compare clinical characteristics, prophylactic treatment, markers of inflammation, and thrombotic outcomes in inpatients positive for SARS-CoV2 during hospitalization associated with thromboprophylaxis with enoxaparin (40 mg or 60 mg once daily) or fondaparinux (2.5 mg once daily)
Current evidence for COVID-19 therapies: a systematic literature review
February 10, 2021 – Effective therapeutic interventions for the treatment and prevention of coronavirus disease 2019 (COVID-19) are urgently needed
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants
February 10, 2021 – Here we report on the antibody and memory B cell responses in a cohort of 20 volunteers who received either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines1–4
SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801
February 9, 2021 – All known recently emerged human coronaviruses probably originated in bats1
Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19
8 February 2021 – The preconditioned immune dysregulation enables SARS-CoV-2 infection to progress to an uncontrolled hyperinflammatory response
MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein
February 6, 2021 – The molecular interactions between viral proteins form the basis of virus production and can be used to develop strategies against virus infection
Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
February 05, 2021 – To date, only monoclonal antibodies have been shown to be effective for outpatients with COVID-19. Interferon lambda-1 is a type III interferon involved in innate antiviral responses with activity against respiratory pathogens
The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19
February 04, 2021 – In addition to causing health concerns, the new coronavirus has been considered in the world with its unknown mechanism of physiopathogenesis and long-term effects after patient recovery
Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis
February 04, 2021 – The coronavirus disease 2019 (COVID-19) pandemic has become a global health crisis
Anti‑infection mechanism of phosphodiesterase‑5 inhibitors and their roles in coronavirus disease 2019 (Review)
February 3, 2021 – Coronavirus disease 2019 (COVID‑19) has a variety of impacts on the human body
Immunoregulatory therapy strategies that target cytokine storms in patients with COVID‑19 (Review)
February 3, 2021 – A cytokine storm is an uncontrolled, excessive immune response that contributes to the pathogenesis of coronavirus disease 2019 (COVID‑19)
Structural insights into SARS-CoV-2 infection and therapeutics development
February 02, 2021 – The current COVID-19 pandemic is caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)
SARS-CoV-2: From the pathogenesis to potential anti-viral treatments
February 02, 2021 – The world is witnessing the spread of one of the members of Coronaviruses (CoVs) family, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the 21st century
Colchicine and SARS-CoV-2: Management of the hyperinflammatory state
January 31, 2021 – The global COVID-19 pandemic is currently underway. In December 2020, the European Agency of Medicine (EMA) licensed the first Sars-CoV-2 vaccine
Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP
January 30, 2021 – The coronavirus (CoV) infects a broad range of hosts including humans as well as a variety of animals
Targets and strategies for vaccine development against SARS-CoV-2
January 28, 2021 – The SARS-CoV-2, previously called a novel coronavirus, that broke out in the Wuhan city of China caused a significant number of morbidity and mortality in the world
COVID-19: Before the Fall, An Evidence-Based Narrative Review of Treatment Options
January 25, 2021 – The 2019 novel coronavirus (COVID-19) has quickly become one of the most dire international pandemic crises since the 1918 Spanish flu
COVID-19: Characteristics and Therapeutics
January 21, 2021 – Novel coronavirus (COVID-19 or 2019-nCoV or SARS-CoV-2), which suddenly emerged in December 2019 is still haunting the entire human race and has affected not only the healthcare system but also the global socioeconomic balances
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
January 21, 2021 – Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19
January 21, 2021 – Importance Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19
SARS-CoV-2 RNA dependent RNA polymerase as a therapeutic target for COVID-19
January 21, 2021 – The current SARS-CoV-2 pandemic urgently demands for both prevention and treatment strategies
Targeting SARS-CoV-2 Viral Proteases as a Therapeutic Strategy to Treat COVID-19
January 21, 2021 – The 21st century has witnessed three outbreaks of coronavirus (CoVs) infections caused by severe acute respiratory syndrome (SARS)‐CoV, Middle East respiratory syndrome (MERS)‐CoV and SARS‐CoV‐2
In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase
January 21, 2021 – Coronavirus disease 2019 (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused a global pandemic
Enisamium is an inhibitor of the SARS-CoV-2 RNA polymerase and shows improvement of recovery in COVID-19 patients in an interim analysis of a clinical trial
January 21, 2021 – Pandemic SARS-CoV-2 causes a mild to severe respiratory disease called Coronavirus Disease 2019 (COVID-19)
Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19
January 18, 2021 – A recently identified type of pneumonia, referred to as coronavirus disease 2019 (COVID‑19), which is caused by severe acute respiratory syndrome coronavirus‑2, has rapidly spread worldwide
Pharmacological strategies to prevent SARS-CoV-2 infection and to treat the early phases of COVID-19 disease
January 18, 2021 – A novel coronavirus known as SARS-CoV-2 causing the human COVID-19 disease, emerged in China and is spreading worldwide
Cholesterol 25-hydroxylase suppresses porcine deltacoronavirus infection by inhibiting viral entry
January 18, 2021 – Cholesterol 25-hydroxylase (CH25 H) is a key enzyme regulating cholesterol metabolism and also acts as a broad antiviral host restriction factor
An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease
January 18, 2021 – 2020 will be remembered worldwide for the outbreak of Coronavirus disease (COVID-19), which quickly spread until it was declared as a global pandemic
Molecular docking and simulation studies of natural compounds of Vitex negundo L. against papain-like protease (PLpro) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world
January 18, 2021 – The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) is β-coronavirus that is responsible for the pandemic coronavirus disease 2019 (COVID-19) all over the world
Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages
January 14, 2021 – Cannabis sativa is widely used for medical purposes and has anti-inflammatory activity
Efficacy of synthetic glucocorticoids in COVID-19 endothelites
January 14, 2021 – Since March 2020, the world has been fighting a global pandemic caused by a new coronavirus SARS-CoV-2 (COVID-19)
Perinatal Cells: A Promising COVID-19 Therapy?
January 14, 2021 – The COVID-19 pandemic has become a priority in the health systems of all nations worldwide. In fact, there are currently no specific drugs or preventive treatments such as vaccines
A novel ratio of CD8+:B-cells as a prognostic marker of coronavirus disease 2019 patient progression and outcome
January 13, 2021 – Infection with SARS-COV-2 may result in severe pneumonia potentially leading to mechanical ventilation and intensive care treatment
Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease
January 12, 2021 – Coronavirus disease 19 (COVID-19) is the latest pandemic resulted from the coronavirus family
In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19)
January 12, 2021 – The spread of SARS-CoV-2 has affected human health globally. Hence, it is necessary to rapidly find the drug-candidates that can be used to treat the infection
Acquired factor V inhibitor in the setting of coronavirus disease 2019 infection
January 12, 2021 – Factor V inhibitors are a rare cause of life-threatening bleeding. We present a case of an acquired factor V inhibitor likely caused by coronavirus disease 2019 infection
In silico validation of potent phytochemical Orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding
January 11, 2021 – The present wellbeing worry to the whole world is the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also called COVID-19
ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy
January 11, 2021 – COVID-19 is an infectious respiratory illness caused by the virus strain severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and until now, there is no effective therapy against COVID-19
Review of pharmacologic and immunologic agents in the management of COVID-19
January 9, 2021 – The novel coronavirus disease 2019 (COVID-19) is the third coronavirus outbreaks in the last two decades
Impact of oral anticoagulation on clinical outcomes of COVID-19: a nationwide cohort study of hospitalized patients in Germany
January 8, 2021 – The aim of this study was to investigate the impact of concomitant long-term medication—with a focus on ACE inhibitors and oral anticoagulation—on clinical outcomes in patients hospitalized with coronavirus disease 2019
Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19
January 7, 2021 – Coronaviruses are non-segmented and single stranded positive-sense RNA (+ssRNA) viruses
Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction
January 7, 2021 – COVID-19 (coronavirus disease 2019) is the current world health crisis, producing extensive morbidity and mortality across all age groups
Interleukin-38 ameliorates poly(I:C) induced lung inflammation: therapeutic implications in respiratory viral infections
January 7, 2021 – Interleukin-38 has recently been shown to have anti-inflammatory properties in lung inflammatory diseases
Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab
January 6, 2021 – Coronavirus disease 2019 (COVID-19) is associated with considerable morbidity and mortality
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults
January 6, 2021 – Therapies to interrupt the progression of early coronavirus disease 2019 (Covid-19) remain elusive
Matched cohort study on the efficacy of tocilizumab in patients with COVID-19
January 5, 2021 – Tocilizumab has been proposed as a treatment for the new disease COVID-19, however, there is not enough scientific evidence to support this treatment
Review on COVID-19 Etiopathogenesis, Clinical Presentation and Treatment Available with Emphasis on ACE2
January 3, 2021 – In December 2019, Wuhan city in the Hubei province of China reported for the first time a cluster of patients infected with a novel coronavirus, since then there has been an outburst of this disease across the globe affecting millions of human inhabitants
Network pharmacology-based analysis of zukamu granules for the treatment of COVID-19
January 2, 2021 – Zukamu granules may play a potential role in the fight against the Coronavirus, COVID-19
Renin-angiotensin system blockers, risk of SARS-CoV-2 infection and outcomes fromCoViD-19: systematic review and meta-analysis
December 31, 2020 – Concern has been raised about the safety of the renin–angiotensin system (RAS) blockers in relation to infection with severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2)
Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues
December 31, 2020 – The mitogen-activated protein kinase (MAPK) pathway links the cell-surface receptors to the transcription machinery, transducing the extracellular signals into several outputs, which may also adapt the host defense mechanism to viral attacks
A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening
December 29, 2020 – The unparalleled global effort to combat the continuing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic over the last year has resulted in promising prophylactic measures
Clinical Outcomes From COVID-19 Following Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers Among Patients with Hypertension in South Korea: A nationwide study
December 29, 2020 – Recent evidence show no harm associated with the use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-receptor blockers (ARBs) and coronavirus disease-2019 (COVID-19)
A Comprehensive Analysis of cis-Acting RNA Elements in the SARS-CoV-2 Genome by a Bioinformatics Approach
December 23, 2020 – The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes severe respiratory disease in humans, is called the coronavirus disease of 2019 (COVID-19)
Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2
December 23, 2020 – The rapidly developing pandemic, known as coronavirus disease 2019 (COVID-19) and caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has recently spread across 213 countries and territories
Computational and network pharmacology analysis of bioflavonoids as possible natural antiviral compounds in COVID-19
December 23, 2020 – Bioflavonoids are the largest group of plant-derived polyphenolic compounds with diverse biological potential and have also been proven efficacious in the treatment of Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS)
The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective
December 22, 2020 – Respiratory failure due to SARS-CoV-2 has caused widespread mortality, creating an urgent need for effective treatments and a long-term need for antivirals for future emergent coronaviruses
Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial
December 18, 2020 – Effective treatments are urgently needed to tackle the novel coronavirus disease 2019 (COVID-19)
Biochemical and biophysical characterization of the main protease, 3-chymotrypsin-like protease (3CLpro) from the novel coronavirus SARS-CoV 2
December 17, 2020 – Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) is responsible for the novel coronavirus disease 2019 (COVID-19)
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
December 17, 2020 – Recent data suggest that complications and death from coronavirus disease 2019 (Covid-19) may be related to high viral loads
Dexamethasone Vs. COVID‐19: An Experimental Study in Line with the Preliminary Findings of a Large Trial
December 17, 2020 – The preliminary report of the RECOVERY large randomized controlled trial indicated a promising survival effect for dexamethasone therapy of coronavirus disease 2019 (COVID‐19)
SARS-CoV-2–specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein
December 17, 2020 – T-cell responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been described in recovered patients, and may be important for immunity following infection and vaccination as well as for the development of an adoptive immunotherapy for the treatment of immunocompromised individuals
A retrospective comparison of drugs against COVID-19
December 14, 2020 – Coronavirus disease 19 (COVID-19) has posed serious threats to the general population
Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia
December 13, 2020 – Despite the rapid global increase of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, there is currently no effective treatment for patients who have developed severe coronavirus disease 2019 (COVID-19)
Drug Repurposing for COVID-19 using Graph Neural Network with Genetic, Mechanistic, and Epidemiological Validation
December 11, 2020 – Amid the pandemic of 2019 novel coronavirus disease (COVID-19) infected by SARS-CoV-2, a vast amount of drug research for prevention and treatment has been quickly conducted, but these efforts have been unsuccessful thus far
Tocilizumab and COVID-19: A Meta-Analysis of 2120 Patients with Severe Disease and Implications for Clinical Trial Methodologies
December 2020 – Since the outbreak of the COVID-19, numerous therapies to counteract severe 4 disease have emerged. The benefits of Tocilizumab for severely infected COVID-19 patients 5 and the methodologies of ongoing clinical trials are explored
Genetic mechanisms of critical illness in Covid-19
December 11, 2020 – Host-mediated lung inflammation is present,1 and drives mortality,2 in critical illness caused by Covid-19
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
December 11, 2020 – Severe coronavirus disease 2019 (Covid-19) is associated with dysregulated inflammation. The effects of combination treatment with baricitinib, a Janus kinase inhibitor, plus remdesivir are not known
A data-driven approach to identify risk profiles and protective drugs in COVID-19
December 10, 2020 – The global outbreak of COVID-19 infections generated an unprecedented need to develop novel therapeutic strategies
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
December 10, 2020 – A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
December 10, 2020 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic
Recent progress in the repurposing of drugs/molecules for the management of COVID-19
December 10, 2020 – In the current scenario, COVID-19 is a clinical and public health problem globally
Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
December 09, 2020 – Statins and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors interfere with several pathophysiological pathways of coronavirus disease 2019 (COVID-19)
Binding of SARS-CoV-2 spike protein to ACE2 is disabled by thiol-based drugs; evidence from in vitro SARS-CoV-2 infection studies
December 8, 2020 – Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the SARS-CoV-2 spike protein is an envelope glycoprotein that binds angiotensin converting enzyme 2 as an entry receptor
Remdesivir for the treatment of coronavirus COVID-19: a meta-analysis of randomised controlled trials
December 08, 2020 – A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing COVID-19, was identified in December 2019 and rapidly spread worldwide
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
December 08, 2020 – A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic
HMGB1 as a Potential Biomarker and Therapeutic Target for Severe COVID-19
December 07, 2020 – COVID-19 has attracted global attention due to its rapid spread around the world with substantial morbidity and associated mortality
Impact of repurposed drugs on the symptomatic COVID-19 patients
December 07, 2020 – An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel coronavirus capable of causing coronavirus disease 2019 (COVID-19), was declared as a global public health emergency on January 30, 2020, by the World Health Organization
Transcriptional response modules characterise IL-1β and IL-6 activity in COVID-19
December 07, 2020 – Dysregulated IL-1β and IL-6 responses have been implicated in the pathogenesis of severe Coronavirus Disease 2019 (COVID-19)
Effect of nelfinavir stereoisomers on coronavirus main protease: Molecular docking, molecular dynamics simulation and MM/GBSA study
December 04, 2020 – In this study, the binding strength of 32 diastereomers of nelfinavir, a proposed drug for the treatment of COVID-19, was considered against main protease
Plant-based vaccines and antibodies to combat COVID-19: current status and prospects
December 03, 2020 – Globally, researchers are undertaking significant efforts to design and develop effective vaccines, therapeutics, and antiviral drugs to curb the spread of coronavirus disease 2019 (COVID-19)
New proposal involving nanoformulated melatonin targeted to the mitochondria as a potential COVID-19 treatment
December 03, 2020 – Melatonin may be a powerful auxiliary therapy in the prevention and treatment of viral infections, such as coronavirus disease 2019 (COVID-19)
Micro-RNAs in the regulation of immune response against SARS COV-2 and other viral infections
December 02, 2020 -Micro-RNAs (miRNAS) are non-coding, small RNAs that have essential roles in different biological processes through silencing genes, they consist of 18-24 nucleotide length RNA molecules
COVID-19 and cancer: From basic mechanisms to vaccine development using nanotechnology
December 02, 2020 – Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a global pandemic which has induced unprecedented ramifications, severely affecting our society due to the long incubation time, unpredictably high prevalence and lack of effective vaccines
2-Pyridone natural products as inhibitors of SARS-CoV-2 main protease
December 02, 2020 – The disease, COVID-19, is caused by the severe acute respiratory coronavirus 2 (SARS-CoV-2) for which there is currently no treatment
Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease
December 1, 2020 – The cell surface protein TMPRSS2 (transmembrane protease serine 2) is an androgen-responsive serine protease important for prostate cancer progression and therefore an attractive therapeutic target
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19
December 01, 2020 – There is urgent therapeutic need for COVID-19, a disease for which there are currently no widely effective approved treatments and the emergency use authorized drugs do not result in significant and widespread patient improvement
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19
December 01, 2020 – There is urgent therapeutic need for COVID-19, a disease for which there are currently no widely effective approved treatments and the emergency use authorized drugs do not result in significant and widespread patient improvement
Investigation of beta-lactoglobulin derived bioactive peptides against SARS-CoV-2 (COVID-19): in silico analysis
December 01, 2020 – The coronavirus disease of 2019 (COVID-19) outbreak caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which started in late 2019 in Wuhan, China spread to the whole world in a short period of time, and thousands of people have died due to this epidemic
High rate of major drug–drug interactions of lopinavir–ritonavir for COVID-19 treatment
December 01, 2020 – The impact of drug–drug interactions (DDI) between ritonavir-boosted lopinavir (LPV-r) to treat patients with coronavirus disease 2019 (COVID-19) and commonly used drugs in clinical practice is not well-known
D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization
December 01, 2020 – The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired a D614G mutation early in the pandemic that confers greater infectivity and is now the globally dominant form
Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model
November 30, 2020 – Two outbreaks of severe respiratory infection caused by severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV) caused global pandemics and highlighted the importance of preparedness for respiratory CoVs
Challenges and stepwise fit-for-purpose optimization for bioanalyses of remdesivir metabolites nucleotide monophosphate and triphosphate in mouse tissues using LC–MS/MS
November 30, 2020 – Remdesivir is a prodrug of the nucleotide analogue and used for COVID-19 treatment
A Neutralizing Antibody-Conjugated Photothermal Nanoparticle Captures and Inactivates SARS-CoV-2
November 30, 2020 – The outbreak of 2019 coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic
How Could In Vitro Antiviral Activity Be Applied to Optimize the Dosing Regimens of Candidates for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)?
November 27, 2020 – Recently, Yao et al reported an optimized dosing regimen design of hydroxychloroquine (HCQ) for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on model and simulation (M&S)
The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines
November 26, 2020 – The coronavirus disease 2019 (COVID-19) pandemic has created an urgent need for therapeutics that inhibit the SARS−COV-2 virus and suppress the fulminant inflammation characteristic of advanced illness
Aerosol inhalation delivery of triazavirin in mice: outlooks for advanced therapy against novel viral infections
November 25, 2020 – Under pandemic-caused emergency, evaluation of the potential of existing antiviral drugs for the treatment of COVID-19 is relevant. Triazavirin, an antiviral drug developed in Russia for per-oral administration, is involved in clinical trials against SARS-CoV-2 coronavirus
SARS-CoV-2 infection: can ferroptosis be a potential treatment target for multiple organ involvement?
November 25, 2020 – Since the outbreak of the new coronavirus in 2019 (SARS-CoV-2), many studies have been performed to better understand the basic mechanisms and clinical features of the disease
DFT and Molecular Docking Study of Chloroquine Derivatives as Antiviral to Coronavirus COVID-19
November 25, 2020 – The recently emerged COVID-19 virus caused hundreds of thousands of deaths and instigated a widespread fear, threatening the world’s most advanced health security
A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro
November 24, 2020 – We recently discovered a superantigen-like motif, similar to Staphylococcal enterotoxin B (SEB), near the S1/S2 cleavage site of SARS-CoV-2 Spike protein, which might explain the multisystem-inflammatory syndrome (MIS-C) observed in children and cytokine storm in severe COVID-19 patients
Identification of natural inhibitors against prime targets of SARS-CoV-2 using molecular docking, molecular dynamics simulation and MM-PBSA approaches
November 13, 2020 – The recently emerged COVID-19 has been declared a pandemic by the World Health Organization as to date; no therapeutic drug/vaccine is available for the treatment
Virulence and pathogenesis of SARS-CoV-2 infection in rhesus macaques: A nonhuman primate model of COVID-19 progression
November 12, 2020 – The COVID-19 has emerged as an epidemic, causing severe pneumonia with a high infection rate globally
Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking
November 12, 2020 – The outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus has spread rapidly around the globe during the past 3 months
Network Pharmacology and bioinformatics analyses identify intersection genes of niacin and COVID-19 as potential therapeutic targets
November 10, 2020 – Patients with colorectal cancer (CRC) may be susceptible to the coronavirus disease-2019 (COVID-19)
COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice
November 09, 2020 – The ongoing COVID-19 pandemic is associated with substantial morbidity and mortality
A pharmacology‐based comprehensive review on medicinal plants and phytoactive constituents possibly effective in the management of COVID‐19
November 06, 2020 – Arisen in China, COVID‐19 (SARS‐CoV‐II) is a novel coronavirus that has been expanding fast worldwide
An overview of antiviral strategies for coronavirus 2 (SARS-CoV-2) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine
November 06, 2020 – At present, neither specific antiviral drugs, nor vaccine is recommended for coronavirus disease 2019 (COVID‐19) treatment
Searching for target-specific and multi-targeting organics for Covid-19 in the Drugbank database with a double scoring approach
November 05, 2020 – The current outbreak of Covid-19 infection due to SARS-CoV-2, a virus from the coronavirus family, has become a major threat to human healthcare
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
November 05, 2020 – Cost-effective, efficacious therapeutics are urgently needed against the COVID-19 pandemic
An overview on the use of antivirals for the treatment of patients with COVID19 disease
November 05, 2020 – There is an urgent need for safe and efficacious antiviral drugs to improve outcomes for COVID-19 patients
Remdesivir for the Treatment of Covid-19 — Final Report
November 05, 2020 – Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), no antiviral agents have yet been shown to be efficacious
Canadian Immunization Guide: “Anaphylaxis and other acute reactions following vaccination” chapter update
November 5, 2020 – The Canadian Immunization Guide (CIG) is a comprehensive resource on immunization for health professionals and vaccine program decision-makers
Insights from nanotechnology in COVID-19 treatment
November 04, 2020 – In just a few months, SARS-CoV-2 and the disease it causes, COVID-19, created a worldwide pandemic
Computer aided identification of potential SARS CoV-2 main protease inhibitors from diterpenoids and biflavonoids of Torreya nucifera leaves
November 3, 2020 – SARS CoV-2 is the causative agent of the pandemic disease COVID-19. There is an urgent need for effective drugs or vaccines which can effectively combat this outbreak
Toward COVID-19 Therapeutics: A Viewpoint from the Nonprotein Amino Acid Based Synthetic Peptide Design Approach
November 3, 2020 – Cell entry, the fundamental step in cross-species transmission of SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), is initiated by the recognition of the host cell angiotensin-converting enzyme-2 (ACE2) receptor by the receptor-binding domain (RBD) of the spike protein of SARS-CoV-2
CRISPR-Cas System: An Approach With Potentials for COVID-19 Diagnosis and Therapeutics
November 02, 2020 – COVID-19, the human coronavirus disease caused by SARS-CoV-2, was reported for the first time in Wuhan, China in late 2019
Rapid identification of a human antibody with high prophylactic and therapeutic efficacy in three animal models of SARS-CoV-2 infection
November 2, 2020 – Effective therapies are urgently needed for the SARS-CoV-2/COVID-19 pandemic. We identified panels of fully human monoclonal antibodies (mAbs) from large phage-displayed Fab, scFv, and VH libraries by panning against the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) glycoprotein
New Perspectives on Antimicrobial Agents: Remdesivir Treatment for COVID-19
November 2, 2020 – Remdesivir was recently approved by the Food and Drug Administration for the treatment of hospitalized patients with COVID-19
Hyperimmune anti-COVID-19 IVIG (C-IVIG) Therapy for Passive Immunization of Severe and Critically Ill COVID-19 Patients: A structured summary of a study protocol for a randomised controlled trial
November 2, 2020 – The aim of this trial is to investigate the safety and clinical efficacy of passive immunization therapy through Hyperimmune anti-COVID-19 Intravenous Immunoglobulin (C-IVIG: 5% liquid formulation), on severe and critically ill patients with COVID-19
Safety and efficacy of Artemisinin-Piperaquine for treatment of COVID-19: an open-label, non-randomized, and controlled trial
November 2, 2020 – In patients with mild to moderate COVID-19, the time to reach undetectable SARS-CoV-2 was significantly shorter in the AP group than that in the control group
GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia
November 01, 2020 – To assess the efficacy and safety of lenzilumab in patients with severe coronavirus disease 2019 (COVID-19) pneumonia
Boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against coronaviruses in cell culture
November 1, 2020 – As the COVID-19 pandemic continues to fold out, the morbidity and mortality are increasing daily
Integrative transcriptome analyses empower the anti-COVID-19 drug arsenal
November, 2020 – The beginning of the 21st century has been marked by three distinct waves of zoonotic coronavirus outbreaks into the human population
Combined Interventions for Severe Novel Coronavirus Disease (COVID-19): Experience from 350 Patients
October 30, 2020 – In this retrospective, multicenter study, the medical records of COVID-19 patients in Hunan, from January 21, 2020 to February 19, 2020 were reviewed
Atorvastatin and Aspirin as Adjuvant Therapy in Patients with SARS-CoV-2 Infection: A structured summary of a study protocol for a randomised controlled trial
October 30, 2020 – To assess the impact of adding statin (atorvastatin) and/or aspirin on clinical deterioration in patients infected with SARS-CoV-2 who require hospitalisation
Exploring RdRp-remdesivir interactions to screen RdRp inhibitors for the management of novel coronavirus 2019-nCoV
October 26, 2020 – A novel coronavirus recently identified in Wuhan, China (2019-nCoV) has resulted in an increasing number of patients globally, and has become a highly lethal pathogenic member of the coronavirus family affecting humans
Use of a Humanized Anti-CD6 Monoclonal Antibody (Itolizumab) in Elderly Patients with Moderate COVID-19
October 26, 2020 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a recent outbreak of coronavirus disease (COVID-19). In Cuba, the first case of COVID-19 was reported on March 11, 2020
Development of Remdesivir as a Dry Powder for Inhalation by Thin Film Freezing
October 22, 2020 – Remdesivir exhibits in vitro activity against SARS-CoV-2 and was granted approval for emergency use. To maximize delivery to the lungs, we formulated remdesivir as a dry powder for inhalation using thin film freezing (TFF)
Discovery of small molecule PLpro inhibitor against COVID-19 using structure-based virtual screening, molecular dynamics simulation, and molecular mechanics/Generalized Born surface area (MM/GBSA) calculation
October 22, 2020 – COVID-19 is spreading in a global pandemic that is endangering human life and health. Therefore, there is an urgent need to target COVID-19 to find effective treatments for this emerging acute respiratory infection
A potential treatment for COVID-19 based on modal characteristics and dynamic responses analysis of 2019-nCoV
October 21, 2020 – The 2019-nCoV is ravaging the world, taking lots of lives, and it is emergent to find a solution to deal with this novel pneumonia
Clinical features and antibody response of patients from a COVID-19 treatment hospital in Wuhan, China
October 21, 2020 – A total of 1578 patients admitted into a newly built hospital specialized for COVID‐19 treatment in Wuhan, China, were enrolled. Clinical features and the levels of SARS‐CoV‐2 IgM and IgG were analyzed
Efficacy of Tocilizumab in Patients Hospitalized with Covid-19
October 21, 2020 – The efficacy of interleukin-6 receptor blockade in hospitalized patients with coronavirus disease 2019 (Covid-19) who are not receiving mechanical ventilation is unclear
Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium
October 19, 2020 – The human airway epithelium is the initial site of SARS-CoV-2 infection. We used flow cytometry and single cell RNA-sequencing to understand how the heterogeneity of this diverse cell population contributes to elements of viral tropism and pathogenesis, antiviral immunity, and treatment response to remdesivir
Favipiravir as an antiviral agent in COVID-19: same script, different cast?
October 19, 2020 – Publicado pela Oxford University Press para a Infectious Diseases Society of America
Comparison of Transgenic and Adenovirus hACE2 Mouse Models for SARS-CoV-2 Infection
October 17, 2020 – Severe acute respiratory syndrome CoV-2 (SARS-CoV-2) is currently causing a worldwide pandemic with high morbidity and mortality
Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for COVID-19 patients
October 17, 2020 – Among haematological parameters of patients seriously ill with the coronavirus infectious disease 2019 (COVID-19), leucocytosis, lymphocytopenia, and the abnormal release of circulating cytokines, termed cytokine storm syndrome (CSS, also known as cytokine release syndrome or CRS), were found associated with disease severity
Methylene blue inhibits the replication of SARS-Cov-2 in vitro
October 16, 2020 – In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China
Computer-aided drug design against spike glycoprotein of SARS-CoV-2 to aid COVID-19 treatment
October 15, 2020 – The current study was conducted to explore drugs against Receptor Binding Domain (RBD) of SARS-CoV-2 using in silico pharmacophore modelling and virtual screening approach to combat COVID-19
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study
October 14, 2020 – Coronavirus disease 2019 (COVID‐19) outbreak is a major challenge all over the world, without acknowledged treatment
Molecular screening of antimalarial, antiviral, anti-inflammatory and HIV protease inhibitors against spike glycoprotein of coronavirus
October 13, 2020 – Coronavirus outbreak in December 2019 (COVID-19) is an emerging viral disease that poses major menace to Humans and it’s a crucial need to find the possible treatment strategies
Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome
October 10, 2020 – Many laboratory parameters have been associated with morbidity and mortality in SARS‐CoV‐2 (COVID‐19), which emerged in an animal market in Wuhan, China in December 2019 and has infected over 20 million people
Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs
October 9, 2020 – The repurposing of FDA approved drugs is presently receiving attention for COVID-19 drug discovery
Hot spot profiles of SARS-CoV-2 and human ACE2 receptor protein protein interaction obtained by density functional tight binding fragment molecular orbital method
October 08, 2020 – The prevalence of a novel β-coronavirus (SARS-CoV-2) was declared as a public health emergency of international concern on 30 January 2020 and a global pandemic on 11 March 2020 by WHO
Tackling SARS‐CoV‐2 Infections using Remdesivir and Favipiravir as Therapeutic Options
October 08, 2020 – The outbreak of pandemic COVID‐19 causes severe damage to the human world, including infections, deaths, and economic disruptions. The world has focused on developing treatment and controlling measures against COVID‐19
Angiotensin‐converting enzyme 2: A protective factor in regulating disease virulence of SARS‐COV‐2
October 08, 2020 – Novel SARS‐CoV‐2 named due to its close homology with severe acute respiratory syndrome coronavirus (SARS‐CoV) is the etiologic agent for the ongoing pandemic outbreak causing loss of life and severe economic burden globally
Efficacy and safety of tocilizumab in COVID-19 patients
October 08, 2020 – In this retrospective study we assessed the efficacy and safety of tocilizumab in patients with critical or severe coronavirus disease 2019 (COVID-19)
Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19
October 06, 2020 – The novel human coronavirus-2 (HCoV-2), called SARS-CoV-2, is the causative agent of Coronavirus Induced Disease (COVID-19) and has spread causing a global pandemic
A Systems Biology Workflow for Drug and Vaccine Repurposing: Identifying Small-Molecule BCG Mimics to Reduce or Prevent COVID-19 Mortality
October 6, 2020 – Coronavirus disease 2019 (COVID-19) is expected to continue to cause worldwide fatalities until the World population develops ‘herd immunity’, or until a vaccine is developed and used as a prevention
COVID-19: molecular targets, drug repurposing and new avenues for drug discovery
October 2, 2020 – Here, we aimed at presenting a critical view of ongoing drug repurposing efforts for COVID-19 as well as discussing opportunities for development of new treatments based on current knowledge of the mechanism of infection and potential targets within
ACTIVating Resources for the COVID-19 Pandemic: In Vivo Models for Vaccines and Therapeutics
October 01, 2020 – The Preclinical Working Group of Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV), a public-private partnership spearheaded by the National Institutes of Health, has been charged with identifying, prioritizing, and communicating SARS-CoV-2 preclinical resources
Antiviral activity of digoxin and ouabain against SARS-CoV-2 infection and its implication for COVID-19
October 01, 2020 – The current coronavirus (COVID-19) pandemic is exacerbated by the absence of effective therapeutic agents. Notably, patients with COVID-19 and comorbidities such as hypertension and cardiac diseases have a higher mortality rate
Targeting the SARS-CoV‑2 RNA Genome with Small Molecule Binders and Ribonuclease Targeting Chimera (RIBOTAC) Degraders
September 30, 2020 – COVID-19 is a global pandemic, thus requiring multiple strategies to develop modalities against it. Herein, we designed multiple bioactive small molecules that target a functional structure within the SARS-CoV-2’s RNA genome, the causative agent of COVID-19
Genetics and genomics of SARS-CoV-2: A review of the literature with the special focus on genetic diversity and SARS-CoV-2 genome detection
September 30, 2020 – The outbreak of 2019-novel coronavirus disease (COVID-19), caused by SARS-CoV-2, started in late 2019; in a short time, it has spread rapidly all over the world
Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins
September 29, 2020 – Severe acute respiratory syndrome virus 2 (SARS-CoV-2) is responsible for the current global coronavirus disease 2019 (COVID-19) pandemic, infecting millions of people and causing hundreds of thousands of deaths
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19
September 29, 2020 – Use of corticosteroids is common in the treatment of coronavirus disease 2019, but the clinical effectiveness was controversial. We aimed to investigate the association of corticosteroids therapy with clinical outcomes of hospitalized COVID-19 patients
Oxidative Stress and Inflammation in COVID-19-Associated Sepsis: The Potential Role of Anti-Oxidant Therapy in Avoiding Disease Progression
September 29, 2020 – Since the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak emerged, countless efforts are being made worldwide to understand the molecular mechanisms underlying the coronavirus disease 2019 (COVID-19) in an attempt to identify the specific clinical characteristics of critically ill COVID-19 patients involved in its pathogenesis and provide therapeutic alternatives to minimize COVID-19 severity
Presence of hyaluronan in lung alveoli in severe Covid-19 – an opening for new treatment options?
September 25, 2020 – Severe corona virus disease 2019 (Covid-19) is characterized by inflammation of the lungs with increasing respiratory impairment. In fatal Covid-19
Inactivation of SARS-CoV-2 and HCoV-229E in vitro by ColdZyme® a medical device mouth spray against common cold
September 25, 2020 – The COVID‐19 pandemic calls for effective and safe treatments. SARS‐CoV‐2 causing COVID‐19 actively replicates in the throat, unlike SARS‐CoV, and shows high pharyngeal viral shedding even in patients with mild symptoms of the disease
Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis
September 24, 2020 – The COVID-19 causing coronavirus is an enveloped RNA virus that utilizes an enzyme RNA dependent RNA polymerase for its replication
Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design
September 24, 2020 – As the SARS-CoV-2 pandemic is rapidly progressing, the need for the development of an effective vaccine is critical
COX2 Inhibition in the Treatment of COVID-19: Review of Literature to Propose Celecoxib Repositioning for Randomized Controlled Studies
September 24, 2020 – Coronavirus triggered pulmonary and systemic disease, i.e. systemic inflammatory response to virally triggered lung injury, named as COVID-19 and still ongoing discussions on refining immunomodulation in COVID-19 without COX2 inhibition directed us to search the related literature to point out a potential target (COX2) and a weapon (celecoxib)
The novel coronavirus Disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies
September 24, 2020 – Novel coronavirus SARS-CoV-2, designated as COVID-19 by the World Health Organization (WHO) on the February 11, 2020, is one of the highly pathogenic β‐coronaviruses which infects human
Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects
September 23, 2020 – Development of specific antiviral agents is an urgent unmet need for SARS-coronavirus 2 (SARS-CoV-2) infection
SARS-CoV-2 vaccines in development
September 23, 2020 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 in China and caused a coronavirus disease 2019 (COVID-19) pandemic
Animal models for COVID-19
September 23, 2020 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of coronavirus disease 2019 (COVID-19), an emerging respiratory infection caused by introduction of a novel coronavirus into humans in late 2019 in China’s Hubei province
Therapeutic versus prophylactic anticoagulation for severe COVID-19: A randomized phase II clinical trial (HESACOVID)
September 20, 2020 – Coronavirus disease 2019 (COVID-19) causes a hypercoagulable state. Several autopsy studies have found microthrombi in pulmonary circulation
CRISPR/Cas13: A potential therapeutic option of COVID-19
September 17, 2020 – The novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be considered as the most important current global issue, as it has caused the novel coronavirus disease (COVID-19) pandemic, which has resulted in high mortality and morbidity rates all around the world
Pulmonary administration of remdesivir in the treatment of COVID-19
September 17, 2020 – We read, with great interest, the commentary “Remdesivir for Treatment of COVID-19: Combination of Pulmonary and IV Administration May Offer Additional Benefit” by Sun [1]
Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion
September 17, 2020 – SARS-CoV-2 infection is initiated by virus binding to ACE2 cell surface receptors1–4, followed by fusion of virus and cell membranes to release the virus genome into the cell
Painel mostra dados sobre medicamentos para Covid-19
17 de setembro de 2020 – Ferramenta traz informações do monitoramento sobre fabricação, importação e distribuição de fármacos utilizados em pacientes infectados pelo Sars-CoV-2
Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial
September 16, 2020 – In some patients, acute, life-threatening respiratory injury produced by viruses such as SARS-CoV and other viral pneumonia are associated with an over-exuberant cytokine release
Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease
September 13, 2020 – Human ubiquitin carboxyl-terminal hydrolase-2 (USP2) inhibitors, such as thiopurine analogs, have been reported to inhibit SARS-CoV papain-like proteases (PLpro)
Identification of potential mRNA panels for severe acute respiratory syndrome coronavirus 2 (COVID-19) diagnosis and treatment using microarray dataset and bioinformatics methods
September 11,2020 – The goal of the present investigation is to identify the differentially expressed genes (DEGs) between SARS-CoV-2 infected and normal control samples to investigate the molecular mechanisms of infection with SARS-CoV-2
Safety assessment of drug combinations used in COVID-19 treatment: in silico toxicogenomic data-mining approach
September 11, 2020 – Improvement of COVID-19 clinical condition was seen in studies where combination of antiretroviral drugs, lopinavir and ritonavir, as well as immunomodulant antimalaric, chloroquine/hydroxychloroquine together with the macrolide-type antibiotic, azithromycin, was used for patient’s treatment
Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor binding domain IgG correlate with virus neutralization
September 10, 2020 – The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the urgent need for assays that detect protective levels of neutralizing antibodies
Virtual screening of approved clinic drugs with main protease (3CLpro) reveals potential inhibitory effects on SARS-CoV-2
September 10, 2020 – 3CLpro is the main protease of the novel coronavirus (SARS-CoV-2) responsible for their intracellular duplication
The inorganic polymer, polyphosphate, blocks binding of SARS-CoV-2 spike protein to ACE2 receptor at physiological concentrations
September 6, 2020 – Inorganic polyphosphate (polyP) is a morphogenetically active and metabolic energy-delivering physiological polymer that is released from blood platelets
Gastrointestinal symptoms, pathophysiology, and treatment in COVID-19
September 5, 2020 – The novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has emerged and is responsible for the Coronavirus Disease 2019 global pandemic
Potential Role of Acacia Senegal (Gum Arabic) as Immunomodulatory Agent among newly diagnosed COVID 19 Patients: A structured summary of a protocol for a randomised, controlled, clinical trial
September 5, 2020 – To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients
Terapia medicamentosa para infecções por coronavírus em humanos: revisão sistemática rápida
Setembro de 2020 – O objetivo deste trabalho foi avaliar efeitos de tratamentos medicamentosos para infecções por coronavírus
Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment – United States, January-June 2020
September 4, 2020 – Hydroxychloroquine and chloroquine are approved to treat autoimmune diseases and to prevent and treat malaria. Earlier this year, they were widely reported to be of potential benefit in the prevention and treatment of COVID-19; however, current data indicate that the potential benefits of these drugs do not outweigh their risks
Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial
September 4, 2020 – The efficacy and safety of azithromycin in the treatment of COVID-19 remain uncertain. We assessed whether adding azithromycin to standard of care, which included hydroxychloroquine, would improve clinical outcomes of patients admitted to the hospital with severe COVID-19
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
September 4, 2020 – We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S)
The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial
September 3, 2020 – Tocilizumab is a humanized monoclonal antibody which targets and inhibits interleukin-6 (IL-6) and has demonstrated efficacy in treating diseases associated with hyper-inflammation
Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19 The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial
September 2, 2020 – Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine
September 2, 2020 – NVX-CoV2373 is a recombinant severe acute respiratory syndrome coronavirus 2 (rSARS-CoV-2) nanoparticle vaccine composed of trimeric full-length SARS-CoV-2 spike glycoproteins and Matrix-M1 adjuvant
Favipiravir: A new and emerging antiviral option in COVID-19
September 2, 2020 – With over 16 million cases reported from across the globe, the SARS-CoV-2, a mere 125 microns in diameter, has left an indelible impact on our world
Statistical design of Phase II/III clinical trials for testing therapeutic interventions in COVID-19 patients
August 31, 2020 – Because of unknown features of the COVID-19 and the complexity of the population affected, standard clinical trial designs on treatments may not be optimal in such patient
COVID-19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays
August 30, 2020 -The situation of coronavirus disease 2019 (COVID‐19) pandemic is rapidly evolving, and medical researchers around the globe are dedicated to finding cures for the disease
Computation screening and molecular docking of FDA approved viral protease inhibitors as a potential drug against COVID-19
August 29, 2020 – This study demonstrated potent inhibitors against COVID-19 using the molecular docking approach of FDA approved viral antiprotease drug
Efficacy of tocilizumab treatment in severely ill COVID-19 patients
August 27, 2020 -The current coronavirus disease 2019 (COVID-19) pandemic induced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already caused a global increase in hospitalizations and deaths
Design and Evaluation of Anti-SARS-Coronavirus Agents Based on Molecular Interactions with the Viral Protease
August 27, 2020 – Three types of new coronaviruses (CoVs) have been identified recently as the causative viruses for the severe pneumonia-like respiratory illnesses, severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and corona-virus disease 2019 (COVID-19)
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
August 26, 2020 – Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide
The effect of prostacyclin (Iloprost) infusion at a dose of 1 ng/kg/min for 72 hours compared to placebo in mechanically ventilated patients with COVID-19: A structured summary of a study protocol for a randomized controlled trial
August 26, 2020 – To investigate the effect of continuous infusion of the potential endothelial cytoprotective agent prostacyclin (Iloprost) 1 ng/kg/min vs. placebo for 72 hours on pulmonary endotheliopathy in mechanically ventilated COVID-19 patients
High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial
August 26, 2020 – The aim of this study is to explore the effectiveness and safety of high dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to SARS-Cov-2 pneumonia
Dynamics of the ACE2–SARS-CoV-2/SARS-CoV spike protein interface reveal unique mechanisms
August 26, 2020 – The coronavirus disease 2019 (COVID-19) pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major public health concern
Recent advances in therapeutic modalities and vaccines to counter COVID-19/SARS-CoV-2
August 26, 2020 – The novel coronavirus disease (COVID-19) caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) has rapidly spread across the world
Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19
August 26, 2020 – Coronavirus disease-2019 (COVID-19) pandemic has become a global threat and death tolls are increasing worldwide. The SARS-CoV-2 though shares similarities with SARS-CoV and MERS-CoV, immunopathology of the novel virus is not understood properly
COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic
August 23, 2020 -The recent corona virus disease (COVID-19) outbreak has claimed the lives of many around the world and highlighted an urgent need for experimental strategies to prevent, treat and eradicate the virus
Virtual screening and molecular dynamics study of approved drugs as inhibitors of spike protein S1 domain and ACE2 interaction in SARS-CoV-2
August 21, 2020 – The receptor binding domain (RBD) of spike protein S1 domain SARS-CoV-2 plays a key role in the interaction with ACE2, which leads to subsequent S2 domain mediated membrane fusion and incorporation of viral RNA into host cells
Interleukin-6 in Covid-19: A systematic review and meta-analysis
August 26, 2020 – Coronaviruses may activate dysregulated host immune responses. As exploratory studies have suggested that interleukin-6 (IL-6) levels are elevated in cases of complicated Covid-19, we undertook a systematic review and meta-analysis to assess the evidence in this field
Evolutionary and structural analyses of SARS-CoV-2 D614G spike protein mutation now documented worldwide
August 20, 2020 – The COVID-19 pandemic, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), was declared on March 11, 2020 by the World Health Organization
An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors
August 17, 2020 – The Coronavirus disease 2019 (COVID-19) is an infectious disease caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2)
Efficacy of Tocilizumab in Covid 19: A metanalysis of case series studies
August 15, 2020 – Characteristic feature of COVID-19 during its progression in severity is the cytokine storm (via interleukin-6, IL-6) which is responsible for secondary acute respiratory distress syndrome (ARDS) [4]
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge
August 14, 2020 – The unprecedented coronavirus disease 2019 (COVID-19) epidemic has created a worldwide public health emergency, and there is an urgent need to develop an effective vaccine to control this severe infectious disease
Clinical characteristics and corticosteroids application of different clinical types in patients with corona virus disease 2019
August 13, 2020 – To describe the epidemiological and clinical characteristics of patients with Corona Virus Disease 2019 (COVID-19) in Beijing
A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation
August 13, 2020 – Virus neutralization remains the gold standard for determining antibody efficacy
Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults
August 12, 2020 – In March 2020, the World Health Organization (WHO) declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)1
Convalescent Plasma Therapy for COVID-19: State of the Art
August 12, 2020 – Convalescent plasma (CP) therapy has been used since the early 1900s to treat emerging infectious diseases; its efficacy was later associated with the evidence that polyclonal neutralizing antibodies can reduce the duration of viremia
Anthraquinone Derivatives as an Immune Booster and their Therapeutic Option Against COVID-19
August 08, 2020 – Anthraquinone derivatives are identified for their immune-boosting, anti-inflammatory, and anti-viral efficacy
Global multi-omics and systems pharmacological strategy unravel the multi-targeted therapeutic potential of natural bioactive molecules against COVID-19: An in silico approach
August 07, 2020 – Understanding the immunological behavior of COVID-19 cases at molecular level is essential for therapeutic development
A systematic review and meta-analysis of the efficacy and safety of western medicine routine treatment combined with Chinese herbal medicine in the treatment of COVID-19
August 07, 2020 – COVID-19 is a global public health emergency. At present, there is no highly effective medicine for the prevention and treatment of 2019-nCoV
A Rational Design of a Multi-Epitope Vaccine Against SARS-CoV-2 Which Accounts for the Glycan Shield of the Spike Glycoprotein
August 07, 2020 – The ongoing global health crisis caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the virus which leads to Coronavirus Disease 2019 (COVID-19) has impacted not only the health of people everywhere, but the economy in nations across the world
Structural analysis of full-length SARS-CoV-2 spike protein from an advanced vaccine candidate
August 06, 2020 – Vaccine efforts against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) responsible for the current COVID-19 pandemic are focused on SARS-CoV-2 spike glycoprotein, the primary target for neutralizing antibodies
Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19
August 06, 2020 – Respiratory failure and acute kidney injury (AKI) are associated with high mortality in SARS-CoV-2-associated Coronavirus disease 2019 (COVID-19)
Presidente assina Medida Provisória que garante produção de vacina contra a Covid-19
06 de Agosto de 2020 – Crédito orçamentário de R$ 1,9 bilhão viabilizará a aquisição e produção de 100 milhões de doses da vacina contra a doença, produzida pelo laboratório AtraZeneca e Universidade de Oxford
Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm
August 06, 2020 – Several studies show that the immunosuppressive drugs targeting the interleukin-6 (IL-6) receptor, including tocilizumab, ameliorate lethal inflammatory responses in COVID-19 patients infected with SARS-CoV-2
Mitochondrial-targeted ubiquinone: A potential treatment for COVID-19
August 5, 2020 – Immune dysregulation characterized by T cell exhaustion and high level of inflammatory cytokines is associated with severe COVID-19
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial
August 05, 2020 – Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2
August 05, 2020 – The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective and safe vaccines
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness
August 05, 2020 – A vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is needed to control the global coronavirus infectious disease (COVID-19) public health crisis
In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication
August 04, 2020 – A novel coronavirus, named SARS-CoV-2, emerged in 2019 in China and rapidly spread worldwide
Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors: a cohort study using a rapid and sensitive high-throughput neutralization assay
August 04, 2020 – Rapid and specific antibody testing is crucial for improved understanding, control, and treatment of COVID-19 pathogenesis
De novo design of ACE2 protein decoys to neutralize SARS-CoV-2
August 03, 2020 – We have developed a generalized computational design strategy to rapidly engineer de novo proteins that precisely recapitulate the protein surface targeted by biological agents, like viruses, to gain entry into cells
Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19
August 03, 2020 – Coronavirus disease 2019 is a newly emerging infectious disease currently spreading across the world. It is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
August 03, 2020 – The recent outbreak of the SARS-CoV-2 virus leading to the disease COVID 19, a global pandemic has resulted in an unprecedented loss of life and economy worldwide
Identification of potential drug candidates to combat COVID-19: a structural study using the main protease (mpro) of SARS-CoV-2
August 03, 2020 – The recent outbreak of the SARS-CoV-2 virus leading to the disease COVID 19 has become a global pandemic that is spreading rapidly and has caused a global health emergency
Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic
August 03, 2020 – A new pathogen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide and become pandemic with thousands new deaths and infected cases globally
Antirheumatic Disease Therapies for the Treatment of COVID-19: A Systematic Review and Meta-analysis
August 2, 2020 – Antirheumatic disease therapies have been used to treat coronavirus disease 2019 (COVID-19) and its complications. We conducted a systematic review and meta-analysis to describe the current evidence
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil
July 31, 2020 – The first case of COVID-19 was detected in Brazil on 25 February 2020
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients
July 31, 2020 – Human infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19) and there is no cure currently
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants
July 30, 2020 – Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants, and a need exists for prevention of RSV in healthy infants
Classification of the present pharmaceutical agents based on the possible effective mechanism on the COVID-19 infection
July 30, 2020 – There are several types of research on the COVID-19 disease which have been conducting
Potential treatment methods targeting 2019-nCoV infection
July 28, 2020 – The novel coronavirus, 2019-nCoV, has quickly spread across the world and pose serious threat to public health because it can infect people very easily
Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID‐19 patients
July 26, 2020 – We propose a new hypothesis that the established drug pentoxifylline deserves attention as a potential repurposed therapeutic for COVID‐19
Development of a Multi-Antigenic SARS-CoV-2 Vaccine Using a Synthetic Poxvirus Platform
July, 2020 – Modied Vaccinia Ankara (MVA) is a highly attenuated poxvirus vector that is widely used to develop vaccines for infectious diseases and cancer
Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro
July 24, 2020 – COVID-19, caused by the SARS-CoV-2 virus, has now spread worldwide with catastrophic human and economic impacts and currently has infected over 10 million people and killed over 500,000
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
July 24, 2020 – This is a PDF fle of a peer-reviewed paper that has been accepted for publication. Although unedited, the content has been subjected to preliminary formatting.
Targeting SARS‐CoV‐2 RBD interface: a supervised computational data‐driven approach to identify potential modulators
July 23, 2020 – Coronavirus Disease 2019 (COVID‐19) has spread out as a pandemic threat affecting over 2 million people
Safety, tolerability, and clinical outcomes of hydroxychloroquine for hospitalized patients with coronavirus 2019 disease
July 23, 2020 – Severe acute respiratory coronavirus 2 (SARS-CoV-2) has caused a devastating worldwide pandemic. Hydroxychloroquine (HCQ) has in vitro activity against SARS-CoV-2, but clinical data supporting HCQ for coronavirus disease 2019 (COVID-19) are limited
Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19
July 23, 2020 – Hydroxychloroquine and azithromycin have been used to treat patients with coronavirus disease 2019 (Covid-19). However, evidence on the safety and efficacy of these therapies is limited.
Tocilizumab for severe COVID-19: a systematic review and meta-analysis
July 23, 2020 – This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19)
Ribavirin Therapy For Severe COVID-19: A Retrospective Cohort Study
July 23, 2020 – We aimed to compare ribavirin therapy for patients with severe COVID-19 with a supportive therapy only
Immunomodulatory effect of mesenchymal stem cells and mesenchymal stem-cell-derived exosomes for COVID-19 treatment
July 22, 2020 – The world has witnessed unimaginable damages at the hands of the coronavirus disease-19 (COVID-19) pandemic
Drugs targeting various stages of the SARS-CoV-2 life cycle: Exploring promising drugs for the treatment of Covid-19
July 22, 2020 – The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a positive-sense, single-stranded RNA virus that causes the potentially lethal Covid-19 respiratory tract infection
Potent neutralizing antibodies directed to multiple epitopes on SARS-CoV-2 spike
July 22, 2020 – The SARS-CoV-2 pandemic rages on with devasting consequences on human lives and the global economy
Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review
July 20, 2020 – Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebocontrolled, phase 2 trial
July 20, 2020 – This is the first randomised controlled trial for assessment of the immunogenicity and safety of a candidate non-replicating adenovirus type-5 (Ad5)-vectored COVID-19 vaccine, aiming to determine an appropriate dose of the candidate vaccine for an efficacy study
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
July 20, 2020 – The pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might be curtailed by vaccination
Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report
July 17, 2020 – Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death
Effects on QT interval of hydroxychloroquine associated with ritonavir/darunavir or azithromycin in patients with SARS-CoV-2 infection
July 16, 2020 – To evaluate the effects of an association therapy of hydroxychloroquine (HY) plus ritonavir/darunavir (RD) or azithromycin (AZ) on QTc intervals
Exploring an Integrative Therapy for Treating COVID-19: A Randomized Controlled Trial
July 16, 2020 – To develop a new Chinese medicine (CM)-based drug and to evaluate its safety and effect for suppressing acute respiratory distress syndrome (ARDS) in COVID-19 patients
Intermolecular interaction among Remdesivir, RNA and RNA-dependent RNA polymerase of SARS-CoV-2 analyzed by fragment molecular orbital calculation
July 15, 2020 – COVID-19, a disease caused by a new strain of coronavirus (SARS-CoV-2) originating from Wuhan, China, has now spread around the world, triggering a global pandemic, leaving the public eagerly awaiting the development of a specific medicine and vaccine
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
July 14, 2020 – The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in late 2019 and spread globally, prompting an international effort to accelerate development of a vaccine
Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines
July 14, 2020 – Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, it has spread rapidly worldwide and poses a great threat to public health
The renin–angiotensin–aldosterone system: Role in pathogenesis and potential therapeutic target in COVID‐19
July 13, 2020 – Coronavirus disease 2019 (COVID‐19), caused by the SARS‐CoV‐2 novel coronavirus, has spread worldwide causing high fatality rates
A perspective on potential antibodydependent enhancement of SARS-CoV-2
July 13, 2020 – This is a PDF fle of a peer-reviewed paper that has been accepted for publication
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics
July 13, 2020 – Since a novel coronavirus pneumonia outbreak in late December 2019, coronavirus disease -19 (COVID-19) epidemic has gradually spread worldwide, becoming a major public health event
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?
July 13, 2020 – Based on the observation that patients with hypertension appear to have adverse outcomes with coronavirus disease-2019
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19
July 12, 2020 – In a longitudinal analysis of SARS-CoV-2- infected people, Kreer et al. find highly potent neutralizing antibodies that use a broad spectrum of variable (V) genes and show low levels of somatic mutations
A molecular docking study repurposes FDA approved iron oxide nanoparticles to treat and control COVID-19 infection
July 12, 2020 – COVID-19, is a disease resulting from the SARS-CoV-2 global pandemic. Due to the current global emergency and the length of time required to develop specific antiviral agent(s) and a vaccine for SARS-CoV-2
Tocilizumab for treatment of mechanically ventilated patients with COVID-19
July 11, 2020 – Severe COVID-19 can manifest in rapid decompensation and respiratory failure with elevated inflammatory markers, consistent with cytokine release syndrome for which IL-6 blockade is approved treatment
Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis
July 11, 2020 – The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is spreading worldwide.
Emerging pharmacological therapies for ARDS: COVID-19 and beyond
July 11, 2020 – Acute respiratory distress syndrome (ARDS) is the commonest form of acute severe hypoxemic respiratory failure in the critically ill
Control of SARS-CoV-2 infection in rituximab-treated neuroimmunological patients
July 11, 2020 – Individuals with autoimmune diseases, such as multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD), that require long-term immunosuppression are regarded as particularly vulnerable in the current COVID-19 pandemic
Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2
July 10, 2020 – An outbreak of infection caused by SARS-CoV-2 recently has brought a great challenge to public health. Rapid identification of immune epitopes would be an efficient way to screen the candidates for vaccine development at the time of pandemic
Maior estudo sobre COVID-19 analisou proporção de anticorpos da população brasileira
10.07.2020 – O trabalho “Evolução da Prevalência de Infecção por Covid-19 no Brasil: Estudo de Base Populacional”, financiado pelo Ministério da Saúde e o maior já feito sobre a circulação do Sars-Cov-2 no país, foi concluído
Efficacy of Corticosteroids in Non-Intensive Care Unit Patients with COVID-19 Pneumonia from the New York Metropolitan region
July 10, 2020 – The role of systemic corticosteroid as a therapeutic agent for patients with COVID 19 pneumonia is controversial
COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not
July 10, 2020 – On December 31, 2019, novel SARS-CoV2 spread from Wuhan China to more than 200 territories around world and the World Health Organization declared a COVID-19 pandemic on January 30, 2020
Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions
July 09, 2020 – – Severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) has resulted in a pandemic and continues to spread around the globe at an unprecedented rate
Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice
July 09, 2020 – The spread of the SARS-CoV-2 into a global pandemic within a few months of onset motivates the development of a rapidly scalable vaccine
Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)
July 08, 2020 – To date no effective therapy has been demonstrated for COVID-19. In vitro, studies indicated that ivermectin (IVM) has antiviral effect
Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study
July 07, 2020 – There are plausible mechanisms by which angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) may increase the risk of COVID-19 infection or affect disease severity
SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings
July 07, 2020 – The rapidly evolving coronavirus disease 2019 (COVID-19, caused by severe acute respiratory syndrome coronavirus 2- SARS-CoV-2), has greatly burdened the global healthcare system and led it into crisis in several countries
GPU-Accelerated Drug Discovery with Docking on the Summit Supercomputer: Porting, Optimization, and Application to COVID-19 Research
July 06, 2020 – Protein-ligand docking is an in silico tool used to screen potential drug compounds for their ability to bind to a given protein receptor within a drug-discovery campaign
Discovery of Drug-like Ligands for the Mac1 Domain of SARS-CoV-2 Nsp3
July 06, 2020 – The Mac1 domain of the multifunctional SARS-CoV-2 non-structural protein 3 (nsp3) is a potential COVID-19 drug target because it is suspected to enhance the ability of the virus to evade the human immune system
Conserved Genomic Terminals of SARS-CoV-2 as Co-evolving Functional Elements and Potential Therapeutic Targets
July 06, 2020 – To identify features in the genome of the SARS-CoV-2 pathogen responsible for the COVID-19 pandemic that may contribute to its viral replication, host pathogenicity, and vulnerabilities, we investigated how and to what extent the SARS-CoV-2 genome sequence differs from other well-characterized human and animal coronavirus genomes
Safety and efficacy of anti-il6-receptor tocilizumab use in severe and critical patients affected by coronavirus disease 2019: a comparative analysis
July 06, 2020 – This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record
Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination
July 06, 2020 – Various human pathogenic viruses employ envelope glycoproteins for host cell receptor recognition and binding, membrane fusion and viral entry
Role of IgD in prevention and treatment of SARS CoV-2 infection “The Unknown Soldier”
July 05, 2020 – COVID-19 presents varied clinical features, ranging from asymptomatic, mild, to acute respiratory distress syndrome (ARDS)
Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy
July 04, 2020 – Convalescent plasma (CP) has been used successfully to treat many types of infectious diseases, and it has shown initial effects in the treatment of the emerging 2019 coronavirus disease (COVID-19)
Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study
July 04, 2020 – Anti-inflammatory drugs such as corticosteroids may beneficially modulate the host inflammatory response to CoVID-19 pneumonia
Update on therapeutic approaches and emerging therapies for SARS-CoV-2 virus
July 04, 2020 – The global pandemic of coronavirus disease 2019 (COVID-19), caused by novel severe acute respiratory syndrome coronavirus
Recent insights for the emerging COVID-19: drug discovery, therapeutic options and vaccine development
July 04, 2020 – SARS-CoV-2 has been marked as a highly pathogenic coronavirus of COVID-19 disease into the human population, causing over 5.5 million confirmed cases worldwide
A Perspective on Emerging Therapeutic Interventions for COVID-19
July 03, 2020 – Coronaviruses are enveloped positive-sense RNA viruses with an unusual large RNA genome and a unique replication mechanism, which are characterized by club-like spikes that protrude from their surface
Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID‐19): A systematic review and meta‐analysis
July 03, 2020 – We conducted this systemic review and meta‐analysis in an attempt to evaluate the efficacy and safety of umifenovir in COVID‐19
Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products
July 03, 2020 – Most recently, an outbreak of severe pneumonia caused by the infection of SARS-CoV-2, a novel coronavirus first identified in Wuhan, China, imposes serious threats to public health
Microstructure, pathophysiology and potential therapeutics of COVID‐19: A comprehensive review
July 03, 2020 – This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record
Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection
July 02, 2020 – The novel and highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), has become a continued focus of global attention due to the serious threat it poses to public health
A Network Medicine Approach to Investigation and Population-based Validation of Disease Manifestations and Drug Repurposing for COVID-19
July 02, 2020 – The global Coronavirus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to unprecedented social and economic consequences
Whole Genome Analysis and Targeted Drug Discovery Using Computational Methods and High Throughput Screening Tools for Emerged Novel Coronavirus (2019-nCoV)
July 02, 2020 – A novel coronavirus designated as SARS-CoV-2 in February 2020 by World Health organization (WHO) was identified as main cause of SARS like pneumonia cases in Wuhan city in Hubei Province of China at the end of 2019
In silico Drug Repurposing to combat COVID-19 based on Pharmacogenomics of Patient Transcriptomic Data
June 30, 2020 – The ongoing global pandemic of coronavirus disease 2019 (COVID-19) continues to affect a growing number of populations in different parts of the world. In the current situation, drug repurposing is a viable strategy to combat COVID-19
O reposicionamento de fármacos como uma potencial estratégia para o tratamento da COVID-19
29 de junho de 2020 – No final de 2019 uma nova cepa de coronavírus foi descoberta na China, responsável por causar a doença COVID-19, caracterizada pela OMS como uma pandemia em março de 20207
Brasil entra em parceria para produção de vacina contra Covid-19
27 de Junho de 2020 – País receberá a transferência de tecnologia da tecnologia mais promissora contra a doença no mundo. Quando demonstrada segurança, serão 100 milhões de doses
Combating COVID-19 with integrated traditional Chinese and Western medicine in China
June 27, 2020 – COVID-19, an acute respiratory infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread throughout the world
The role of angiotensin-converting enzyme 2 in the pathogenesis of COVID-19: the villain or the hero?
June 27, 2020 – Angiotensin-converting enzyme 2 (ACE 2) is the entry receptor for the novel coronavirus SARS-CoV-2, the aetiological agent of COVID-19
Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis
June 27, 2020 – The novel coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a pandemic, threatening global public health
Drug treatment of coronavirus disease 2019 (COVID-19) in Chin
June 27, 2020 – Since December 2019, the coronavirus disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has spread throughout China as well as other countries
Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles
June 26, 2020 – Coronavirus disease 2019 (COVID-19) is rapidly spreading around the world, causing much morbidity and mortality everywhere
Transcriptomic Signatures and Immunomodulatory Treatments for COVID-19 Patients
June 26, 2020 – Since December 2019, the novel coronavirus SARS-CoV-2 has infected over 9.0 million and led to death of over 472,000 people, damaging the world’s social and economic fabrics
SARS-CoV-2 Exoribonuclease (NSP14) As a Potential Therapeutic Target to Treat COVID-19
June 26, 2020 – Although the global health emergency caused by SARS-CoV-2 has led to unprecedented health and socioeconomic crisis, as of today neither an antiviral treatment has been approved for COVID-19, nor is a vaccine available
Glycans on the SARS-CoV-2 Spike Control the Receptor Binding Domain Conformation
June 26, 2020 – The glycan shield of the beta-coronavirus (β-CoV) Spike (S) glycoprotein provides protection from host immune responses, acting as a steric block to potentially neutralizing antibody responses
High-dose but not low-dose corticosteroids potentially delay viral shedding of patients with COVID-19
June 26, 2020 – Article PDF
Auxiliary role of mesenchymal stem cells as regenerative medicine soldiers to attenuate inflammatory processes of severe acute respiratory infections caused by COVID-19
June 25, 2020 – Acute respiratory infections as one of the most common problems of healthcare systems also can be considered as an important reason for worldwide morbidity and mortality from infectious diseases
Antiviral mechanisms of candidate chemical medicines and traditional Chinese medicines for SARS-CoV-2 infection
June 24, 2020 – The Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly become a global pandemic
Tocilizumab in patients with severe COVID-19: a retrospective cohort study
June 24, 2020 – No therapy is approved for COVID-19 pneumonia. The aim of this study was to assess the role of tocilizumab in reducing the risk of invasive mechanical ventilation and death in patients with severe COVID-19 pneumonia who received standard of care treatment
In-hospital Use of Statins is Associated with a Reduced Risk of Mortality among Individuals with COVID-19
June 24, 2020 – Statins are lipid-lowering therapeutics with favorable anti-inflammatory profiles and have been proposed as an adjunct therapy for COVID-19. However, statins may increase the risk of SARS-CoV-2 viral entry by inducing ACE2 expression
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
June 23, 2020 – While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis
Structures of human antibodies bound to SARS-CoV-2 spike reveal common epitopes and recurrent features of antibodies
June 23, 2020 – Neutralizing antibody responses to coronaviruses mainly target the receptor-binding domain (RBD) of the trimeric spike
Treatment of Coronavirus Disease 2019 (COVID-19): Investigational Drugs and Other Therapies
June 22, 2020 – Coronavirus disease 2019 (COVID-19) is defined as illness caused by a novel coronavirus now called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; formerly called 2019-nCoV), which was first identified amid an outbreak of respiratory illness cases in Wuhan City, Hubei Province, China
nCOV-19 peptides mass fingerprinting identification, binding, and blocking of inhibitors flavonoids and anthraquinone of Moringa oleifera and hydroxychloroquine
June 22, 2020 – An rare pandemic of viral pneumonia occurs in December 2019 in Wuhan, China, which is now recognized internationally as Corona Virus Disease 2019 (COVID-19), the etiological agent classified as Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2)
Constituents of buriti oil (Mauritia flexuosa L.) like inhibitors of the SARS-Coronavirus main peptidase: an investigation by docking and molecular dynamics
June 22, 2020 – Statistics show alarming numbers of infected and killed in the world, caused by the Covid-19 pandemic, which still doesn’t have a specific treatment and effective in combating all efforts to seek treatments and medications against this disease
Autophagy and SARS-CoV-2 infection: Apossible smart targeting of the autophagy pathway
June 22, 2020 – The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak resulted in 5,993,317 confirmed cases worldwide with 365,394 confirmed deaths (as of May 29 th , 2020, WHO)
Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19
June 22, 2020 – The recent pandemic caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) calls the whole world into a medical emergency
Promising inhibitors of main protease of novel corona virus to prevent the spread of COVID-19 using docking and molecular dynamics simulation
June 22, 2020 – Coronavirus disease-2019 (COVID-19) is a global health emergency and the matter of serious concern, which has been declared a pandemic by WHO
Current status of COVID-19 therapies and drug repositioning applications
June 19, 2020 – The rapid and global spread of a new human coronavirus (SARS-CoV-2) has produced an immediate urgency to discover promising targets for treatment of COVID-19
Convergent antibody responses to SARS-CoV-2 in convalescent individuals
June 18, 2020 – During the COVID-19 pandemic, SARS-CoV-2 infected millions of people and claimed hundreds of thousands of lives
A narrative literature review on traditional medicine options for treatment of corona virus disease 2019 (COVID-19)
June 17, 2020 – Coronavirus disease 2019 (COVID-19) as a life-threatening disease is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is accounted as global public health concern
Overview of therapeutic drug research for COVID-19 in China
June 17, 2020 – Since the outbreak of novel coronavirus pneumonia (COVID-19) in December 2019, more than 2,500,000 people worldwide have been diagnosed with SARS-CoV-2 as of April 22. In response to this epidemic, China has issued seven trial versions of diagnosis and treatment protocol for COVID-19
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
June 15, 2020 – A new coronavirus SARS-CoV-2, also called novel coronavirus 2019 (2019-nCoV), started to circulate among humans around December 2019, and it is now widespread as a global pandemic
The use of renin angiotensin system inhibitor on mortality in patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis
June 14, 2020 – Coronavirus disease 2019, commonly known as COVID-19, is a raging global pandemic
Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19 Therapy
June 14, 2020 – The co-administration of hydroxychloroquine with azithromycin is proposed in COVID-19 therapy
Antiviral activity of the high-molecular-weight plant polysaccharides (Panavir(R))
June 14, 2020 – This short report is dedicated to the description of the wide antiviral and antibacterial activity of the immune-modulating agent Panavir(R)
Coronavirus breakthrough: dexamethasone is first drug shown to save lives
June 13, 2020 – In a large trial, a cheap and widely available steroid cut deaths by one-third among patients critically ill with COVID-19
Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial
June 13, 2020 – A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain
Vaccination strategies to combat novel corona virus SARS-CoV-2
June 12, 2020 – The 2019-novel coronavirus disease (COVID-19) is caused by SARS-CoV-2 is transmitted from human to human has recently reported in China
Virtual screening, ADME/Tox predictions and the drug repurposing concept for future use of old drugs against the COVID-19
June 11, 2020 – The new Coronavirus (SARS-CoV-2) is the cause of a serious infection in the respiratory tract called COVID-19
Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors
June 11, 2020 – Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), similar to SARS-CoV and the Middle East respiratory syndrome coronavirus (MERS-CoV), which belong to the same β-coronavirus group, induces sever acute respiratory disease, threatening human health
Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2
June 10, 2020 – The current appearance of the new SARS coronavirus 2 (SARS-CoV-2) and it quickly spreading across the world poses a global health emergency
Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
June 10, 2020 – The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options
Aminoglycosides can be a better choice over macrolides in COVID-19 regimen: Plausible mechanism for repurposing strategy
June 10, 2020 – In the current COVID-19 pandemic, prioritizing the immunity enhancers is equally important to anti-virals
BCG vaccine protection from severe coronavirus disease 2019 (COVID-19)
June 09, 2020 – The bacillus Calmette−Guérin (BCG) vaccine, an attenuated Mycobacterium bovis (1), has been extensively used in national vaccination programs, as it confers cross-protection from Mycobacterium tuberculosis infection
Statins as early therapy to mitigate COVID-19 (SARS-CoV-2)-associated ARDS and cytokine storm syndrome – time is of the essence
June 09, 2020 -While most coronavirus disease 2019 (COVID-19) infections run a benign course with recovery, the inexorable rise in case fatalities in several countries is grim testimony to the lack of effective therapies to arrest the course of severe infections
Vacina nacional de Bio-Manguinhos/Fiocruz para novo coronavírus entrará em estudo pré-clínico
09.06.2020 – Vacina nacional de Bio-Manguinhos/Fiocruz para novo coronavírus entrará em estudo pré-clínico. Projeto está pronto para avançar em estudos in vivo
Narrative review of the immune response against coronavirus: An overview, applicability for SARS-COV-2, and therapeutic implications
June 8, 2020 – The new coronavirus (SARS-CoV-2) that causes a severe acute respiratory syndrome emerges in Wuhan, China, in December 2019
EMA receives application for conditional authorisation of first COVID-19 treatment in the EU
June 08, 2020 – EMA has now received an application for conditional marketing authorisation (CMA) of the antiviral medicine remdesivir for the treatment of COVID-19 and has formally started its evaluation
α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19
June 08, 2020 – The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has pushed the health systems of many countries to breaking point and precipitated social distancing measures that have crippled economic activities across the globe
Monoclonal antibody as a potential anti-COVID-19
June 04, 2020 – Coronavirus disease 2019 (COVID-19) is expanding rapidly, which made it as one of top priorities for scientists to develop novel treatment strategies
A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
June 3, 2020 – Coronavirus disease 2019 (Covid-19) occurs after exposure to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). For persons who are exposed, the standard of care is observation and quarantine
Natural RNA dependent RNA polymerase inhibitors: Molecular docking studies of some biologically active alkaloids of Argemone mexicana
June 01, 2020 – COVID-19 has become disastrous for world and spread all over. Researchers all around the globe are working to discover a drug to cure from COVID-19
Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients
June 01, 2020 – Given the ongoing SARS-CoV-2 pandemic, identification of immunogenic targets against the coronavirus spike glycoprotein will provide crucial advances towards the development of sensitive diagnostic
Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2
May 29, 2020 – To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments
Potentially repurposable drugs for COVID-19 identified from SARS-CoV-2 Host Protein Interactome
May 28, 2020 – We previously presented the protein-protein interaction network (‘HoP Interactome’) of 332 host proteins that were identified to interact with 27 nCoV19 viral proteins by Gordon et al
Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
May 27, 2020 – The efficacies of lopinavir-ritonavir or hydroxychloroquine remain to be determined in patients with coronavirus disease 2019 (COVID-19
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
May 27, 2020 – Remdesivir is an RNA polymerase inhibitor with potent antiviral activity in vitro and efficacy in animal models of coronavirus disease 2019 (Covid-19)
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
May 24, 2020 – Coronavirus disease 2019 (COVID-19), caused by a novel corinavirus (later named SARS-CoV-2 virus), was fistly reported in Wuhan, Hubei Province, China towards the end of 2019.
A human neutralizing antibody targets the receptor binding site of SARS-CoV-2
May 22, 2020 – An outbreak of the coronavirus disease 2019 (COVID-19)1–3, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)4 spread globally
Remdesivir for the Treatment of Covid-19 — Preliminary Report
May 22, 2020 – Although several therapeutic agents have been evaluated for the treatment of coronavirus disease 2019 (Covid-19), none have yet been shown to be efficacious
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
May 22, 2020 – Often in combination with a second-generation macrolide, are being widely used for treatment of COVID-19, despite no conclusive evidence of their benefit
No Benefit for Lopinavir–Ritonavir in Severe COVID-19
May 21, 2020 – Treatment with the HIV combination drug lopinavir-ritonavir did not accelerate recovery or improve mortality rates among hospitalized patients with severe coronavirus disease 2019 (COVID-19), a trial in the New England Journal of Medicine reported.
Beximco Pharma introduces world’s first generic remdesivir for COVID-19 treatment
May 21, 2020 -Beximco Pharmaceuticals Limited (“Beximco Pharma”, “BPL” or “the Company”), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, announces the launch of remdesivir (under the brand name Bemsivir), an antiviral drug, which has been recently granted Emergency Use Authorization by the U.S. Food and Drug Administration for the treatment of COVID-19
An in-silico approach to develop of a multi-epitope vaccine candidate against SARS-CoV-2 envelope (E) protein
May 20, 2020 – Since the rst appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS- CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS- CoV-2 outbreak
Immunogenicity of a DNA vaccine candidate for COVID-19
May 20, 2020 – The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for the pandemic viral pneumonia disease, COVID-19
Ministério da Saúde divulga diretrizes para tratamento medicamentoso de pacientes
20.05.2020 – As recomendações publicadas nesta quarta-feira (20) são para o tratamento precoce, com cloroquina e hidroxicloroquina, de pacientes com COVID-19, no Sistema Único da Saúde (SUS)
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
May 18, 2020 – SARS-CoV-2 is a newly emerged coronavirus responsible for the current COVID-19 pandemic that has resulted in more than 3.7 million infections and 260,000 deaths as of 6 May 2020
Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
May 14, 2020 – A novel coronavirus was recently discovered and termed SARS-CoV-2. Human infection can cause coronavirus disease 2019 (COVID-19), which has been rapidly spreading around the globe1,2
JAK Inhibition as a New Treatment Strategy for Patients with COVID-19
May 11, 2020 – After the advent of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the outbreak of coronavirus disease 2019 (COVID-19) commenced across the world
An Update on Current Therapeutic Drugs Treating COVID-19
May 11, 2020 – The current pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has presented unprecedented challenges to the healthcare systems in almost every country around the world
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
May 11, 2020 – Among patients with coronavirus disease 2019 (COVID-19), is there an association between use of hydroxychloroquine, with or without azithromycin, and in-hospital mortality?
Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
May 08, 2020 – Effective antiviral therapy is important for tackling the coronavirus disease 2019 (COVID-19) pandemic. We assessed the efficacy and safety of combined interferon beta-1b, lopinavir–ritonavir, and ribavirin for treating patients with COVID-19
The COVID-19 Gene and Drug Set Library
May 06, 2020 – The coronavirus (CoV) severe acute respiratory syndrome (SARS)-CoV-2 (COVID-19) pandemic has received rapid response by the research community to offer suggestions for repurposing of approved drugs as well as to improve our understanding of the COVID-19 viral life cycle molecular
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
May 01, 2020 – Today, the U.S. Food and Drug Administration issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease
Identification of new drug treatments to combat COVID19: A signature-based approach using iLINCS
April 30, 2020 – The COVID-19 pandemic caused by the novel SARS-CoV-2 is more contagious than other coronaviruses and has higher rates of mortality than influenza
EMA starts rolling review of remdesivir for COVID-19
April 30, 2020 – EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of the investigational antiviral medicine remdesivir for the treatment of coronavirus disease (COVID-19)
Plataforma reúne gráficos interativos sobre a evolução da COVID-19 no Brasil
30.04.2020 – Os gráficos mostram a quantidade total de casos e óbitos confirmados, a incidência na população, a taxa de letalidade e o número de novos casos
Hopes rise for coronavirus drug remdesivir
April 29, 2020 – Despite conflicting studies, results from largest trial yet show the antiviral speeds up recovery, putting it on track to become a standard of care in the United States
Covid-19 Drugs & Vaccines Tracker
April, 2020 – In the months since the novel coronavirus rose from a regional crisis to a global threat, drug makers large and small have scrambled to advance their best ideas for thwarting a pandemic
COVID-19 Resource Centre
April 25, 2020 – To assist health workers and researchers working under challenging conditions to bring this outbreak to a close, The Lancet has created a Coronavirus Resource Centre. This resource brings together new 2019 novel coronavirus disease (COVID-19) content from across The Lancet journals as it is published. All of our COVID-19 content is free to access
Covid-19 Arrived in Seattle. Where It Went From There Stunned the Scientists
April 22, 2020 – As the coronavirus outbreak consumed the city of Wuhan in China, new cases of the virus began to spread out like sparks flung from a fire
Información técnica, precios y registros sanitarios de pruebas diagnósticas para detección del virus SARS-CoV-2 en 5 países de América Latina y otras regiones
Abil de 2020 – Información técnica, precios y registros sanitarios de pruebas diagnósticas para detección del virus SARS-CoV-2 en 5 países de América Latina y otras regiones
Exceptional GMP flexibilities for medicines manufacturers during the coronavirus (COVID-19) outbreak
April 22, 2020 – These temporary good manufacturing practice (GMP) flexibilities will be allowed to address the current exceptional circumstances
Connecting clusters of COVID-19: an epidemiological and serological investigation
April 21, 2020 – Elucidation of the chain of disease transmission and identification of the source of coronavirus disease 2019 (COVID-19) infections are crucial for effective disease containment
Coronavirus Infections May Not Be Uncommon, Tests Suggest
April 21, 2020 – Two preliminary efforts to survey citizens for antibodies to the virus have produced controversial results
Developing therapeutic monoclonal antibodies at pandemic pace
April 21, 2020 -The time from discovery to proof-of-concept trials could be reduced to 5–6 months from a traditional timeline of 10–12 months
Coronavirus (COVID-19) Update: FDA Authorizes First Test for Patient At-Home Sample Collection
April 21, 2020 – The U.S. Food and Drug Administration authorized the first diagnostic test with a home collection option for COVID-19
Launch of enhanced monitoring system for availability of medicines used for treating COVID-19
April 21, 2020 – EMA, together with the pharmaceutical industry and the EU Member States, has launched its enhanced fast-track monitoring system to help prevent and mitigate supply issues with crucial medicines used for treating patients with COVID-19
Update to guidance on regulatory expectations in the context of COVID-19 pandemic
April 20, 2020 – The European Commission, EMA and the national competent authorities have agreed a series of measures to mitigate the impact of disruptions caused by COVID-19 on the conduct0 of inspections of manufacturing facilities or other sites relevant for medicinal products in the European Union
Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2) – an update on the status
April 19, 2020 – Coronaviruses are a large group of viruses known to cause illnesses that vary between the common cold and more severe diseases to include severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS)
NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
April 17, 2020 – The National Institutes of Health and the Foundation for the NIH (FNIH) are bringing together more than a dozen leading biopharmaceutical companies, the Health and Human Services Office of the Assistant Secretary for Preparedness and Response, the Centers for Disease Control and Prevention, the U.S.
Immunity from COVID-19 antibodies not certain, HIV co-discoverer cautions
April 14, 2020 – The race is on to develop and distribute antibody tests for the coronavirus, driven by the idea that these tests will inform individuals when they are immune to the virus and can return to their normal lives
Drug Evaluation during the Covid-19 Pandemic
April 14, 2020 – The search for a treatment for Covid-19 is testing our country’s ability to quickly develop, test, and deploy medications, presenting both opportunities and challenges to our drug-assessment apparatus
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
April 13, 2020 – The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19)
April 13, 2020 – The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment
Trade set to plunge as COVID-19 pandemic upends global economy
April 13, 2020 – World trade is expected to fall by between 13% and 32% in 2020 as the COVID 19 pandemic disrupts normal economic activity and life around the world
Update on EU actions to support availability of medicines during COVID-19 pandemic
April 10, 2020 – The continued availability of medicines is one of the most important priorities for EU authorities that are adopting measures to mitigate possible disruptions to the supply of medicines caused by the ongoing COVID-19 pandemic
Compassionate Use of Remdesivir for Patients with Severe Covid-19
April 10, 2020 -O remdesivir, um pró-fármaco análogo de nucleotídeo que inibe a polimerase de RNA viral, demonstrou atividade in vitro contra SARS-CoV-2
COVID-19 and risks to the supply and quality of tests, drugs, and vaccines
April 09, 2020 – Emergency efforts are underway to find optimum medical products to prevent infection and diagnose and treat patients during the coronavirus disease 2019 (COVID-19) pandemic
Structure of Mpro from COVID-19 virus and discovery of its inhibitors
April 09, 2020 – A new coronavirus (CoV) identified as COVID-19 virus is the etiological agent responsible for the 2019-2020 viral pneumonia outbreak that commenced in Wuhan
Treatment options for COVID-19: The reality and challenges
April 04, 2020 – An outbreak related to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019
Situação patentária de produtos passíveis para uso contra à Covid-19
09.04.2020 – Dando prosseguimento ao estudo sobre possíveis moléculas e produtos para tratamento e prevenção da COVID-19, após os estudos elaborados a partir das informações obtidas no estudo publicado pela American Chemical Society , a ABIFINA traz um levantamento das patentes correspondentes brasileiras de produtos já comercializados para prevenção e tratamento de outras doenças que possam ser utilizados para prevenção e tratamento de COVID-19
Global regulators stress need for robust evidence on COVID-19 treatments
April 09, 2020 – International regulators have published a report today highlighting their considerations on the development of potential COVID-19 therapeutics, clinical trials and compassionate use programmes
BMJ’s Coronavirus (covid-19) Hub
April 09, 2020 -BMJ’s covid-19 hub supports health professionals and researchers with practical guidance, online CPD courses, as well as the latest news, comment, and research from The BMJ.
Situação patentária de vacinas relacionadas à Covid-19
08.04.2020 – Dando prosseguimento ao estudo sobre possíveis moléculas para tratamento e prevenção da COVID-19, a partir das informações obtidas no estudo publicado pela American Chemical Society , a ABIFINA traz um levantamento das patentes correspondentes brasileiras de vacinas que possam ser utilizadas na pandemia de COVID-19
Global regulators discuss observational studies of real world data for COVID-19 medicines
April 07, 2020 – In a dedicated COVID-19 workshop, organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), international regulators discussed how data generated during clinical practice could complement evidence from clinical trials with potential therapeutics or vaccines against COVID-19
Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production
April 07, 2020 – Besides social isolation, identification of the suitable clinically approved drugs to be repurposed could lead to short-term action to reduce mortality
Open for outbreaks
April 07, 2020 – In the onslaught of the COVID-19 pandemic, the open sharing of materials, information and data is gaining increasing importance in biotech.
Coalition launched to accelerate research on the prevention and treatment of COVID-19 in low- and middle-income countries
April 03, 2020 – A group of scientists, physicians, funders, and policy makers from over 70 institutions from over 30 countries have launched an international coalition to respond to COVID-19 in resource-poor settings
EMA provides recommendations on compassionate use of remdesivir for COVID-19
April 03, 2020 – During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral medicine remdesivir should be used for treating coronavirus disease (COVID-19) in compassionate use programmes in the European Union
International regulators discuss available knowledge supporting COVID-19 medicine development
April 03, 2020 – On 2 April, regulators from around the world joined the second workshop on COVID-19 organised by the European Medicines Agency (EMA) under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA)
Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS, or COVID‐19: initial assessment
April 02, 2020 – Several antiretroviral drugs are being considered the treatment of COVID‐19, the disease caused by a newly identified coronavirus, (SARS‐CoV‐2).
HHS accepts donations of medicine to Strategic National Stockpile as possible treatments for COVID-19 patients
April 02, 2020 – FDA issues emergency use authorization for donated hydroxychloroquine sulfate, chloroquine phosphate
Coronavirus disease (COVID-2019) R&D
April 02, 2020 – On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China
Optimizing the Trade-off Between Learning and Doing in a Pandemic
April 02, 2020 – The world is united regarding the goal of ending the coronavirus disease 2019 (COVID-19) pandemic but not the strategy to achieve that goal
COVID-19: combining antiviral and anti-inflammatory treatments
April 01, 2020 – Both coronavirus disease 2019 (COVID-19) and severe acute respiratory syndrome (SARS) are characterised by an overexuberant inflammatory response and, for SARS, viral load is not correlated with the worsening of symptoms
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
March 30, 2020 – The renin–angiotensin– aldosterone system (RAAS) is an elegant cascade of vasoactive peptides that orchestrate key processes in human physiology.
NOTA INFORMATIVA Nº 5/2020-DAF/SCTIE/MS
27.03.2020 – Uso da Cloroquina como terapia adjuvante no tratamento de formas graves do COVID-19
Use of antiviral drugs to reduce COVID-19 transmission
March 27, 2020 – As the coronavirus disease 2019 (COVID-19) spreads, efforts are being made to reduce transmission via standard public health interventions based on isolation of cases and tracing of contacts.
EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic
March 27, 2020 – EMA is aware of recent media reports and publications which question whether some medicines, for instance angiotensin converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs, or sartan medicines), could worsen coronavirus disease (COVID-19)
Exportação de cloroquina e azitromicina: veja a RDC 352
March 27, 2020 – De acordo com a Resolução da Diretoria Colegiada 352, a exportação necessitará temporariamente de autorização prévia da Anvisa.
Situação patentária de moléculas e composições relacionadas à Covid-19
25.03.2020 – Diante da pandemia da COVID-19, e a partir das informações obtidas por um estudo publicado pela American Chemical Society , a ABIFINA fez um levantamento preliminar das patentes brasileiras correspondentes para as moléculas que estão sendo estudadas para prevenção e/ou tratamento da COVID-19.
Gilead Declines ‘Rare Disease’ Status For Experimental Coronavirus Drug
March 26, 2020 – In a surprising turnabout, drugmaker Gilead Sciences asked the Food and Drug administration on Wednesday to rescind orphan status for remdesivir, the company’s experimental coronavirus treatment
India bans exports of drug touted by Trump as potential Covid-19 treatment
March 26, 2020 – Amendment in Export Policy of Hydroxychloroquine
Global regulatory workshop on COVID-19 vaccine development
March 25, 2020 – A virtual meeting, held under the umbrella of the International Coalition of Medicines Regulatory Authorities (ICMRA), convening experts from medicines regulatory authorities, the World Health Organisation (WHO) and the European Commission
Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)
March 25, 2020 – In vitro studies revealed that lopinavir/ritonavir and hydroxychloroquine have antiviral activity against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
The Official Chinese Government Guide to Diagnosing and Treating the Novel Coronavirus
March 25, 2020 – You may not have heard of it. It’s now on version 7. You should read it.
Resources and Use of Approved Therapies for Treatment of n-CoViD-19 Disease
March 2020 – Therapies Approved by US FDA for Other Conditions
Insights from nanomedicine into chloroquine efficacy against COVID-19
March 23, 2020 – Chloroquine — an approved malaria drug — is known in nanomedicine research for the investigation of nanoparticle uptake in cells, and may have potential for the treatment of COVID-19
FDA and EMA Collaborate to Facilitate SARS-CoV-2 Vaccine Development
March 23, 2020 – Vaccines offer a way to build immunity to a disease-causing microorganism before one has ever been exposed to it. They have been highly effective in preventing a whole range of serious infectious diseases
The first study of a potential coronavirus vaccine will soon start recruiting healthy volunteers in Georgia at Emory University
Mar 23, 2020 – A pharmacist gives Jennifer Haller, left, the first shot in the first-stage safety study clinical trial of a potential vaccine for COVID-19, the disease caused by the new coronavirus, Monday, March 16, 2020, at the Kaiser Permanente Washington Health Research Institute in Seattle.
Genentech Announces FDA Approval of Clinical Trial for Actemra to Treat Hospitalized Patients With Severe COVID-19 Pneumonia
March 23, 2020 – Genentech will also provide 10,000 vials of Actemra to the U.S. Strategic National Stockpile. Current U.S. supply of Actemra for approved indications is not expected to be impacted
WHO launches global megatrial of the four most promising coronavirus treatments
Mar. 22, 2020 – Could any of these drugs hold the key to saving coronavirus disease 2019 (COVID-19) patients from serious harm or death? On Friday, the World Health Organization (WHO) announced a large global trial, called SOLIDARITY, to find out whether any can treat infections with the new coronavirus for the dangerous respiratory disease.
The pandemic pipeline
20 March 2020 – Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
The pandemic pipeline
20 March 2020 – Companies are doing their best to accelerate experimental drugs and vaccines for COVID-19 through the pipeline. Each faces its own set of challenges, but all agree on the need for a radical rethink of the clinical development process for pandemics.
Chloroquine, Past and Present
20 March, 2020 – Derek Lowe’s commentary on drug discovery and the pharma industry. An editorially independent blog from the publishers of Science Translational Medicine. All content is Derek’s own, and he does not in any way speak for his employer.
A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19
March 18, 2020 – No therapeutics have yet been proven effective for the treatment of severe illness caused by SARS-CoV-2
Sanofi, Regeneron test arthritis drug against COVID-19
March 18, 2020 – New study explores whether dampening IL-6 could address serious coronavirus infections
Chilean Chamber of Deputies approves resolution for compulsory licenses for patents relating to the coronavirus virus
March 17, 2020 – Today, with an overwhelming 127 votes in favor and 0 votes against, the Chilean Chamber of Deputies approved a strong resolution asking the Chilean Government to declare that there is justification for compulsory licenses for vaccines, drugs, diagnostics, devices, supplies, and other technologies useful for the surveillance, prevention, detection, diagnosis and treatment of people infected by the coronavirus virus in Chile.
Hydroxychloroquine would be effective, according to Professor Raoult of the IHU in Marseille, after a first limited test
March 17, 2020 – Professor Didier Raoult, director of the IHU in Marseille, presented the first results of the hydroxychloroquine clinical test carried out on 24 patients suffering from coronavirus.
Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus
16 March 2020 – Estimation of the prevalence and contagiousness of undocumented novel coronavirus (SARS-CoV2) infections is critical for understanding the overall prevalence and pandemic potential of this disease.
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
March 12, 2020 – Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccine
Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study
12/12/2022 – Two doses of either vaccine did not provide significant protection against COVID-19 infection. However, receipt of a BNT162b2 booster or CoronaVac booster was associated with a significantly lower risk of omicron BA.2 infection and symptomatic infection. Our findings confirm the effectiveness of booster doses to protect against mild and asymptomatic infection.
Repurposing FDA-approved drugs cetilistat, abiraterone, diiodohydroxyquinoline, bexarotene, and remdesivir as potential inhibitors against RNA dependent RNA polymerase of SARS-CoV-2: A comparative in silico perspective
08/12/2022 – Our finding indicated that the selected drugs have a high potential to be developed as RdRp inhibitors and, with further validation studies, could serve as potential drugs for the treatment of COVID-19
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
05/12/2012 – Our findings underline the importance of continued SARS-CoV-2 vaccination programmes, including second-generation bivalent vaccines, especially in patient subgroups where vaccine immunogenicity and efficacy might be reduced, such as those on anti-TNF therapies
SARS-CoV-2 epitopes inform future vaccination strategies
25/11/2022 – Augmenting vaccination-induced T-cell responses against SARS-CoV-2 may provide adequate protection despite broad antibody escape by VOCs
Profiling the B cell immune response elicited by vaccination against the respiratory virus SARS-CoV-2
24/11/2022 – Considering the physiological decline of circulating antibodies overtime, the lack of a threshold value for protection from infection, and the rapid appearance of novel viral variants, the measurement of MBC can be evaluated as an indicator of potentially antibody-producing cells upon antigen encounter
Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis
23/11/2022 – JAK inhibitors appear to be a promising treatment for COVID-19 concerning reducing mortality, and they do not increase the risk of adverse events vs. standard of care. A network meta-analysis suggests that mortality benefits are associated with specific JAK inhibitors, and among these, ruxolitinib presents the greatest likelihood of having benefits for mortality and adverse events
